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ABSTRACT 
The regulation of blood glucose levels post-prandial relies on insulin-stimulated 
glucose uptake within adipocytes and striated muscle. The insulin effect in these 
tissues is a result of the translocation of the facilitative glucose transporter type IV 
(GLUT4) from intracellular storage vesicles to the plasma membrane. GLUT4 
translocation results in the majority of glucose uptake in the body post-prandial. A 
major contribution to developing Type-2 diabetes is insulin-resistance, which is a 
result of ineffective insulin signalling, and glucose uptake.  
GLUT4 is found in insulin sensitive tissue, such as adipose and striated muscle, it is 
sequestered and stored intracellularly in specialised GLUT4 storage vesicles (GSV) in 
the absence of insulin. GSVs are a dynamic vesicle which translocate in response to 
insulin stimulation to the plasma membrane. In the absence of insulin stimulation 
GSVs which arrive at the PM show reduced fusion to the membrane and are quickly 
re-endocytosed. Upon insulin stimulation there is an increase in GSVs translocation 
to the plasma membrane and upon arrival fusion with retention at the plasma 
membrane is increased.  
At the plasma membrane GLUT4 arrives within in a cluster. Within this cluster GLUT4 
is dynamic but corralled within in the cluster. In the absence of insulin GLUT4 is 
quickly re-endocytosed in a “kiss-and-run” type event. In the insulin-stimulated cell 
GLUT4 arrives in clusters which have been observed to disperse from the original 
site of fusion. In response to insulin stimulation GLUT4 mobility at the plasma 
membrane is increased with increased dispersal. This indicates that insulin 
stimulation has an effect on the behaviour of GLUT4 at the plasma membrane. This 
dispersal is hypothesised to increase GLUT4 dwell time at the plasma membrane 
increasing the effect of insulin signalling for a greater period of time. The dispersal 
of GLUT4 at the plasma membrane is an insulin mediated response which has no 
known molecular mechanism.  
A genetic screen conducted in S. cerevisiae indicate a role for a mutant allele, fgy1-
1, of the protein Efr3. This protein has two homologous mammalian orthologues 
EFR3A and EFR3B. The mammalian EFR3 is a palymitoylated protein responsible for 
membrane localisation and as a result the activity of the phosphoinositide kinase, 
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PI4K type IIIα. PI4KIIIα activity is required for generation of phosphoinositide 4-
phosphate (PI4P) at the plasma membrane inner leaflet.  
The phospho-identity of the membrane phosphoinositide has been shown to affect a 
variety of cellular functions. Mobility of plasma membrane inserted proteins is 
dictated by the composition of the membrane and cytoskeletal network below the 
membrane. Single molecule tracking of GLUT4 at the plasma membrane shows 
increased mobility in the insulin-stimulated cell. Increased mobility and increased 
dispersal of GLUT4 in response to insulin stimulation has no known molecular 
mechanism which made EFR3 a promising candidate for further investigation.  
This thesis aims to investigate EFR3A and of PI4P during insulin stimulated GLUT4 
dispersal. 
The results from these experiments showed that EFR3A is the expressed homolog 
within adipocyte cell types used in this investigation. Results indicating that in mice 
with impaired glucose tolerance EFR3A and PI4KIIIα protein levels are increased in 
insulin responsive striated muscle samples. This indicates a compensatory effect as 
insulin resistance occurs in these animals. Results showed that increased expression 
of EFR3A led to increasing the plasma membrane GLUT4 in the absence of insulin 
stimulation signifying GLUT4 is enriched in the plasma membrane instead of 
intracellularly within GSVs when EFR3A is over expressed. Inhibition of EFR3A plasma 
membrane localisation through expression of a cytosolic mutant leads to inhibition 
of the insulin stimulated increase of GLUT4 at the plasma membrane. This indicates 
that EFR3A at the plasma membrane is important for insulin stimulated GLUT4 
increase. In concurrence with these data inhibition of EFR3A and PI4KIIIα through 
siRNA depletion resulted in inhibited insulin stimulated glucose uptake. Increased 
glucose uptake is the end result of insulin stimulation, and inhibition of EFR3A 
machinery inhibits this activity.  
Taken together these findings indicate that EFR3A has a positive effect on plasma 
membrane GLUT4 and insulin stimulated glucose uptake. A role for the generation 
of PI4P at the plasma membrane is proposed to be behind this positive effect, which 
future work could aim to elucidate. 
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DEFINITIONS AND ABBREVIATIONS 
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Akt Protein Kinase B (PKB) 
AS160 Akt substrate of 160kDa 
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FGY functional expression of Glut4 in yeast 
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HCV Hepatitis C virus 
DAG diacyglycerol 
IP3 inositol 1,4,5 tri-phosphate 
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2 INTRODUCTION 
2.1 DIABETES  
Diabetes is a disease of un-regulated blood glucose; a characteristic component of 
the diabetes mellitus disease is high glucose blood concentrations caused by defects 
in insulin secretion and, or action (Genuth et al., 2003; The Expert Committee on 
the Diagnosis and Classification of Diabetes Mellitus, 2003; American Diabetes 
Association, 2010). A result of un-managed diabetes is chronic hyperglycaemia, the 
long-term consequences of which marks a variety of organs, in particular the 
kidneys, nerves at the extremities, eyes, blood vessels and the heart are adversely 
affected by this condition (Diabetes and American Diabetes Association, 2010). 
Diabetes can largely be classed as two forms, Type-1 and Type-2. Type-1 diabetes 
(T1D) is defined by a total lack of insulin production, commonly a result of an 
autoimmune response to the insulin producing β-islet cells (The Expert Committee 
on the Diagnosis and Classification of Diabetes Mellitus, 2003). Type-2 diabetes (T2D) 
is defined by insulin-resistance, when insulin is produced but the response no longer 
results in a decrease of blood glucose concentration (Weyer et al., 1999; Kahn et 
al., 2014; Diabetes UK, 2016). The cause of insulin resistance is associated with 
obesity but ultimately unknown, and there are multiple processes during insulin 
signalling which could be affected (Perley and Kipnis, 1966; Weyer et al., 1999; Kahn 
et al., 2006). As of 2015 global estimates indicated that 415 million adults live with 
the disease, with a predicted rise to over 600 million by 2040, this makes diabetes 
a growing problem for society. Currently in the UK 3.5 million people are diagnosed 
with diabetes, with a further estimated 1.1 million undiagnosed persons (Diabetes 
UK, 2016). T1D accounts for 10% of patients with diabetes in the UK and the other 
90% live with T2D (Diabetes UK, 2016).  
Currently it is estimated that up to 10% of the NHS budget is spent on diabetes 
associated treatments, which is equivalent to £10 billion, a number predicted to rise 
in the future (Hex et al., 2012). The discovery of insulin was one of the most 
powerful treatments in modern times, its delivery reversed the severe symptoms 
related to T1D (Abel, 1926). However, despite insulin’s capability as a therapeutic 
treatment it is not a simple solution as the body’s ability to self-regulate glucose 
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levels is unparalleled. Complications related to hyperglycaemia are common for 
many T1D patients and life expectancy is significantly reduced (Livingstone et al., 
2015). The treatment of T2D, however, has been a far more complex issue, with no 
silver bullet treatment like insulin for this disease. Similarly to T1D patients with 
T2D have reduced life expectancy, those diagnosed in their 50s on average live 6 
years less (Seshasai et al., 2014).  
2.2 BLOOD GLUCOSE REGULATION 
In healthy humans, blood glucose is usually kept within fairly narrow limits between 
4 and 6mM, and a range of complex mechanisms achieves this. Blood glucose levels 
spike considerably after meals, it is essential that post-prandial blood glucose is 
lowered to avoid the effects of chronic hyperglycaemia. Glucose homeostasis is the 
process whereby a constant sugar is available in the blood for the maintenance of 
muscle activity and glucose hungry synaptic activity in the brain. The lowering of 
blood glucose post-prandial not only provides a mechanism to store the excess 
glucose but also serves to ensure proper osmotic pressure of the blood vessels (Tups 
et al., 2011). The regulation of glucose is therefore vital for a variety of cellular 
processes.   
Glucose homeostasis can be regarded as being primarily regulated by two opposing 
hormones: glucagon and insulin, both produced in respective specialised cells within 
the islet of Langerhans of the pancreas (Herman & Kahn 2006; Tirone & Brunicardi 
2001). During the fasting state hypoglycaemia is sensed by the α-cells of the islet of 
Langerhans which release glucagon (Brelje et al., 1989; Brissova, 2005). A schematic 
diagram of glucose homeostasis is shown in Figure 1.  
The action of these two opposing hormones has been widely investigated, this thesis 
will focus on the effect of insulin stimulation at the plasma membrane in adipocytes. 
Glucagon primarily acts in the liver through a G-protein coupled receptor (GPCR), a 
Gα coupled receptor which signals through cAMP and protein kinase A pathway. This 
signalling pathway stimulates gluconeogenesis and glycogenolysis resulting in an 
increase in glucose release from stores. Therefore increasing and stabilising the 
blood glucose to normal levels (Quesada et al., 2008).  
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β-cells of the islet of Langerhans are responsible for the sensing of glucose in 
response to hypo/hyperglycaemia. Insulin is produced and released from the β-cells 
in response to raised ATP levels in the cell when an abundance of glucose is present 
(Brelje et al., 1989; Brissova, 2005). The primary function of insulin is to signal to 
peripheral tissue the requirement to store the excess glucose, and therefore lower 
the blood glucose levels to within the normal range (Park and Johnson, 1955; Levine 
and Goldstein, 1958). Insulin signals through the insulin receptor (IR), a tyrosine 
kinase receptor which is located at the PM dimerised. The IR is predominantly found 
in; striated muscle, adipose tissue, and the liver (Shia and Pilch, 1983; Gammeltoft 
and Van Obberghen, 1986; Rowland et al., 2011). In the liver and muscle insulin 
stimulates glycogen synthesis and in adipose tissue insulin stimulates triacylglycerol 
Glucose is removed from 
the blood and stores are 
created 
Glucose stores 
are released 
 
Hypoglycaemia Hyperglycaemia 
Pancrea
s 
Fat and Muscle 
cells 
Glucagon is released 
by α-cells 
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by β-cells 
Liver 
4-6 mM glucose concentration 
 
The islet of Langerhans α-cell and β-cell produce the opposing hormones glucagon 
and insulin respectively. Glucagon is released in response to hypoglycaemia and 
works to release stores of glucose from the liver. Insulin is released in response to 
hyperglycaemia and lowers glucose concentration by promoting the storing of 
excess glucose. 
Figure 1: Schematic of glucose homeostasis. 
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synthesis (Dimitriadis et al., 2011). Both of these tissues react to insulin by storing 
glucose for later use as glycogen or triacylglycerides respectively.  
In both muscle and adipose tissue the rate of glucose uptake is increased during 
insulin signalling. The glucose transporter type IV (GLUT4) has been identified as the 
signalling target within this system (Cushman and Wardzala, 1980; Suzuki and Kono, 
1980; Fukumoto et al., 1989; James et al., 1989; Wieczorke et al., 2003). Insulin 
induced glucose uptake in this tissue is due to the translocation of GLUT4 from 
internal stores to the plasma membrane. The translocation of GLUT4 acts as a 
molecular dam system increasing the ability for glucose to enter the cell in times of 
plenty (Marette et al., 1992; Bryant et al., 2002; Bradley et al., 2015). GLUT4 is a 
member of the facilitative glucose transporter family, covered below in 2.2.1, and 
is predominantly found in striated muscle, adipose tissue and the brain (Kobayashi 
et al., 1996). GLUT4 is responsible for the majority of insulin stimulated glucose 
uptake, and the predominantly expressed isoform in insulin sensitive tissue.  
As previously covered in 2.1 Diabetes is a disease of glucose homeostasis, of which 
there are two predominant classifications, type 1 and Type 2. T1D is the result of 
pancreatic β-cell destruction or inability to produce insulin. T2D is associated with 
a lack of an appropriate insulin response, insulin is produced but cells are resistant 
to insulin signalling.     
2.2.1 Overview of Glucose Transport 
The 12-member glucose transporter (GLUT) protein family orchestrate the transport 
of sugars throughout the body. GLUT transporters were initially identified as 12 
transmembrane proteins from hydrophobicity plots, which has later been confirmed 
by modelling of crystal structures (Mohan et al., 2009, 2010; Deng et al., 2014). 
GLUT transporters are glucose, fructose or dual specific channels with varying tissue 
specificity (Wieczorke et al., 2003; Zhao and Keating, 2007). GLUT transporters 
transport sugar through facilitative transport down its concentration gradient; by 
comparison the sodium glucose co-transporters (SGLT) family transport glucose using 
the coupled movement of NA+ ions (Gould and Holman, 1993; Zhao and Keating, 
2007). The affinity for glucose and other saccharides vary between transporters. 
This allows for sugar sensing and the absorption of sugar in specialised cells (Zhao 
and Keating, 2007). 
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The ubiquitously expressed GLUT1 is responsible for the glucose distribution in most 
cell types in the absence of insulin signalling (Zhao and Keating, 2007). After a meal 
glucose is absorbed through the intestinal lumen (Turner et al., 1997). Initially the 
Na+ coupled SGLT1 transports glucose against the concentration gradient into the 
lumen epithelial cells (Hediger et al., 1987; Takata, 1996; Röder et al., 2014). SGLT1 
localisation is confined to the apical plasma membrane insuring an influx from the 
intestinal lumen into the cell (Suzuki et al., 2001). The transport of increased 
intracellular glucose concentration out of the epithelial cells into the interstitial 
space is coordinated through GLUT2 (Thorens, 1993; Röder et al., 2014). GLUT2 is a 
facilitative glucose transporter with a high capacity and low affinity which is 
localised basolaterally ensuring a flow through the epithelial cell postprandial 
(Mueckler, 1994; Uldry et al., 2002). Glucose is further absorbed into the 
microvasculature and carried around the body. In response to increased postprandial 
blood glucose concentration insulin is released by islet β-cells. GLUT2 has a low 
affinity for glucose and is localised to β-cells, which allows for glucose to influx into 
the cells in response to increased glucose (Thorens, 2001). The release of insulin 
results in the uptake of glucose by adipose, skeletal, cardiac and brain tissue (Leney 
and Tavaré, 2009; Ashrafi et al., 2017). This is mediated through insulin mediated 
GLUT4 translocation (Gibbs et al., 1988; Zaid et al., 2008; Rowland et al., 2011). 
This thesis will focus mainly on GLUT4, and consequently subsequent sections 
emphasise the role and regulation of this protein during glucose regulation.  
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2.3 INSULIN SIGNALLING 
Insulin is a 5kDa peptide hormone originally discovered in 1921 by Banting and Best 
which is composed of an A chain and B chain linked by disulphide bonds (Dodson and 
Steiner, 1998; Mayer et al., 2007). Insulin is synthesised in the β-cells of the islet of 
Langerhans and is processed through the Golgi apparatus which generated the 
precursor called proinsulin (Howel et al., 1978; Huang and Arvan, 1995). Proinsulin 
is cleaved during the formation of storage vesicles for exocytosis by membrane 
associated endopeptidase PC2, leaving the A and B chain linked and kept in a 
crystalline state (Abel, 1926; Bennett et al., 1992). Insulin is released by exocytosis 
into the blood in proportion to blood glucose concentration. 
When Insulin signals through binding to the α subunit of the dimerised insulin 
receptor (IR), the tyrosine kinase activity of the β subunit is activated via auto 
phosphorylation (Kasuga et al., 1982; Shia and Pilch, 1983). Activation of the IR 
results in a cascade of tyrosine kinase signalling through insulin receptor substrate 
(IRS) and adaptor protein with pleckstrin homology and Src homology domains (APS) 
activation, depicted in Figure 3. The variety of effects caused by insulin signalling 
are summarised in Figure 2.   
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2.3.1 Insulin receptor substrate (IRS) signalling pathway 
There are more than one IR substrate proteins (IRS-1,-2,-3,and-4) which mediate 
differential signalling cascades in differing cell types (White et al., 1985; Patti et 
al., 1995; Lavan et al., 1997a, 1997b). IRS-1 and -2 are ubiquitously expressed across 
all insulin sensitive tissue and are the primary mediators of the insulin signal (White, 
2002; Mardilovich et al., 2009). IRS proteins contain no intrinsic enzymatic 
capabilities, they mediate their function as adaptors to activated IR to organise 
signalling complexes (Sun et al., 1991). IRS proteins share homology at the N-
terminus with two highly conserved regions, the pleckstrin homology (PH) and the 
phosphotyrosine binding (PTB) domains (Voliovitch Hedva et al., 1995; Sawka-
verhelle et al., 1996; Yenush et al., 1996; Backer et al., 1997).   
Insulin action in muscle and adipose tissue is a result of IRS-1 action (White, 2002). 
IRS-1 activation results in the activation phosphatidylinositol 3-kinase (PI3K) and 
generation of phosphatidylinositol 3,4,5 triphosphate (PI-3,4,5P3) at the inner leaflet 
Figure 2: Intracellular effects of insulin stimulation 
A schematic showing the various intracellular effects insulin stimulation regulates 
through insulin receptor binding and activation. The effects can vary between cell 
types; for example, lipogenesis is a primary effect in adipocyte cells whereas 
glycogen synthesis is a primary response in hepatic cells.  
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of the plasma membrane (Okada et al., 1994; Collins et al., 2003). The generation 
of these PI 3,4,5 P3 allows for docking of phosphoinositide dependant kinase 1 (PDK1) 
and Protein kinase B (Akt) through via pleckstin homology (PH) binding domain 
(Rowland et al., 2011).  
2.3.1.1 Adaptor protein with Pleckstrin homology and Src homology 
domains (APS) signalling pathway 
Some studies suggest that IR stimulates two signalling cascades which are both 
required for GLUT4 translocation: the insulin receptor substrate (IRS) pathway 
outlined above (2.1.1.1), and the adaptor protein with pleckstrin homology and Src 
homology domains (APS) signalling branches. Both branches are proposed to be 
required for GLUT4 translocation, and depicted in Figure 3(Isakoff, 1995; Wiese et 
al., 1995). The APS signalling cascade is less well characterised in comparison to the 
IRS pathway. It is suggested that APS activation results in the recruitment of c-CBL 
associated protein (CAP) which in turn recruits c-CBL (Liu et al., 2002). The final 
result is the recruitment of the guanine nucleotide exchange factor (GEF) C3G via 
CRK recruitment by c-CBL (Knudsen et al., 1994; Liu et al., 2003). The GEF activity 
of C3G promotes the exchange of GDP for GTP within the effector TC10 (Neudauer 
et al., 1998; Chiang et al., 2001; Chang et al., 2002). Active TC10 is able to bind to 
Cdc42-interacting protein 4 (CIP4) and exocyst machinery aiding the translocation 
of GLUT4 to the plasma membrane (Chang et al., 2002). 
2.3.1.2 Akt and AS160 activation 
Akt is a serine/threonine protein kinase (aka protein kinase B), binding to PI 3,4,5 
P3 via its PH domain results in activation of kinase activity due to conformational 
changes allowing for the phosphorylation of Thr308 by PDK1(Stephens et al., 1998; 
Song et al., 2005). Akt activity is required for the translocation of GLUT4 to the 
plasma membrane, specifically Akt2 activation is sufficient to translocate GLUT4 (Ng 
et al., 2008). A major target of Akt is AS160 (Akt substrate of 160kDa), which 
contains a GTPase activating protein (GAP) domain. The GAP domain of AS160 
promotes GTP hydrolysis, preventing the GTP loading and activation of its effectors. 
In adipocytes the primary target of this activity is Rab10, a component linked to the 
translocation of GLUT4 storage vesicles (GSVs) to the plasma membrane. Active 
AS160 inhibits Rab10 activity, and Akt phosphorylation of AS160 inhibits this activity, 
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allowing Rab10 GTP loading and effector activation (Sano et al., 2007; Chen and 
Lippincott-Schwartz, 2013). 
 
Figure 3: Schematic diagram of insulin signalling cascade for GLUT4 
translocation.   
Schematic of the two branches of IR signalling required for GLUT4 translocation. 
The IRS branch results in the formation of PIP3 patches for PH domain containing 
PDK1 and AKt to localise to. PH domain localisation results in protein kinase 
activation, PDK1 phosphorylation of Akt1 results in AS160 inhibition, which allows 
for Rab10 to remain bound with GTP and therefore active. Rab10 activity is 
intrinsic to translocate GSV to the PM.  The second APS branch of IR signalling is 
less well characterised, however results in the activation of the effector TC10-
GTP, which is able to aid exocyst machinery CIP4 allowing for GLUT4 
translocation.  
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2.4 GLUT4  
The human hexose transporters family is composed of 14 expressed proteins. GLUT4 
is the only insulin responsive glucose transporter. GLUT4 is an integral membrane 
protein composed of 12 transmembrane domains. This transporter is expressed in 
insulin sensitive tissues; striated muscle and adipose tissue. GLUT4 at the PM is 
dependent on insulin signalling. At the cell surface GLUT4 acts as a facilitative 
glucose transporter, allowing the excess post-prandial glucose to be absorbed from 
the blood stream (Huang and Czech, 2007).  
2.4.1 GLUT4 Intracellular Trafficking 
In the absence of insulin signalling GLUT4 is predominantly stored intracellularly 
with some GLUT4 present at the PM. GLUT4 is primarily localised to low density 
membrane (LDM) vesicles known as GLUT4 storage vesicles (GSVs). GSVs have been 
identified as a specialised pool of insulin sensitive vesicles primed to respond to 
insulin signalling. To achieve this GLUT4 must be trafficked and sorted within the 
cell, this is achieved through two distinct but interlinked cycles. The GLUT4 cycle 
has been well documented. GLUT4 is internalised via clathrin and cholesterol 
dependant endocytosis (Blot and McGraw, 2006, 2008; Hresko et al., 2016). Once 
endocytosed GLUT4 has been shown to co-localised with TfR, an example of a PM 
protein which populates the prototypical endosomal cycle. We understand that 
GLUT4 from the PM traffics through the prototypical endosomal cycle, as most PM 
proteins do, and from this cycle GLUT4 is sequestered into a second cycle, shown in 
Figure 4, which delivers GLUT4 into GSVs. These two cycles have been investigated 
by various endosomal blocks (Zeigerer et al., 2002; Livingstone et al., 1996; Martin 
et al., 1996) The formation of GSVs from cycle one is shown to be through the trans-
Golgi network (TGN), removing GLUT4 from the rapidly recycling pool. GSVs act as 
a pool of GLUT4 within the cell which react to insulin signalling and are delivered to 
the plasma membrane. 
Much of the understanding of GLUT4 sorting is derived from specific motifs on GLUT4 
at the N- and C- terminals.  Initial studies showed that the chimera GLUT1 or 
transferrin receptor protein containing the final C-terminal 30 AA sequence from 
GLUT4 results in internalisation and retention of these proteins in a similar manner 
to GLUT4 (Corvera et al., 1994). Similarly chimeras of the first 8 amino acids of 
29 
GLUT4 result in sorting to perinuclear compartments which are localised with 
endogenous GLUT4 (Piper et al., 1993).  
2.4.1.1 GLUT4 C-terminal mediated trafficking 
In regards to the C terminal, within this sorting motif the double leucine motif L489, 
L490 has been shown to be essential (Verhey and Birnbaum, 1994). This LL sequence 
is not the only signal however, as mutation does not inhibit internalisation of GLUT4 
but does slow the retention of GLUT4 in cells where insulin stimulation has ended 
(Blot and McGraw, 2006). This is evidence that GLUT4 internalisation and retention 
is reliant on more than this motif; this may reflect what appears to be a complex 
endocytic profile of GLUT4. We also know that TELEYLGP (498-505) sequence is 
important for the sequestering of GLUT4 to GSVs from the endosomal cycle, as 
mutations within this sequence result in a block and GLUT4 being stuck in the 
endosomal cycle (Shewan et al., 2000). Subsequent studies showed that the 
mutation of the E499 and E501 points to alanine reduces GLUT4 within GSV 
compartments but does not entirely inhibit the formation of GSVs (Shewan et al., 
2000).  
2.4.1.2 GLUT4 N-terminal mediated trafficking 
N-terminus mediated GLUT4 localisation is determined by the first 8 amino acids, in 
particular F5 (Piper et al., 1993; Palacios et al., 2001). After insulin signalling GLUT4 
internalisation is dependent on cholesterol, the C-terminal LL 489,490 motif, and the 
N-terminus FQQI5-8 motif (Piper et al., 1993; Blot and McGraw, 2006). F5 to S 
mutation prevents entry into the perinuclear compartment and targets GLUT4 for 
degradation (Palacios et al., 2001). F5 mutation to alanine results in decreased GSV 
formation, and increases GLUT4 in the endosomal cycle (Blot and McGraw, 2008). 
Suggesting F5 is required for the sequestering of GLUT4 after endocytosis.  
GLUT4 internalisation is altered in accordance to whether the cell is stimulated or 
not by insulin. The FQQI5-8 and LL 489,490 motifs appear to allow for GLUT4 to be 
trapped intracellularly in GSVs in the absence of insulin signalling. This tells us that 
the formation of these GSVs are key to the GLUT4 function (Omata et al., 2000; Yeh 
et al., 2007; Bryant and Gould, 2011; Kioumourtzoglou et al., 2014).  
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Figure 4: Schematic of intracellular GLUT4 trafficking 
GLUT4 is sequestered into storage vesicles (GSVs) that upon insulin stimulation 
translocate to the plasma membrane (PM). The sequestering of GLUT4 into GSVs 
requires the sorting of GLUT4 from the pro-typical endosomal cycle (cycle 1) into a 
specialised GLUT4 sorting cycle (cycle 2). GLUT4 sorts through the trans-Golgi 
network before the formation of GSVs. Upon insulin stimulation GSVs translocate en 
mass to the PM. It is hypothesised that the fusion of GSVs to the PM delivers GLUT4 
as a cluster. These clusters may be re-endocytosed in a “kiss-and-run” like fashion 
during the absence of insulin signalling. Insulin triggered GSV translocation accounts 
for an initial burst of GLUT4 delivery at the PM, however to potentiate this effect 
GLUT4 is dispersed across the plasma membrane. We hypothesise that GLUT4 
dispersal at the PM in response to insulin stimulation results in an increased dwell 
time at the PM, which in turn allows for a sustained glucose uptake period. 
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2.4.2 Proteins associated with GLUT4 translocation 
2.4.2.1 IRAP (Insulin-regulated Aminopeptidase) 
IRAP is a zinc-dependent membrane aminopeptidase which is expressed in a variety 
of cell types (Nikolaou et al., 2014). This protein was initially identified as a 
component of GSVs, known as vp165, making the association with GLUT4 in an insulin 
responsive manner the most characterised behaviour of IRAP (Mastick et al., 1994). 
IRAP is composed of a N-terminus tail, a single transmembrane domain and a large 
C-terminal domain, which contains aminopeptidase catalytic activity (Keller et al., 
1995). IRAP localises to intracellular vesicles in the absence of insulin stimulation 
and upon insulin stimulation increases at the PM 8-fold, in parallel with GLUT4 
translocation (Ross et al., 1997, 1998). The single trans-membrane domain structure 
and co-localisation with GSVs allows IRAP to be used during investigations of GSV 
fusion to the PM (Stenkula et al., 2010). Experimental data suggests that IRAP and 
GLUT4 may have a functional interaction, as the knockout of IRAP or GLUT4 affects 
the expression stability of the other (Jiang et al., 2001; Keller et al., 2002; Abel et 
al., 2004). IRAP knockdown results in an increase in GLUT4 present in endosomes, 
therefore miss-sorted away from GSVs. IRAP KD combined with the GLUT4 FQQI (F5A) 
mutation has an additive effect in the miss-sorting from the endosomal compartment 
to GSV compartment. Together this showed IRAP has an independent role for 
retention of GLUT4 in the absence of insulin stimulation, specifically the sorting of 
GLUT4 from endosomes to the GSVs (Jordens et al., 2010). IRAP specific inhibitors 
such as HFI-419 do not affect blood glucose concentrations in normal or diabetic 
mouse models, indicating that IRAP enzymatic activity has a minimal role in glucose 
homeostasis (Albiston et al., 2017).  
2.4.2.2 Tankyrase 
Tankyrases are a family of poly(ADP-ribose) polymerases which was initially 
identified from a yeast two-hybrid showing the ANK domain of Tankyrase interacts 
with the telomeric protein TRF-1 (Smith et al., 1998). Cloning and characterisation 
revealed a family of TNKS with high identities and near identical domain structures 
(Kuimov et al., 2001). Tankyrase localisation has been shown to be cell-cycle 
dependent (Smith and Lange, 1999). It has been shown that the cytosolic domain of 
IRAP binds to TNKS1/2, and co-localises with a pool of GSVs in 3T3-L1 adipocytes 
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(Chi and Lodish, 2000). Knockdown of Tankyrase results in impaired glucose uptake, 
inhibition of GLUT4 and IRAP translocation, and alters intracellular distribution of 
these proteins (Yeh et al., 2007). TNKS2 forms a complex with the proteins Axin and 
KIF3A which is critical for translocation of GLUT4 in response to insulin stimulation. 
TNKS1 has overlapping effect to TNKS2 in this system, pointing to a compensatory 
effect between homologs (Guo et al., 2012). The exact role for Tankyrase is not fully 
defined but a role within insulin stimulated GLUT4 translocation, and sorting is 
forming. 
2.4.2.3 SNARE and SM proteins 
SNARE (soluble N-ethlmaleimide-sensitive factor activating protein receptor) 
proteins are capable of driving membrane fusion in vitro (Weber et al., 1998). This 
makes SNAREs of interest in stimulated trafficking events such as the insulin 
dependent GLUT4 trafficking to the PM (Bryant and Gould, 2011). SNARE proteins 
contain the ~60 amino acid SNARE domain essential for function, and are anchored 
to the membrane via a transmembrane region or palmitoylation (Hong, 2005). The 
SNARE hypothesis postulates that a vesicle with specific v-SNARE can only fuse with 
the appropriate target membrane containing the complementary t-SNAREs, shown 
in 5. The recognition of complimentary SNARE domains of the approaching vesicle 
allow for docking of the vesicle by the formation of the trans-SNARE complex 
(Fukuda, 2000; Kioumourtzoglou, et al., 2014). The trans-SNARE complex is a helical 
bundle made up of four complimentary SNARE domains arranged in parallel which 
has been visualised using x-ray crystallography (Sutton et al., 1998). The formation 
of the trans-SNARE complex initiates zippering of the SNARE proteins and is 
sufficient to drive membrane fusion. SNARE proteins are commonly regulated 
through phosphorylation, direct or indirect through the phosphorylation of 
regulatory proteins such as NSF (N-ethylmaleimide-sensitive factor), Munc18, and 
Sec1 (Matveeva et al., 2001; Snyder et al., 2006; Jewell et al., 2011; Laidlaw et al., 
2017). Insulin signalling is mediated through tyrosine phosphorylation, and insulin 
dependent tyrosine phosphorylation of Munc18c at amino acid positions Y219 and 
Y521 has been found (Jewell et al., 2011).  
The specificity of SNAREs means that separate SNAREs and SM proteins regulate the 
various stages of GLUT4 trafficking. Key SNAREs involved in GLUT4 trafficking 
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include; t-SNAREs Sx4 and SNAP-23 at the PM; v-SNARE VAMP2 at the PM; t-SNAREs 
Sx16 and Sx6 intracellularly; v-SNAREs VAMP3, VAMP4 and VAMP8 intracellularly 
(Schoch et al., 2001; Perera et al., 2003; Shewan et al., 2003; Proctor et al., 2006; 
Williams and Pessin, 2008). In relation to GSV approach to the PM GSVs are known 
to be enriched with the v-SNARE VAMP2, which bind on arrival at the PM to the 
complimentary t-SNAREs identified as Sx4 and SNAP-23, shown in Figure 5(Sadler, et 
al., 2015). The SNARE regulatory SM proteins Munc18c and mVps45 are implicated in 
insulin stimulated GLUT4 vesicle fusion events (Khan et al., 2001; Sadler, Roccisana, 
et al., 2015). 
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Figure 5: Schematic of SNARE mediated GSV docking to the PM. 
 The lipid bilayer is thermodynamically stable, which means membrane fusion such 
as GSVs to the plasma membrane requires accessory proteins to facilitate fusion 
and overcome the energy requirement for fusion. A. GSV containing V-SNARE 
VAMP2 approach the target membrane. B. Docking of GSV to plasma membrane 
through binding of complimentary t-SNAREs; SNAP23 and syntaxin4. C. The 
formation of the trans-SNARE complex leads to zippering, where the tight binding 
of this complex over comes the energy required for membrane fusion.  
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2.4.2.4 Cytoskeletal proteins 
Cytoskeletal proteins play an important role in the delivery of GSVs to the PM in 
response to insulin stimulation, as well as the sequestering of GLUT4 in GSVs in the 
absence of insulin stimulation. Studies which visualise the mobilisation of GSVs to 
the PM in response to insulin stimulation have shown co-localisation of movement of 
GSVs along the tubulin positions (Semiz et al., 2003). TIRF microscopy observing 
mCherry-tubulin and HA-GLUT4-eGFP identified a role for microtubules in the 
delivery of GSVs to the PM, depicted in Figure 6 A (Dawicki-McKenna et al., 2012). 
Time-lapse images from the TIRF zone showed that the microtubule density 
increases in an insulin dependent manner beneath the PM. In addition to increased 
microtubule density the population of microtubules at the PM within the cell display 
an increase in curvature upon insulin stimulation. IRAP-pHluorin is used to determine 
the sites of GSV fusion, pHluorin is a pH sensitive fluorescent tag which is quenched 
at low pH found in small intracellular vesicles. Upon fusion with the plasma 
membrane IRAP-pHluorin is exposed to neutral pH which allows for GSV fusion to be 
visualised and to occur in close proximity to the microtubules populations near the 
PM, these are correlative and insulin dependent effects (Dawicki-McKenna et al., 
2012).  
The trafficking of GSVs to the PM in response to insulin stimulation has been 
attributed to myosin and kinesin proteins, specifically; KIF5B, MYO5A, and MYO1C 
(Semiz et al., 2003; Boguslavsky et al., 2012; Sun et al., 2014). The microtubule 
kinesin KIF5B has been identified as highly expressed in adipocytes (Semiz et al., 
2003; Cui et al., 2016). KIF5B was shown to be partially co-localised with 
intracellular GLUT4 and is required for the transport of GLUT4 to the PM (Semiz et 
al., 2003). Myo1c, a actin based motor protein is associated with GLUT4 
translocation in response to insulin stimulation (Toyoda et al., 2011). The tethering 
of GSVs at the PM in response to insulin stimulation is mediated by Myo1c binding at 
the sub PM actin population, shown in Figure 6 B (Boguslavsky et al., 2012). In both 
muscle and fat cells insulin stimulation results in a the rapid formation of cortical 
actin projections, and the trafficking of GLUT4 is dependent on the formation of 
these structures (Kanzaki and Pessin, 2001; Brozinick et al., 2004).  
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2.4.2.5 GTPase proteins 
The activation of GTPase family proteins regulate almost every facet of intracellular 
membrane trafficking, and insulin stimulated GLUT4 translocation is no different 
(Sano et al., 2003; Mizuno-Yamasaki et al., 2012). GTPase proteins activity is 
dependent on the state of protein binding to GTP or GDP. In the GTP bound state 
GTPase proteins bind to specific effector proteins to orchestrate membrane 
trafficking events (Mizuno-Yamasaki et al., 2012). The activation of Rho family 
GTPase TC10 has been demonstrated to be required for insulin stimulated glucose 
uptake, and GLUT4 translocation (Chiang et al., 2001). TC10 activity induces actin 
Figure 6: Schematic of Cytoskeletal activity in response to insulin signalling. 
 A. The activity of microtubule network in response to insulin stimulation alters in 
two key ways. The density of microtubules at the TIRF zone increases upon insulin 
stimulation in adipocytes. The curvature of microtubules Microtubule network at 
the PM increases in curvature. Kinesin KIF5B has been shown to have a role in the 
insulin dependent translocation of GLUT4 to the Pm and sites of fusion are linked 
to areas of high microtubule density. B. The actin network beneath the PM is 
efficiently restructured in response to insulin stimulation forming new projections. 
The motor proteins Myo1c and Myo5a are involved in actin based GSV transport and 
tethering to the PM in response to insulin stimulation in adipocytes and striated 
muscle cells.  
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filament formation, which has been observed to be an important part of GSV 
mobilisation as well as part of the insulin response in adipocytes. Activation of TC10 
in response to Insulin stimulation is a PI3K independent pathway. The activation of 
TC10 requires translocation to lipid rafts of Cbl, CrkII, and C3G, shown in Figure 3 
(Chiang et al., 2001).  
The Rab GTPase Rab10 is a downstream target of AS160, one of the downstream 
effectors of the insulin receptor tyrosine kinase activity (Larance et al., 2005; Sano 
et al., 2007). Rab10 has been identified as the only Rab protein component of GSVs 
(Brewer et al., 2016). One downstream effector for Rab10 has been identified as 
SEC16A, a protein required for the organisation of endoplasmic reticulum exit sites, 
both proteins have been shown to be required for GLUT4 trafficking to GSVs in 
adipocytes  (Bruno et al., 2016). Rab10 has been identified as the major Rab protein 
involved in GLUT4 translocation to the PM, shown in Figure 3 (Chen and Lippincott-
Schwartz, 2013). The Rab protein Rab14 has been identified in GLUT4 positive 
endosomal compartments. Rab14 has a proposed role for the recycling of GLUT4 
which has arrived from the PM to the early endosomes into the Golgi network (Reed 
et al., 2013). Rab14 is required for this recycling and the presence of dominant 
negative Rab14Q70L results in GLUT4 stalling within enlarged vesicles. The other 
Rab proteins involved in the intracellular recycling of GLUt4; Rab4a, Rab4B and 
Rab8A (Kaddai et al., 2009; Sun et al., 2014).  
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2.5  GLUT4 MOBILISATION AT THE PLASMA MEMBRANE 
As previously stated the ability for GLUT4 to remain sequestered intracellularly until 
required at the PM is essential to its function in lowering blood glucose. The control 
of when GLUT4 arrives at the PM is therefore tightly regulated. Insulin is the 
predominant signal for GLUT4 mobilisation to the PM in adipocytes (Bryant et al., 
2002). This study will focus on the insulin-mediated response of GLUT4.The other 
documented GLUT4 translocation signals are skeletal muscle contraction and, in the 
brain, neuronal activity (Bradley et al., 2015, Ashrafi et al., 2017). It is important 
to appreciate these other regulatory pathways, but as insulin is the primary 
influence when lowering blood glucose concentration, it is the focus of this thesis. 
New understanding of insulin stimulated GLUT4 regulation is based upon the 
behaviour of GLUT4 at the plasma membrane.  
2.5.1 GLUT4 behaviour at the plasma membrane 
Further understanding of GLUT4 regulation and behaviour has been directed at the 
plasma membrane. Observations using super resolution microscopy techniques have 
shown that GLUT4 behaviour at the plasma membrane is affected by insulin 
signalling. GLUT4-containing vesicles continually recycle to and from the membrane 
in a non-stimulated adipocytes and other GLUT4 containing cell types (Stenkula et 
al., 2010; Lizunov, Lee, et al., 2013; Lizunov, Stenkula, et al., 2013).  
2.5.1.1 GSV fusion behaviour altered by insulin 
Evidence suggesting that GLUT4 behaviour once in the plane of the PM was also 
modulated by insulin came from Stenkula et al., 2010. Results were gathered using 
total internal reflection (TIRF) microscopy, and the pH sensitive tag pHluorin to the 
N-terminus of IRAP. IRAP is co-localised with GLUT4 within GSVs and acts with 
Tankyrase protein to enhance GSV translocation to the PM (Yeh et al., 2007). TIRF 
microscopy only visualises the first 100nm of sample, ideal for the study of PM 
protein interactions (Kudalkar et al., 2016). pHluorin is quenched at low pH such as 
that found in small intracellular vesicles like GSVs, pHluorin flashes when the vesicle 
fuse with the PM and it is exposed to the neutral extracellular pH (Kavalali and 
Jorgensen, 2014). Therefore, the flash of IRAP-pHluorin corresponds directly to GSV 
fusion with the PM. Time lapse images of the TIRF zone of HA-GLUT4-mcherry and 
IRAP-pH positive adipocytes not stimulated with insulin show GSVs arriving into the 
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TIRF zone at a constant, slow, constitutive rate. The arrival of GSVs at the PM can 
be measured in two distinct fashions termed as; fusion with retention and fusion 
with dispersal, a schematic of these events is depicted in Figure 7.  
Figure 7: Schematic of GSV fusion events 
 Arrival of GSVs at the plasma membrane (PM) has been investigated and 
characterised. GSVs approach and dock without fusion. GSVs fuse with the PM 
and are re-endocytosed, known as fusion with retention. GSV arrive and fuse at 
the PM with the dispersal of GLUT4 across the PM.  
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Fusion with retention is characterised by once the flash of IRAP-pH has occurred 
signalling fusion the cluster of GLUT4-mcherry remains intact and disappears from 
the TIRF zone in the Z-direction as a cluster. This fusion with retention is similar to 
a kiss and run type fusion event. Fusion with retention is the most common event 
observed in an un-stimulated cell. In response to insulin stimulation fusion with 
retention occurs at a slightly increased rate in the stimulated adipocyte cell (~2-fold 
increase) in comparison to the basal cell. This increase is indicative of increased GSV 
trafficking to the PM in response to insulin signalling. The fusion with dispersal is 
characterised by IRAP-pH flash and the GLUT4-mcherry cluster signal diffuses at the 
PM. This diffusion of GLUT4-mcherry shows GLUT4 remaining at the PM and is 
hypothesised to increase GLUT4 dwell time at the PM. The measured fusion with 
dispersal events increases 60-fold in response to insulin stimulation; the effect on 
insulin stimulation on GSV fusion events is depicted in Figure 8. GSVs fusion with 
dispersal is one of the most up regulated trafficking processes in response to insulin 
stimulation in adipocytes. Fusion with dispersal occurs at the greatest rate in an 
insulin-stimulated cell in comparison to fusion with retention, this combined with 
the fold. Increase indicates that insulin stimulates the dispersal of GLUT4 at the PM 
(Stenkula et al., 2010). This reported dispersal of GLUT4 at the PM in response to 
insulin stimulation is further validated using the GSV associated SNARE protein 
VAMP2. VAMP2-pHluorin is validated to co-localise with GLUT4 and was utilised to 
investigate GSV arrival at the PM. This study confirmed the occurrence of “kiss-and-
run” GSV fusion events are most prevalent in un stimulated adipocytes, and that 
insulin stimulation resulted in increased dispersal of GLUT4 at the plasma membrane 
(Xu et al., 2011). This study further highlighted that the dispersal of GLUT4 at the 
PM is an insulin-stimulated event, providing further credence to this observation.  
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Figure 8: Schematic model of GLUT4 fusion at the plasma membrane 
 The delivery of GSVs to the PM is an insulin-regulated process. GSVs are sequestered 
in the cell in the absence of insulin signalling. The fusion of GSVs to the PM has been 
characterised into two modes, fusion with retention and fusion with dispersal. GSVs 
undergo a slow and constant recycling to the PM in the absence of insulin 
stimulation. In the absence of insulin stimulation, the majority of arriving GSVs 
arriving undergo fusion with retention, similar to a “kiss-and-run” event. Therefore, 
the majority of fusion events do not lead to GLUT4 retention at the PM in the basal 
cell. In the insulin stimulated cell there is an increase in GSV delivery at the PM. 
The GSVs that arrive show fusion of the vesicle with GLUT4 dispersal across the 
membrane. This is defined as fusion with dispersal, which is increased 60-fold in 
insulin stimulated cell. The fusion with dispersal step is hypothesised to allow for 
increased dwell time of GLUT4 at the PM. Red arrows denote increases in events in 
response to insulin stimulation.  
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2.5.1.2 Single Molecule tracking of GLUT4 at the PM 
Single molecule tracking imaging at the TIRF zone has been harnessed in further 
studies of GLUT4 at the PM, this allowed for tracking and characterisation of 
individual GLUT4 molecule behaviour at the PM (Lizunov, Stenkula, et al., 2013). 
These results gathered when following the trajectory of GLUT4 at the TIRF zone led 
to the categorization of three distinct forms of GLUT4 motion at the PM; random 
free diffusion, confined motion and directed motion. Schematic representations of 
the trajectories of GLUT4 within these definitions is shown below in Figure 9. 
Random free diffusion is characterised by an indirect and constant motion of GLUT4 
at the PM. Confined motion is characterised by constant motion within a confined 
area at the PM, as defined in the picket and fence model, described in detail below 
2.5.1.3 (Nakada et al., 2003). Directed motion of GLUT4 is characterised by long 
distance travel of GLUT4 at the PM with minimal random free diffusion (Lizunov, 
Stenkula, et al., 2013). The stimulation of 3T3-L1 adipocytes with insulin results in 
an increase in free diffusion and a decrease in confined GLUT4 motion at the PM. 
Directed motion is the least prominent form of GLUT4 trajectory at the TIRF zone 
and is seen at marginally increased levels in the un-stimulated cell compared to the 
insulin stimulated cell. The directed motion is correlated vesicular transport, which 
would be GLUT4 pre-fusion to the PM.  
Figure 9: Schematic representation of GLUT4 trajectories at the PM 
 
   
 
  
 
  
A B C 
Schematic of GLUT4 trajectory at the PM of different types of motion. A. Directed 
motion, defined by a long distance travelled and minimal lateral diffusion B. Free 
lateral diffusion is characterised by constant motion within a confined area of the 
PM. C. Confined diffusion is shown by a period of constant motion within a confined 
area as defined in the picket and fence model. 
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To further characterise the clusters of GLUT4 at the PM super resolution microscopy 
techniques; fluorescence photo-activation localization microscopy (FPALM) and 
electron microscopy (EM) were used in this study (Lizunov, Stenkula, et al., 2013). 
The clusters of GLUT4 at the PM where characterised as 110 ± 20nm patches which 
are not circular, but oblong. Within these clusters the GLUT4 is constantly mobile. 
The mobility of GLUT4 within the cluster eliminates the hypothesis of simple cluster 
models such as cross-linking and solid phase domain for GLUT4 at the PM. This points 
to a separate method of corralling for GLUT4 at the PM in adipocytes. Rates for 
GLUT4 dissociation from the clusters and the endocytosis of the clusters were 
measured. KCN was used to deplete ATP and block GLUT4 endocytosis to separate 
the two events, hypothesising that endocytosis requires ATP but GLUT4 dissociation 
from clusters is a ATP independent function (Kono et al., 1971). The measurements 
showed that diffusion from clusters is increased ~3-fold in response to insulin 
stimulation. Insulin stimulation resulted in endocytosis events decreasing ~2-fold 
(Lizunov, Stenkula, et al., 2013).  
Due to the complex nature of both T1D and T2D future therapeutics which target 
umbrella steps, such as the dispersal of GLUT4 at the PM, during the insulin response 
could be of particular interest. 
2.5.1.3 Picket and fence plasma membrane model 
The understanding of the plasma membrane has moved beyond the random dispersal 
and diffusion of lipids hypothesised in the lipid mosaic model. Current understanding 
is based on a more defined structured hypothesis, the picket and fence model 
(Nakada et al., 2003; Kusumi et al., 2005). It has been demonstrated that proteins 
and lipids do not freely disperse across the PM as once thought. The composition of 
the lipid bilayer is understood to affect protein diffusion and movement. Therefore, 
proteins that are involved with lipid dynamics are of particular interest when 
investigating the membrane dynamics of a PM protein such as GLUT4 (Di Paolo and 
De Camilli, 2006; Shisheva, 2008; van den Bogaart et al., 2013; Hresko et al., 2016).  
To investigate the mobility of proteins at the PM techniques were required which 
permitted single particle tracking at a high resolution. Unravelling the detailed 
mobility of proteins required a high speed camera at the TIRF zone for the 
observation of cell surface components (Fujiwara et al., 2002; Nakada et al., 2003). 
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The picket and fence hypothesis was originally developed in studies investigating the 
transmembrane transferrin receptor (TfR) and the unsaturated phospholipid L-α-
dioleoylphosphatidylethanolamine (DOPE) using Cy3 to fluorescently label and track 
these membrane components (Fujiwara et al., 2002; Nakada et al., 2003). TfR and 
DOPE both displayed confinement within the membrane, in which free diffusion of 
both occurred within a 230 ηm2-confined space. The average residency time of DOPE 
within a 230 ηm2 compartment is measured at 13 ms, which is much shorter than 
the measured compartment confinement time of 65 ms for TfR. This suggests a 
hindrance to diffusion for the larger TfR (Fujiwara et al., 2002). These studies 
showed the model of free diffusion required updating and diffusion at the membrane 
is suppressed within a 230 ηm2-confined area. This proposed model is described as 
the anchored membrane-protein picket model (Fujiwara et al., 2002). This model 
hypothesized that due to the effects of steric hindrance and friction-like effects 
theorized in various transmembrane proteins. A variety of transmembrane proteins 
are anchored to the actin-based cytoskeleton. These act as rows of pickets following 
the underlying cytoskeletal network (Dodd et al., 1995).  
The confinement at the membrane is regularly overcome in a rapid hop like diffusion 
event (Suzuki et al., 2005). Diffusion of a G-protein coupled receptor, µ-opioid 
receptor (µOR) was observed using colloidal gold probes. This study was able to 
obtain long term trajectories, without fluorophore bleaching, of individual receptors 
at the PM known as, single particle tracking (SPT). These results showed short-term 
confinement within a compartment, followed by slow hop diffusion into a new 
compartment. The average hop rate measured was once per 45 ms (Suzuki et al., 
2005). Further evidence for the picket fence model is collected from a study 
gathering three-dimensional (3D) images using electron tomography of 0.85 ηm thick 
sections made 100 ηm below the PM surface. This methodology corresponds with 3D 
images of the structures under the PM, of the cell type used, normal rat kidney 
fibroblasts. The actin filaments at the near boundary to the PM correspond to the 
boundaries of lateral diffusion, PM 230 ηm2 compartments which were described in 
previous studies (Morone et al., 2006).  
The confinement and hop diffusion rates of proteins at the PM are altered depending 
on the conditions for the protein. As explained above the behaviour of GLUT4 within 
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the PM is altered by insulin stimulation, with increased mobility stimulated by insulin 
signalling. Therefore, the understanding of the mechanism behind this is a new field 
of interest.  
 
2.5.1.4 Insulin resistance and GSVs at the PM 
The effect of insulin resistance on GLUT4 behaviour at the PM has been studied in 
samples from insulin-resistant human adipose cells (Lizunov, Lee, et al., 2013). 
Using TIRF microscopy the mobility of GSVs at the cell surface area was calculated. 
In a healthy individual the mobile GSVs detected at the PM in adipose cells 
significantly decreases, (3-fold), in response to insulin stimulation. Systematic 
insulin resistance resulted in no effect on the basal level of GSV mobility but 
affected the insulin response. Increased insulin resistance resulted in a non-
significant minimal decrease in GSV mobility, with mobility being similar to that of 
basal cells. The mobility of GSVs is correlated to GLUT4 remaining clustered at the 
PM and not dispersing. Fusion of GSVs upon insulin stimulation increases as 
demonstrated in previous studies. In samples from high insulin resistant subjects the 
increase in GSV fusion events is diminished in comparison to healthy samples 
(Lizunov, Lee, et al., 2013). Fusion of GSVs is integral to the delivery and dispersal 
of GLUT4. The evidence shows that insulin resistance results in the failure of proper 
GSV fusion and GLUT4 dispersal at the PM, both steps are essential for proper insulin 
stimulated glucose uptake.   
Increased dispersal of GLUT4 clusters and increased mobility of GLUT4 at the PM in 
response to insulin stimulation has been demonstrated in these studies using super 
resolution microscopy techniques (Stenkula et al., 2010; Xu et al., 2011; Lizunov, 
Stenkula, et al., 2013). The studies carried out show that insulin stimulation 
increases GLUT4 mobility at the plasma membrane, increases the diffusion of GLUT4 
across the plasma membrane and concurrently inhibiting endocytosis of GLUT4. This 
data collected reveal that the dwell time of GLUT4 is increase in insulin-stimulated 
adipocytes; increased dwell time of GLUT4 is hypothesised to be critical for 
sustained glucose uptake resulting in lowered blood glucose concentrations. The 
results from these observations when taken together show that insulin sensitivity is 
imperative for proper GSV mobility. GSV mobility is indicated as a positive effect of 
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insulin signalling which is critical for proper glucose homeostasis. The results from 
patients with uncontrolled blood glucose homeostasis showed limited mobility. 
Future studies have potential to demonstrate if the mobility of GLUT4 at the PM 
improves glucose uptake and is a requirement for proper homeostasis. 
Understanding the molecular mechanism behind GLUT4 mobility is not yet defined. 
This study aims to investigate a potential role for EFR3 in GLUT4 dispersal at the PM.  
2.5.2 Identification of a potential molecular mechanism behind 
GLUT4 dispersal 
Genetic model organisms, such as S. cerevisiae, have long been a tool for identifying 
proteins of interest when understanding new molecular mechanisms (Botstein and 
Fink, 2011). It has been shown that GLUT4 trafficking has been demonstrated to be 
a conserved process from yeast S. cerevisiae to mammals (Lamb et al., 2010; Shewan 
et al., 2013). Studies have showed that mammalian GLUT4 expressed in S. cerevisiae 
traffic through the yeast Golgi in an ubiquitin dependent manner, this same process 
has been shown in adipocytes (Lamb et al., 2010).  
Yeast provides an ideal model organism as the simplest form of eukaryotic cell, with 
a haploid genetic makeup used in this screen. This along with fast growth makes 
yeast a valuable tool to gain insight into molecular interactions. To investigate 
potential interactions for GLUT4 a S. cerevisiae strain deficient in hexose 
transporters (Δhxt) was developed by Wieczorke et al., 2003. This is a temperature 
sensitive strain, in which hexose transporters are depleted at restrictive growth 
temperatures, above 30oC. This system was used to characterise the mammalian 
glucose transporters GLUT (Wieczorke et al., 2003). Mammalian GLUT4 expressed in 
the Δhxt strain is incapable of maintaining life when fed glucose at restrictive growth 
temperatures. Visualisation of GLUT4-GFP in this system shows intracellular 
localisation within structures resembling the endoplasmic reticulum or endosome 
like organelles similar to GSVs (Wieczorke et al., 2003).  
Reasoning that the expressed GLUT4 is unable to rescue the mutant and sustain life 
when fed glucose at restrictive temperatures due to this localisation within GSV like 
post Golgi compartments within the cell. Simply put no GLUT4 at the PM results in 
no glucose uptake and therefore cell death. A genetic screen was preformed using a 
suppressor model to generate mutations which have selective advantages to the 
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yeast and allow for survival of the cell. It is theorised any mutations which result in 
cell survival are involved in the delivery of GLUT4 to the PM. The Δhxt GLUT4 
expressing strain of yeast are incubated for prolonged periods on glucose medium 
after irradiation with UV-light to induce spontaneous genetic mutations. The 
suppressor colonies able to consume glucose as the sole carbon source were 
analysed. This screen revealed that the mutation double mutation fgy1-1 fgy4X 
rescues the phenotype allowing for GLUT4 mediated cell growth on glucose medium. 
The term FGY stands for functional expression of Glut4 in yeast (Wieczorke et al., 
2003). The mutation fgy1-1 is a recessive mutation of allele FGY1, which corresponds 
to the protein Efr3 (PHO Eighty Five Requiring) (Voss, 2005). Efr3 is a membrane 
localised protein required for the localisation of the PI kinase Stt4 complex to the 
PM (Baird et al., 2008). The mutation fgy4X is a recessive mutation of allele FGY4, 
which corresponds to the protein Erg4 (Dlugai, 2003). Erg4 is a sterol reductase 
involved in the final stage of ergosterol biosynthesis (H.Lai et al., 1994). The 
mutation within Efr3 and Erg4 required for GLUT4 arrival to the PM in yeast is not 
clear, as a gain or loss of function mutation. This study focuses on the behaviour of 
GLUT4 at the PM and how insulin mediates dispersal and increased motility of GLUT4 
at the PM. Therefore, the investigation is focused on Efr3; a membrane localised 
protein involved in membrane lipid regulation.  
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2.6 EFR3 
2.6.1 EFR3 biological function 
Efr3 in yeast S. cerevisiae and the homolog RBO in Drosophila have been shown to 
be essential genes (Faulkner et al., 1998; Baird et al., 2008; Vijayakrishnan et al., 
2010). Efr3 and its binding partners are conserved from yeast to mammals, with two 
EFR3 homologs, A & B, present in mammalian genome (Baird et al., 2008). In 
Drosophila RBO is a transmembrane PIP2-DAG pathway lipase, with lipase 
independent functions (F.-D. Huang et al., 2004; Huang, 2006; Vijayakrishnan et al., 
2010). Yeast and mammalian EFR3 have no lipase function domains, this has allowed 
for yeast to be a model organism for the discovery and initial study of Efr3 function 
(Vijayakrishnan et al., 2010). The mammalian homologs EFR3A and EFR3B have a 
64% amino acid sequence identity and 78% positive alignment. This indicates a 
homologous protein but scope for differences in molecular function. For simplicity 
EFR3 is used when discussing general mammalian protein features unless homolog is 
specified assume both are mentioned. 
2.6.2 EFR3 interacting proteins 
Homology from yeast to mammals has allowed for the study of proteins, which are 
associated with EFR3 to be carried out in a yeast model system. It has been shown 
that EFR3 is required for the localisation of Stt4 in yeast to the PM, and that EFR3 is 
the membrane associated portion of the Stt4 machinery (Baird et al., 2008; Wu et 
al., 2014). In yeast the lipid kinase Stt4, orthologue of mammalian 
phosphatidylinositol-4 kinases, has been shown to cluster in distinct PM patches 
enriched with Stt4 protein (Audhya and Emr, 2002; Baird et al., 2008). A genome 
wide protein interaction study found that Efr3 in yeast interacts with the protein 
Ypp1, orthologue of mammalian TTC7 (Tarassov et al., 2008). EFR3 binds to TTC7 
(Ypp1) which in turn binds with PI4KIIIa (Stt4). In yeast the two primary components, 
which have been identified as required for Stt4 (PI4KIIIα) localisation to the PM, are 
Ypp1 and Efr3, with Efr3 providing membrane localisation and Ypp1 providing linkage 
between PI4KIIIa and Efr3. 
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Studies using mouse brain extracts have showed that PI4KIIIα (Stt4) immuno-
precipitates two interacting proteins, EFR3B and TTC7B. These results correlate with 
the yeast results as both are the mammalian homologues of yeast EFR3 and Ypp1 
respectively (Nakatsu, Jeremy M. Baskin, et al., 2012). This confirmed that EFR3 
functions to localise PI4KIIIα/Stt4 to the membrane through intermediary linker 
proteins and that this is a conserved process from yeast to mammals. TTC7, the 
second component of this PI4-KIIIα localization machinery, is composed of HEAT-
repeat domains. The HEAT-repeat domains are arranged into a dumbbell shape of 
TTC7. Both the C-terminal component of EFR3 and TTC7 are required for protein-
protein interaction (Baird et al., 2008). In mammalian cells TTC7 has been shown to 
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Schematic shows PI4KIIIα (Stt4 in yeast) localisation to the PM mediated by EFR3. 
Palmitoylation of the N-terminus of EFR3 allows anchoring to the PM, EFR3 us 
hypothesised to localise to the PM through a conserved basic patch (yeast K12, 
R46, K49, and K52). PI4KIIIα is localised to EFR3 through intermediary proteins, 
this is crucial to membrane localisation of PI4KIIIα. Identified linker proteins 
include TTC7 (Ypp1 in yeast) and FAM126A. These both act as the intermediary 
linkers between both EFR3 and PI4KIIIα in mammalian cells, it is not defined if 
both are required or if they are found in different cell types. PI4KIIIα is a 230kDa 
PI kinase, which phosphorylates the inositol ring at position 4’ of 
phosphoinositide. PI4KIIIα activity is responsible for generation of distinct PI4P 
patches at the PM.    
Figure 10: Schematic of EFR3A and PI4KIIIα localisation to the membrane 
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not be the only linker protein involved as the intermediary interaction of PI4KIIIα to 
EFR3. The protein FAM126A has also been shown to also play a role in forming the 
PI4KIIIα complex at the PM with TTC7 (Baskin et al., 2016). A other protein which 
can localise PI4KIIIα to the PM is TMEM150A, which is able to localise PI4KIIIα 
independent of TTC7 (Chung et al., 2015). TMEM150A is a transmembrane protein 
which interacts with both EFR3 and PI4KIIIα, however it does not bypass the role of 
EFR3 (Chung et al., 2015). Figure 10 depicts the localisation of PI4KIIIα through TTC7 
and FAM126A association to EFR3. 
 
2.6.3 EFR3 structural insights  
In mammalian cells EFR3 mediates the localisation of PI4KIIIα to the PM. The N-
terminal palmitoylation of EFR3 is required for membrane association in mammalian 
cells (Wu et al., 2014). It is hypothesized that a conserved basic patch, from yeast 
to mammals, at the N-terminus (yeast K12, R46, K49, and K52) is further able to 
localize EFR3 to the PM specifically. This patch is shown in Figure 11, denoted by 
magenta residues and arrows to highlight. The conserved basic patch is the primary 
source of membrane localisation in yeast which do not have palmitoylation post 
translational modification (Wu et al., 2014). The conserved basic patch is 
hypothesised to direct localisation to the PM as a consequence of electrostatic 
interactions between the negatively charged inner leaflet of the lipid bilayer 
associated with the PM in the absence of palmitoylation modifications. 
Architecturally EFR3 has a disordered C-terminal and ordered N-terminus domain. 
The results from x-ray crystallography are only viable when the disordered C-
terminal domain is disregarded; the ordered N terminal structure is shown in Figure 
11. Therefore the x-ray crystallography results carried out by (Wu et al., 2014) are 
of the N8–562 region. The mapping of the N terminal reveals an entirely α-helical 
secondary structure. The EFR3 N-terminus represents a ~120 Å long rod, composed 
of VHS, ARM and HEAT repeat domains (Wu et al., 2014). Combined EFR3, TTC7 and 
other proteins may form a rigid scaffold for PI4KIIIα to catalyse PI4P production at 
the PM, seen in Figure 10 (Nakatsu, Jeremy M Baskin, et al., 2012; Wu et al., 2014; 
Chung et al., 2015). The interaction between EFR3 and TTC7 is required for 
membrane localisation of PI4KIIIα (Baird et al., 2008; Wu et al., 2014). This 
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interaction between the EFR3 and Ypp1 is localised to the C-terminal (651-782) 
region of EFR3. Using database searches of EFR3 we know that this C-terminal region 
has over 20 predicted phosphorylation sites, four of which are highly conserved, 
S681, S684, T687, and T690 (http://www.phosphogrid.org). Double phospho-
mimetic mutations of the S and T sites respectively resulted in a weakened binding 
between EFR3 and Ypp1 (Wu et al., 2014).  Furthermore, full phospho-mimetic 
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mutations of all four sites results in a 10% reduction in PI4P levels and a significant 
portion of PI4KIIIα is re-localised to the cytosol. 
 
2.6.3.1 Phosphatidylinositol 4 Kinase IIIα activity 
There are two subsets of the PI4-kinase family, type II and type III, which have been 
characterised based on molecular weight and inhibitor sensitivity (Nakagawa et al., 
N-terminal 
Efr3N 8-562 
Disordered loop 217-232 
C-Terminal tail 563-782 
Figure 11: Structure of Efr3 
X-ray crystallography solved structure of yeast Efr3 N-terminal from Wu et al., 
2015. Helical repeats from N-terminal (8-562) sequence form a structured rod. 
The disordered loop (217-232) structure was not solved. The C-terminal tail (563-
782) is responsible for PI4KIIIα localisation to the PM. Denoted by grey arrows and 
marked in magenta spheres is the conserved basic patch (K12, R46, K49, and K52) 
responsible for PM localisation of Efr3. 
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1996; Barylko et al., 2001; Minogue et al., 2001; Balla et al., 2002). PI4K type III are 
sensitive to wortmannin, and within the PI4K family there is the large molecular 
weight (230kDa) and phenylarsine oxide (PAO) sensitive isoform PI4-kinase IIIα 
(Nakagawa et al., 1996).  PI4K type III are conserved from yeast to humans (Barylko 
et al., 2001).  Stt4 is the yeast orthologue for PI4KIIIα and in yeast Stt4 accounts for 
the production of 40% of the total cellular PI4P in yeast (Strahl and Thorner, 2007). 
Stt4 localises to the PM, and the loss of Stt4 function results in defective yeast cell 
walls, defective polarisation during growth, and abnormal cytoskeleton (Audhya and 
Emr, 2002; Strahl and Thorner, 2007). In yeast loss of Stt4 phenotypes can be rescued 
with the expression of yeast PI5K Mss4. The double Stt4/Mss4 mutation results in 
actin cytoskeletal miss-organisation phenotype which is rescued when the PI4P 
phosphatase Sac1 is inactivated (Foti et al., 2001). Together this information shows 
that Stt4 activity in yeast is important for cytoskeletal function and that PI4P 
production is an important precursor for PI4,5P2 in yeast. The bulk of PI4,5P2 at the 
PM in yeast is dependent on Stt4 activity, and the production of PI4P as a precursor. 
In mammalian cells PI4P has established further roles than PI4,5P2 precursor, which 
is discussed below in 2.7.2.1 (Strahl and Thorner, 2007).  
2.6.3.2 PI4KIIIα localisation 
The initial localisation of PI4KIIIα was reported to be in the endoplasmic reticulum 
and perinuclear compartments (Wong et al., 1997). However PM localisation had 
also been suggested due to its importance for PI4P production at the PM specifically 
(Balla et al., 2002). Later studies using GFP tagged PI4KIIα showed that PI4KIIIα is 
cytosolically localised with no particular membrane localisation. This study found 
that PI4KIIIα is dynamically targeted to the PM through the complex formed with 
EFR3, as explained above in 2.6.2 (Nakatsu, Jeremy M Baskin, et al., 2012). IN 
PI4KIIIα knock-out MEFs the levels of PI4,5P2 are reduced by 20%, a relatively modest 
change in comparison to the 75% loss of PI4P in these cells (Nakatsu, Jeremy M 
Baskin, et al., 2012). Localisation of PI4P in PI4KIIIα KO MEFs showed that the PM 
pool was ablated, and the Golgi complex was unaffected with PI4P localising to the 
Golgi still. PI4KIIIα KO MEFs have reduced PM cholesterol and increased total 
cholesterol. The loss of PI4KIIIα resulted in a loss of plasma membrane identity and 
miss-localisation of PM associated integral membrane proteins such as M1 muscarinic 
receptor and myristoylated/palmitoylated Lck membrane anchor were found to be 
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localised intracellularly (Nakatsu, Jeremy M Baskin, et al., 2012). Taken together 
this provides a wealth of evidence that PI4KIIIα activity is important for the function 
of the PM in mammalian cells and established the PM localisation.  
2.6.3.3 PI4KIIIα and EFR3; a link to Hepatitis C virus 
Approximately 3% of the world’s population is chronically infected with Hepatitis C 
virus HCV, due to limited therapeutic options (Wasley and J., 2000). HCV is a positive 
stranded RNA virus, and as such in order for HCV to replicate the host cellular 
membranes must be reorganised to establish suitable sites for replication (Miller and 
Krijnse-Locker, 2008). The initial HCV protein synthesis occurs at the rough 
endoplasmic reticulum, and HCV viral replication is achieved with modified cellular 
membranes which have protease and nuclease resistant properties, to protect viral 
replication from cellular defences (Yang et al., 2004; Quinkert et al., 2005). As 
membrane re-assortment is integral to HCV replication the identification of 
membrane trafficking associated genes involved during HCV infection was studied. 
A membrane trafficking gene siRNA library was utilised to identify genes involved in 
HCV replication. The identified genes included; actin proteins (CDC42 & ROCK2), 
GTPase (RAB7L1), endosomal proteins (EEA1 & RAB5A), and PI-kinases (PIK3C2G & 
PIK4CA). The gene PIK4CA corresponds to the protein PI4KIIIα, PI4KIIIα has been 
shown to significantly co-localise with dsRNA and the HCV viral protein NS5A (Berger 
et al., 2009). The expression and activity of PI4KIIIα is required for HCV replicase 
formation (Berger et al., 2009, 2011). The effect of HCV infection on total cell PI4P 
production was measured using mass spectrometry, this showed that infection 
increases the level of PI4P but not the expression levels of PI4KIIIα in cells in 
comparison to control cells (Berger et al., 2011). The phosphoprotein NS5A has been 
described to co-localise using with PI4KIIIα using confocal microscopy (Berger et al., 
2009). NS5A is a critical component of HCV host factor interactions during the 
regulation of viral replication (Bartenschlager et al., 2010). This resulted in the 
relationship of endogenous PI4KIIIα enzymatic activity and HCV replication (Harak et 
al., 2014). PI4KIIIα directly interacts with NS5a in co-immunoprecipitation 
experiments. Mapping the site of interaction serial deletions at the N and C terminals 
of PI4KIIIα showed that multiple interaction sights are available for PI4KIIIα 
interaction, as no single deletion resulted in inhibition of PI4KIIIα and NS5A protein 
interaction. PI4KIIIα activity during HCV viral replication is not dependent on the N-
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terminus Δ1-1101 amino acids and function of PI4KIIIα is not compromised by major 
N-terminus deletions (Harak et al., 2014). Of further interest is the ability of HCV 
to hijack PI4KIIIα localisation, as well as PI4KIIIα has been identified as a co-factor 
for viral replication (Borawski et al., 2009; Berger et al., 2011; Reiss et al., 2011; 
Altan-Bonnet and Balla, 2012). In cells infected with HCV PI4KIIIα is miss-localised 
away from the PM and instead found in endoplasmic-reticulum-associated HCV 
replication compartment (Reiss et al., 2011). PI4KIIIα catalytic activity is believed 
to be an essential host factor during HCV replication.  
This is interesting as many epidemiological studies have linked the development of 
T2D and those suffering from chronic HCV infections (Antonelli, 2014). This 
investigation revealed an increased correlation between patients suffering from 
chronic HCV and the development of T2D. Therefore, if EFR3 and its role for PI4KIIIα 
localisation is important for GLUT4 and glucose uptake this could provide the 
causative link between the correlation of these two chronic illnesses. 
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2.7 PHOSPHATIDYLINOSITOL 4 PHOSPHATE 
2.7.1 Phosphatidylinositol  
The compartmentalisation of eukaryotic cells allows for specialisation zones within 
the cell to preform functions efficiently. Coordination within these organelles relies 
on a variety of signalling methods, including the phospholipid identity of the 
membrane (Tan and Brill, 2014). The phosphatidylinositol (PI) lipid is a member of 
the glycerphospholipid family containing a myo-inositol head group. The PI family is 
a minor fraction of total lipid composition with far reaching capabilities; from signal 
transduction to membrane identity and trafficking of vesicles to specific regions 
(Mueller-Roeber and Pical, 2002; Balla and Balla, 2006; Altan-Bonnet and Balla, 
2012). PI is able to exert this regulatory function due to the large variability of 
phosphorylation of the hydroxyl groups at 3’,4’ & 5’ position of the inositide ring, 
shown in Figure 12, providing convertible signals to the cell (Tan and Brill, 2014; 
Bryant et al., 2015). This allows for diverse range of identities, and modification 
intermediaries which have differing degrees of negative charge as a result. These 
phosphoinositide’s are able to contribute to wide varying physiological mechanisms 
within the cell including; vesicle trafficking, transmembrane signalling and ion 
channel regulation (De Camilli et al., 1996; Di Paolo and De Camilli, 2006; Balla et 
al., 2009; Kim et al., 2013; Billcliff and Lowe, 2014). Localisation to specific 
membranes within the cell is a key identifier that PI identity plays an important role 
within membrane trafficking. The distribution of PI at intracellular membranes can 
be seen in Figure 13. Early evidence showed that the regulation of vesicular 
trafficking by PI composition involved PI4,5P2 synthesis during exocytic vesicle 
priming (Eberhard et al., 1990). The breakdown of PI4,5P2 by phosphoinositide 
specific phospholipase C into the signalling molecules diacylglycerol (DAG) and the 
soluble inositol 1,4,5 tri-phosphate (IP3) has long been studied for its ubiquitous role 
within cell Ca2+ signalling (Berridge, 1983; Streb et al., 1983; Thévenod et al., 1986). 
With this in mind PI4P was long been associated as a precursor for the production of 
PI4,5P2 with few roles attributed to PI4P, however P14P has since been shown to be 
involved in a variety of mechanisms (D’Angelo et al., 2008).  
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2.7.2 Roles for Phosphatidylinositol groups during insulin signalling 
Mentioned above is the insulin signalling pathway, where a key part of the pathway 
is activation of PI3K and formation of PI3,4,5P3. Roles for other PIs during insulin 
stimulated GLUT4 dynamics have been identified. HPLC analysis suggests a transient 
increase in PI3P in response to insulin stimulation and that PI3P generation is 
believed to occur at the PM, as part of a lipid raft recruitment of PI3K-C2α (Maffucci 
et al., 2003; Falasca et al., 2007). Over expression of the PI 3-phosphatase 
myotubularin and depletion of PI3K-C2α result in reduced insulin stimulated glucose 
uptake independently. This is suggestive that lowering of PI3P levels affects insulin 
stimulated GLUT4 mediated glucose uptake (Chaussade et al., 2003; Falasca et al., 
2007). Using over expression of polyphosphate 5-phosphatse to increase PI3P levels 
at the PM results in an increase in PM GLUT4, however there is no increase in glucose 
PI(3)P 
PI 
PI(4P) 
PI(3,4)P2 
PI(3,5)P2 
PI(3,4,5) P3 
PI(4,5) P2 
PI(5)P 
DAG + I(1,4,5)P3 
Phosphatase 
Kinase 
(A) The cytosolic phosphatidylinositol (PI) myo-inositol head group, phospho-
available sights at the ring position 3’, 4’, and 5’. (B) Depiction of the PI 
phosphorylation cycle, with kinase pathway in black and phosphatase pathways in 
blue. This represents the complex and variety of regulatory pathways involved in 
phosphoinositide identity. Kinase and phosphatase regulation allow for the PI family 
to actively participate in many signalling.  
 
(A) (B) 
Figure 12 Schematic of Phosphatidylinositol cycle. 
58 
uptake as a result (Kong et al., 2006). This suggests a role for PI3P during GLUT4 
delivery to or near the PM, and a secondary mechanism is required for the full effect 
of GLUT4 mediated glucose uptake.  
PI3,5P2 is a minor constituent of the PI population (>0.2%) in adipocytes (Sbrissa and 
Shisheva, 2005). Varying results have been published in relation to PI3,5P2 levels in 
response to insulin signalling, with reports of increases in intracellular PI3,5P2 and 
no increase measured in total PI3,5P2 (Sbrissa and Shisheva, 2005; Ikonomov et al., 
2007). PI3,5P2 has been linked to the formation of secretory vesicles specifically 
during the fission and maturation process. In HeLa cells PI3,5P2 production has been 
identified to be important for trafficking out of the endocytic cycle to the TGN 
(Rutherford et al., 2006; Sbrissa et al., 2007). In contrast PI5P, which is usually 
undetectable in most cell types, represents <3% of the PI population in adipocytes 
and increases 2.5 fold in response to insulin stimulation (Sbrissa et al., 2002, 2004). 
PI5P production correlates with the F-actin stress fibre break down during insulin 
signalling, and this break down is controlled by PI5P production (Sbrissa et al., 2004). 
This increase in PI5P is thought to be linked to the kinase PIKfyve. In response to 
insulin signalling PIKfyve translocate to intracellular compartments from the cytosol, 
which plausibly accounts for the increase in PI5P (Shisheva et al., 2001). It is 
important to note that PIKfyve is important for PI3,5P2 production and is up 
regulated during the differentiation of 3T3-L1 fibroblasts to adipocytes (Sbrissa et 
al., 2002; Ikonomov et al., 2007). Delivery of PI5P to adipocytes through cytoplasmic 
microinjections results in increased PM GLUT4 in an insulin independent manner. 
Introduction of exogenous PI3,5P2 does not increase PM GLUT4. When PI5P is 
sequestered, therefore enabling binding, the insulin stimulated translocation of 
GLUT4 to the PM is inhibited (Sbrissa et al., 2004). In myotubes delivery of exogenous 
PI5P results in increased Akt phosphorylation and GLUT4 translocation to the PM is 
triggered in a PI3K dependent fashion, suggesting PI5P production in response to 
insulin signalling may promote PI3K signalling (Grainger et al., 2011). This points to 
a role in exocytosis for these PIs in the exocytosis phase of GLUT4 stimulation by 
insulin.  
In contrast to the above PIs PI4,5P2 is an abundant fraction in mammalian cells, 
including muscle and adipocytes. PI4,5P2 is established to have roles within 
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endocytosis and regulated secretion (Di Paolo and De Camilli, 2006).  Specifically 
PI4,5P2 is found at the PM, enriched in certain regions which co-localise with 
endocytic machinery, such as clathrin heavy chains (S. Huang et al., 2004). Inhibition 
of PI4,5P2 arrests clathrin mediated endocytosis in 3T3-L1 adipocytes, independent 
of F-actin inhibition (Kanzaki et al., 2004; S. Huang et al., 2004). Inhibition of PI4,5P2 
binding through sequestering with PLCδ1-PH expression inhibits TfR endocytosis post 
insulin stimulation  (S. Huang et al., 2004). PI5K over expression increases the 
production of PI4,5P2, in adipocytes this results in the inhibition of both TfR and 
GLUT4 endocytosis (Kanzaki et al., 2004). This result is counter intuitive to previous 
findings. PI4,5P2 action during endocytosis is believed to be through clathrin 
mediated endocytosis. The over production of PI4,5P2 may have an effect on the 
established requirement for PI4,5P2 hydrolysis early on during clathrin mediated 
endocytosis. This over production may result in hindering the formation of 
invagination (Czech, 2003; Di Paolo and De Camilli, 2006).  
2.7.2.1 Phosphatidylinositol 4 Phosphate 
PI4P is an abundant member of the PI family. Early characterisation of GLUT4 
containing vesicles isolated from both muscle and adipose tissue rat simples included 
abundant insulin-independent PI4P synthesising activity, however no PI4K has been 
definitively linked to this activity (Del Vecchio and Pilch, 1991; Kristiansen et al., 
1998). The injection of exogenous PI4P into adipocytes does not increase GLUT4 
delivery to the PM as others PI populations are capable of, as discussed above 
(Sbrissa et al., 2004).  
With this in mind PI4P was long been associated as a precursor for the production of 
PI4,5P2 with few roles attributed to PI4P at the PM. However, PI4P has since been 
shown to be involved in a variety of mechanisms intracellularly and to have a distinct 
presence at the PM other than precursor lipid (D’Angelo et al., 2008; Hammond et 
al., 2012; Billcliff and Lowe, 2014). PI4P is generated from PI by members of the PI 
4-kinase family, or as a result of INPPE5 phosphatase activity on PI4,5P2 (Behar-
Bannelier and Murray, 1980; Collins and Wells, 1982; Hammond et al., 2012). Many 
of the PI4P associated protein effectors are lipid transfer proteins and vesicle coat 
proteins (Levine and Munro, 1998; Wang et al., 2003). PI4P has been demonstrated 
to have involvement in cargo sorting and bud formation, in particular within the 
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trans-Golgi network (TGN), this function of PI4P is conserved within yeast to 
mammalian cells (Heldwein et al., 2004; Wang et al., 2007; Ren et al., 2013). As 
further supported by the fact that many TGN sorting proteins have PI4P binding 
motifs, an example of which being the EpsinR protein (Hirst et al., 2003). EpsinR 
binds PI4P via its ENTH domain allowing for the assembly of adaptor protein 1 and 
soluble n-ethylmaleimide sensitive factor adaptor protein receptor into clathrin 
coated vesicles (Hirst et al., 2004).  
PI4P is abundant in the Golgi apparatus and a significant pool is present on the inner 
leaflet of the PM, shown in Figure 13(Nakatsu, Jeremy M Baskin, et al., 2012; 
Hammond et al., 2014). Due to the known high level of PI4K activity in GSVs it is 
conceivable that GSVs are enriched with PI4P. This further goes in hand with the 
fact that GLUT4 is trafficked through the PI4P enriched TGN during the formation of 
GSVs (Shewan et al., 2003; Bryant and Gould, 2011; Rowland et al., 2011). The 
intracellular trafficking from TGN to the PM has been demonstrated to require PI4K 
activity and PI4P for successful direction to the PM in yeast (Thomas and Fromme, 
2016). The improved and evolving understanding of the lipid bilayer reveal that 
dynamics of the membrane can be tightly regulated and associated with the lipid 
identity (Kusumi et al., 2005). It is therefore plausible that the delivery of GLUT4 
clusters to the PM may be regulated by the lipid identity of either the GSVs or the 
PM at the regions of GSV fusion.  
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Phosphoinositide groups enriched at various intracellular membranes.  PI4P is 
shown in blue and can be seen predominantly associated with recycling 
endosomes, the trans-Golgi network and distinct pools have been shown to exist 
at the PM. The importance of PI4P pools at the plasma membrane a thought to 
play a critical role in the trafficking process to and from the PM. The flow of 
various PI populations can also be seen in this image taken from (Billcliff and 
Lowe, 2014). 
Figure 13: Schematic of phosphoinositide (PI) membrane identity. 
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2.8 AIMS AND HYPOTHESIS 
This investigation aims to address the evolving understanding of the mechanism 
behind the insulin response of GLUT4 within adipocytes, with focus on the dynamics 
of GLUT4 at the PM. EFR3 has been identified as potential mechanism of control for 
GLUT4 arrival to the PM. EFR3 is of noteworthy interest due to the established role 
of EFR3 as a membrane localisation protein for the lipid kinase PI4KIIIα. PI4P is 
enriched in GSVs, and isolated GSVs have increased PI4P synthesising activity. EFR3 
and PI4P are membrane components with the potential to regulate GLUT4 at the 
PM. The molecular method behind the dispersal of GLUT4 at the PM is as of yet not 
understood. We believe that EFR3 and associated machinery proteins are involved 
during the insulin dependent dispersal of GLUT4 at the PM, a schematic of our 
working hypothesis is shown in Figure 14. The ability of EFR3 to regulate this system 
is hypothesised to be a result of the pools of PI4P produced by PI4KIIIα. A yeast 
genetic screen identified a mutant allele of Efr3 was required for PM GLUT4 in yeast, 
the literature doesn’t indicate a loss or gain of function mutation. As EFR3 has been 
demonstrated to regulate PI4P levels through the interaction with PI4KIIIα. PI4KIIIα 
is responsible for the formation of PI4P populations at the PM. The formation of PI4P 
PM pools are theorised to be capable of maintaining the cluster of GLUT4 once fused 
at the PM. We hypothesis that the presence of PI4P at the PM is a corralling regulator 
for GLUT4 arrival at the PM, this would indicate that the fgy1-1 mutant allele of Efr3 
is a loss of function as loss of corralling effect of PI4P would allow for GLUT4 
increased mobility and dispersal. Insulin stimulation results in GLUT4 dispersal 
across the PM, and therefore our hypothesis is that insulin stimulation inhibits PI4P 
production at the PM. The aim of this thesis is to investigate a role of the protein 
EFR3 and the regulation of PI4P levels at the PM during insulin dependent GLUT4 
dispersal. We aim to test this hypothesis through a variety of microscopy and 
biochemical techniques.  
This project aims to characterise EFR3 in adipose model cell line 3T3-L1 adipocytes. 
This aim will aid the understanding of EFR3 in an insulin sensitive system. 
Characterisation of PI4P in an insulin sensitive model system is carried out as a 
product of the EFR3 regulated enzyme PI4KIIIα. This thesis aims to understand the 
effect insulin has on PI4P, and if PI4P has a regulatory role during the dispersal of 
63 
GLUT4 at the PM. Finally this thesis aims to demonstrate a regulatory role for EFR3 
machinery during insulin stimulated GLUT4 dispersal at the PM in 3T3-L1 adipocytes.  
Figure 14: Schematic of proposed molecular mechanism for EFR3 and PI4P 
during GLUT4 response to insulin at the plasma membrane. 
This is a representation of the hypothesis of this investigation. A proposed role 
for EFR3 and PI4P during the insulin response of GLUT4 at the plasma membrane 
(PM) is to act in the basal cell when GLUT4 is confined within dynamic clusters 
at the PM. It is hypothesised that the population of PI4P generated at the PM 
inner leaflet by PI4KIIIα is responsible for aiding the confinement of GLUT4 
clusters upon delivery to the PM via GSVs. Upon insulin stimulation the 
maintenance of PI4P at the PM is disturbed. Disruption of the PI4P patches 
results in the dispersal of GLUT4 at the PM. This hypothesis is proposed based 
on the assumption that the fgy1-1 mutant allele of Efr3 is a loss of function 
mutation.    
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3 MATERIALS AND METHODS 
3.1 GENERAL REAGENTS AND ENZYMES 
Applied Biosystems 
Power SYBR® green PCR master mix (#4367659) 
dNTP Mix (#4367381) 
10 x RTP buffer (#4368813) 
25 mM MgCl2 (#4368813) 
RNAase Inhibitor 20 U/µL (#4368813) 
Multiscribe 50 U/µL (#4368813) 
Random Hexamers 50 µM (TO3166) 
 
BD Biosciences, Oxford UK  
Syringes  
24 Gauge needles  
26 ⅝ Gauge needles  
 
BioRad Labatories Ltd, Hemel Hemstead, Hampshire, UK  
Precision Plus Protein™ All Blue Standards (#161-0373)  
Gene Pulser®/MicroPulser™ Electroporation Cuvettes, 0.2 cm gap (#1652086) 
 
Clontech, France  
TakaRa, Lenti-XTM GoStixTM (#631243) 
 
Fisher Scientific UK Ltd., Loughborough, Leicestershire, UK  
2-[4-(2-hydroxyethyl)-1-piperazine] ethanesuphonic acid (HEPES)  
3mm filter paper  
Ethanol  
Glycine  
ImmunoMount  
L-Glucose  
Pierce™ Micro BCA™ Protein Assay Kit  
Tris(hydroxymethyl)aminoethane Base (Tris Base)  
 
Formedium Ltd., Hunstanton, Norfolk, UK  
Bacterial agar  
Yeast extract powder  
 
GE Healthcare BioSciences Ltd, Chalfont, Buckinghamshire, UK  
Protein A Sepharose Fast-Flow 
  
Melford Laboratories Ltd., Chelsworth, Ipswich, UK  
Dithiothreitol (DTT)  
 
New England Bioscience (UK) Ltd., Hitchin, Hertfordshire, UK  
All endonucleases used in this study  
1 kb DNA ladder  
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100 bp DNA ladder  
6x DNA loading buffer Chapter 2 56  
Shrimp Alkaline Phosphatase (rSAP) 
CutSmart® Buffer (10X) 
 
Life Technologies, Paisley, UK  
Dulbecco’s Modified Eagle Medium (DMEM),  
Foetal Bovine Serum (FBS)  
Gateway® LR Clonase® II enzyme mix  
Lipofectamine® 2000 transfection reagent  
Newborn Calf Serum (NCS)  
One Shot Chemically Competent TOP10 E. coli  
One Shot® Stbl3™ Chemically Competent E. coli  
Opti-MEM®  
Penicillin-Streptomycin (10,000 U/mL)  
SYBR ® Safe DNA Gel Stain  
Trypsin-EDTA (0.05%), phenol red  
 
Pall Life Sciences, Portsmouth, UK  
Nitrocellulose transfer membrane, 0.2 µM pore size  
 
Promega, Southampton, UK  
Wizard® Plus SV Minipreps DNA Purification System  
 
Qiagen Ltd., Crawley, West Sussex, UK  
QIAfilter™ Plasmid Maxi Kit  
QIAquick Gel Extraction Kit  
miRNAeasy Mini Kit 
 
Roche Diagnostic Ltd., Burgess Hill, UK  
Agarose MP  
Complete™ Protease Inhibitor Cocktail Tablets  
Complete™ EDTA-free Protease Inhibitor Cocktail Tablets  
 
Severn Biotech Ltd., Kidderminster, Worcestershire, UK  
30 % Acrylamide [Acrylamide: Bis-acrylamide ratio 37.5:1]  
 
Sigma-Aldrich Ltd., Gillingham, Dorset, UK  
Ammonium acetate  
Ammonium persulphate (APS)  
Ampicillin  
β-mercaptoethanol  
Bovine serum albumin (BSA)  
Brilliant Blue-R  
Bromophenol blue  
Dimethyl suphoxide (DMSO)  
Dexamethasone  
Ethylenediaminetetracetic acid (EDTA)  
Gelatine from cold water fish skin  
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Goat serum  
L-Glutathione reduced  
Glycerol  
G418 disulphate salt Chapter 2 57  
3-isobutylmethylxanthine (IBMX)  
Isopropanol  
Kanamycin  
Methanol  
N’-Tetramethylethylenediamine (TEMED)  
Paraformaldehyde  
Ponceau S  
Porcine insulin  
Potassium hydroxide (KOH)  
Reduced glutathione  
Sodium fluoride (NaF)  
Sodium hydrogen carbonate (NaHCO3)  
Sodium dihydrogen phosphate (NaH2PO4)  
Sodium orthovanadate (Na4VO3)  
Sodium dodecyl sulphate (SDS)  
Thrombin (Bovine)  
Triton-X100  
Troglitazone  
Tween -20  
 
Spectrum Europe BV., Breda, The Netherlands  
Float-a-lyzer, 5 mL 5 kDa MWCO  
Float-a-lyzer, 5 mL 20 kDa MWCO  
 
System Biosciences (SBI)  
Lentiviral expression plasmid pCDH-CMV-MCS-EF1-puro 
Lentivirus packaging kit pPACKH1™  
 
TaKaRa  
10-minute Lentiviral Titer Test – Lenti-X™ GoStix™  
 
VWR International Ltd., Lutterworth, Leicestershire, UK  
Glacial Acetic Acid  
Glass cover slips (3mm diameter)  
Disodium hydrogen orthophosphate (Na2HPO4)  
Potassium Acetate  
Potassium Chloride (KCl)  
Potassium dihydrogen orthophosphate (KH2PO4)  
Sodium Chloride (NaCl)  
Sodium Hydroxide (NaOH) 
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3.2 SOLUTIONS  
 
2x LaemmLi Sample Buffer (LSB)  100mM Tris, HCl pH 6.8, 4% (w/v) SDS, 
20% (v/v) glycerol, 0.2% (w/v) 
bromophenol blue, 10% (v/v) β-
mercaptoethanol  
2YT  1.6% (w/v) tryptone, 1.0% (w/v) yeast 
extract, 0.5% (w/v) NaCl (20% Agar)  
Coomassie  0.05% (w/v) Coomassie brilliant blue R-
250, 50% (v/v) methanol, 10% (v/v) acetic 
acid  
Coomassie Destain  15% (v/v) methanol, 15% (v/v) acetic acid  
ECL solution 1  100mM Tris-HCl, pH 8.5, 2.25mM luminol 
in 2% (v/v) DMSO, 0.4 mM ρ-coumaric 
acid in 1% (v/v) DMSO  
 
ECL solution 2  100mM Tris-HCl, pH 8.5, 0.018% (v/v) 
H2O2  
HEPES/EDTA/Sucrose (HES) buffer  250 mM Sucrose, 20 mM HEPES pH 7.4, 1 
mM EDTA  
immunoprecipitation (IP) buffer  50 mM HEPES pH 7.5, 5 mM EDTA, 10 mM 
sodium pyrophosphate, 10 mM NaF, 150 
mM NaCl, 2 mM β-Glycerophosphate, 1 
mM DTT  
Immunofluorescence (IF) buffer 1X PBS, 0.5% (w/v) fish gelatin, 0.1% (v/v) 
donkey serum 
PBS  140mM NaCl 3mM KCl, 1.5mM KH2HPO4, 
8mM Na2HPO4  
PBST  140mM NaCl 3mM KCl, 1.5mM KH2HPO4, 
8mM Na2HPO4, 0.1% (v/v) Tween-20  
Ponceau S  0.2% (w/v) Ponceau S, 1% (v/v) acetic acid  
RIPA Buffer  50mM Tris, HCl pH8, 150mM NaCl, 2mM 
MgCl2, 1% Triton, 0.5% sodium 
deoxycholate (w/v), 0.1% (w/v) SDS, 1mM 
DTT, 50 units/mL Benzonase  
SDS-PAGE running buffer  25mM Tris, 190mM glycine, 0.1% (w/v) 
SDS  
SDS-PAGE transfer buffer  25 mM Tris-HCl, 192 mM glycine, 20% (v/v) 
methanol  
SDS-PAGE transfer buffer (semi-dry)  50 mM Tris base, 40 mM glycine, 0.1% 
(w/v) SDS, 10% (v/v) methanol  
SOC  2% tryptone, 0.5% yeast extract, 10 mM 
NaCl, 2.5 mM KCl, 10 mM MgCl2, 10 mM 
MgSO4, and 20 mM glucose  
TAE buffer  40mM Tris, 1mM EDTA  
20 mM Acetic Acid 
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TBST  20 mM Tris-HCl, pH 7.5, 137 mM NaCl, 
0.1% (v/v) Tween-20  
TE buffer  1 M Tris pH 8.0, 100 mM EDTA  
TST  50mM Tris HCl pH7.6, 150mM NaCl, 0.05% 
(v/v) Tween-20  
Yeast lysate binding buffer  40mM HEPES pH7.4 KOH, 150mM KCl, 
1mM DTT, 1 mM EDTA 0.5% Triton X 100  
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3.2.1 Primary Antibodies 
 
Antigen Working Dilution Description Source 
GLUT4 IB: 1:1000 Rabbit, polyclonal Synaptic Systems 
(235 003) 
HA IF: 1:3000 
 
Mouse, 
monoclonal 
 
Covance Research 
Products (MMS 
101P) 
HA FACS: 1:100 Rat monoclonal Roche applied 
sciences (11 867 
423 001) 
GAPDH IB : 1:10000 Mouse, 
monoclonal 
Applied Biosystems 
(AM4300) 
EFR3A IB : 1:250 Rabbit, polyclonal Sigma-Aldrich 
(HPA023092) 
PI4KIIIα IB : 1:250 Rabbit, polyclonal Abcam   
(ab111565) 
PDI IB : 1:5000 Rabbit, polyclonal Cell Signalling 
(2446S) 
TfR IB : 1:1000 Mouse, 
monoclonal 
Life Technologies 
(13 6800) 
Sx4 IB : 1:1000 Rabbit, polyclonal Synaptic Systems 
(110 042) 
Β-tubulin IF : 1:500  Rabbit Polyclonal Cell Signalling 
(2146) 
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3.2.2 Secondary Antibodies 
 
Antigen Working Dilution Description Source 
Donkey anti 
Rabbit 680 
IB : 1:10000 Donkey, infrared 
dye-labelled 
secondary 
antibodies against 
rabbit IgG  
LI-COR Biosciences  
(925 68023) 
Goat anti Mouse 
680 
IF : 1:10000 Goat, infrared dye-
labelled secondary 
antibodies against 
mouse IgG 
LI-COR Biosciences  
(925 68070) 
Goat anti Mouse 
800 
IF : 1:10000 Goat, infrared dye-
labelled secondary 
antibodies against 
mouse IgG 
LI-COR Biosciences  
(926 32210) 
Anti-Rat 
AlexaFluor® 647 
FACS : 1:300  Goat, infrared dye-
labelled against rat 
IgG 
LI-COR Biosciences  
(A-21247) 
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3.2.3 Plasmids 
 
Plasmid Description Source 
GFP-P4M-SidM CMV promoter, 
Neomycin/Kanamycin 
Resistance, expressing  
Addgene (51469) 
mCherry-P4M-SidM CMV promoter, 
Neomycin/Kanamycin 
Resistance 
Addgene (51471) 
PH-PLCδ1-GFP CMV promoter, 
Neomycin/Kanamycin 
Resistance 
Addgene (51407) 
EFR3A-mcherry CMV promoter, 
Neomycin/Kanamycin 
Resistance, expressing EFR3A 
tagged with mCherry at the 
C-terminal 
Construct provided by 
Pietro De Camilli 
EFR3B-mcherry CMV promoter, 
Neomycin/Kanamycin 
Resistance, expressing EFR3B 
tagged with mCherry at the 
C-terminal 
Construct provided by 
Pietro De Camilli 
EFR3A(C6-9S)-
tdtomato 
CMV promoter, 
Neomycin/Kanamycin 
Resistance, expressing EFR3A 
tagged with tdtomato at the 
C-terminal with mutation of 
palmitoylation sites C6-9 to 
S6-9 (C6-9S).  
Construct provided by 
Pietro De Camilli 
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LYN11-FRB-CFP CMV promoter, 
Neomycin/Kanamycin 
Resistance, expressing the PM 
anchor LYN11 linked with 
FKBP rapamycin binding (FRB) 
protein tagged with CFP 
Addgene (38003) 
mRFP-FKBP-
Pseudojanin 
CMV promoter, 
Neomycin/Kanamycin 
Resistance, 
Addgene (37999) 
mRFP-FKBP-PJ-Sac CMV promoter, 
Neomycin/Kanamycin 
Resistance, 
Addgene (38000) 
mRFP-FKBP-PJ-INPPE5 CMV promoter, 
Neomycin/Kanamycin 
Resistance, 
Addgene (38001) 
mRFP-FKBP-PJ-Dead CMV promoter, 
Neomycin/Kanamycin 
Resistance, 
Addgene (38002) 
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3.3 MOLECULAR METHODS 
3.3.1 Transformation of plasmid into bacterial cells 
Competent XL1-blue bacterial cells were thawed on ice. 1 µL of plasmid DNA was 
added to 20 µL of bacteria cells, this was incubated on ice for 1 hour. Heat shock 
was used to insert the plasmid DNA into the bacteria cells, 42oC for 45 seconds. Cells 
returned to ice for 5 minutes before 300µL pre-warmed SOC media was added to the 
cells. Cells were incubated for 1 hour at 37oC on a shaking platform. Onto pre-
warmed 2YT bacto-agar plates containing the corresponding selection antibiotic (in 
most cases it was 50 µg/mL Kanamycin or 100 µg/mL ampicillin) 50µL of the bacteria 
was streaked and incubated at 37oC overnight.  
3.3.2 Plasmid DNA purification 
50 mL 2YT culture containing the correlating selection antibiotic was inoculated 
using a single colony from the transformation. This was grown for 8 hours at 37oC in 
a shaking incubator and then transferred into 800 mL of 2YT culture overnight. 
Plasmid DNA was isolated using the Qiagen QIAfilter™ Plasmid Maxi Kit. Plasmid DNA 
concentration was measured using ThermoFischer Scientific NanoDrop 1000. The 
plasmid DNA was digested with restriction endonucleases were required and 
analysed using agarose gel electrophoresis.  
3.3.3 Agarose Gel Electrophoresis 
1% agarose (w/v) gels were made up in TAE buffer (40mM Tris, 1mM EDTA). The DNA 
stain used was SYBR safe DNA gel stain (1 in 10,000 dilutions in TAE). Gels were run 
at 70V in TAE buffer. Samples prepared as stated below in 3.3.4 and was mixed with 
6x DNA loading buffer. The gel was run using 5µL of New England BioLabs Quick-Load 
1Kb DNA ladder. When required DNA fragments were extracted from agarose gels 
using the QIAquick extraction kit (Qiagen) according to the manufacturer’s 
instructions.  
3.3.4 DNA Plasmid Digestion using Endonucleases 
DNA plasmid was incubated with the corresponding endonuclease in the buffer most 
suitable according to the manufacturers’ recommendations between 2 and 6 hours 
at 37oC in a final volume of 20µL. 1 unit of enzyme was used per µg of DNA, and 1µg 
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of DNA was digested per digestion. When plasmid DNA required digestion at two or 
more sites using two or more different restriction endonucleases the buffer chosen 
for digestion was compatible with the least stable restriction enzyme. 
3.3.5 DNA Plasmid Ligation  
DNA plasmid containing the desired vector was digested using endonucleases as 
described above (3.3.4) using the corresponding restriction sites in the target 
plasmid multi cloning site. The vector was extracted using agarose gel 
electrophoresis as described above (3.3.3). The 5’ position linearized target plasmid 
was dephosphorylated to inhibit self-ligation of the target plasmid using Shrimp 
Alkaline Phosphatase (rSAP). 1 µg of plasmid DNA was dephosphorylated using 2 µL 
CutSmart® Buffer (10X) and 0.5 µL rSAP made up to 20 µL with nuclease-free water. 
This was incubated at 37oC for 30 minutes, and then 5 minutes at 65oC to stop the 
reaction. For the ligation 1 µL T4 DNA ligase was used with 2 µL T4 DNA ligase buffer 
(10X), 50 ηg vector DNA, 37 ηg insert DNA, which was made up to 20 µL using 
nuclease-free water. This was gently mixed then incubated for 1 hour at room 
temperature and heat inactivated at 65oC for 10 minutes. The mixture was 
transformed into XL-1 blue cells as described above (3.3.1). 
3.4 CELL CULTURE METHODS 
3.4.1 Growth and maintenance of 3T3-L1 Adipocytes 
3T3-L1 murine adipocytes were originally purchased from ATCC (USA), cells 
expressing HA-GLUT4-GFP had previously been generated in the lab. To culture cells 
DMEM (Dulbecco’s Modified Eagle’s Medium) supplemented with 10% (v/v) Newborn 
Calf Serum (NCS) was used. Cells were incubated in a 10% CO2 humid atmosphere 
incubator at 37oC. Cells were fed every second day until cells were ready for 
adipocyte differentiation or for passage.  
3.4.2 3T3-L1 adipocyte passage 
Cells were passaged at 70% confluence, cells were not used past passage 13. The 
media was aspirated, and the cells were washed with 5mL pre-warmed sterile D-PBS 
and 1 mL 0.05% trypsin was added. Cells were incubated for 2-5 minutes at 37oC till 
cells had detached from the flask. DMEM NCS was added to stop the trypsin reaction 
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and the cell suspension was split, no more than 1 in 12 from the original flask. To 
each T75 flask 15 mL of DMEM NCS cell suspension was added, 10 mL to each 10cm 
plate, 1 mL to each well of a 12 well plate, 500 µL to each well of a 24 well plate, 
and 100 µL to each well of a 96 well plate.  
3.4.2.1  Seeding cells onto glass coverslips 
Coverslips were sterilised by dipping into 100% ethanol and placed onto the edge of 
the well to dry in the cell culture hood ventilation for 15 minutes. The coverslips 
were knocked into the wells and left under UV light for a minimum of 45 minutes. 
Before use wells were washed with D-PBS to remove residual ethanol. If coating with 
collagen wells were filled with 1 mL 0.1% (v/v) rat tail collagen type IV and incubated 
for 10 minutes. The collagen was removed, and the wells allowed to dry. Wells were 
washed with D-PBS 3 times to lower the acidity. Cells added as described in the 
passage methods. 
3.4.2.2  Fixing cells on glass coverslips 
Cells serum starved for 2 hours pre-fixing and were washed 3 times using PBS. 
Coverslips were fixed using 4% paraformaldehyde solution for 90 minutes at room 
temperature. Coverslips were quenched using 25mM glycine for 5 minutes and 
washed using PBS.  
3.4.3 3T3-L1 adipocyte differentiation 
Cells were differentiated 2 days post confluence and followed an 8-day protocol. 
Day 0 differentiation media was made up using DMEM supplemented with 10% (v/v) 
Foetal Calf Serum (FCS), 1 µM insulin, 1 ηM troglitazone, 0.5 mM 3-isobutyl-1-
methylxanthine (IBMX), and 0.25 µM dexamethasone. 3 days post the start of 
differentiation media was changed for Day 3 differentiation media. Day 3 
differentiation media was DMEM supplemented with 10% (v/v) FCS, 1 µM insulin, and 
1 ηM troglitazone. 6 days post the start of the differentiation the media was changed 
for day 6, DMEM supplemented with 10% (v/v) FCS. Cells were fully differentiated 
and ready for use by day 8 of the process. Cells to be used by day 12 of 
differentiation and media to be changed every second day after day 6 with DMEM 
supplemented with 10% (v/v) FCS. 
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3.4.4 3T3-L1 fibroblast cryo-preservation 
Cells were preserved in liquid nitrogen. Cells were prepared when at 70% confluence 
using the passage method, after cells have detached 5 mL of DMEM supplemented 
with 10% (v/v) NCS was added and cells were pelleted using centrifugation at 500 x 
g for 5 minutes. The cell pellet was re-suspended in 1 mL, per flask, freeze down 
media, FCS supplemented with 10% (v/v) dimethyl sulfoxide (DMSO). Cells were 
transferred into 1.8 mL cryo-vials. Cells were stored overnight in Nalgene “Mr. 
Frosty” containing isopropanol at -80oC. Cells were transferred to liquid nitrogen for 
long term storage. 
3.4.4.1 Resurrection of cells 
Cells were removed from liquid nitrogen and thawed at 37oC before adding to 15mL 
of pre-warmed growth media in a T75 flask. 12 hours later growth media was 
replaced to remove DMSO. 
3.4.5 Growth of HeLa cells 
The human cervical carcinoma HeLa cells were purchased from ATCC (USA), cells 
expressing HA-GLUT4-GFP were previously generated by the group. Cells were 
cultured in DMEM, 10% (v/v) FCS, 1% (v/v) Glutamine. The media was changed every 
second day until cells were ready for passage or use. Cells were incubated at 5% CO2 
at 37oC in a humid atmosphere incubator.  
3.4.6 HeLa cell passage 
At 70% confluence cells were passaged, the media was aspirated, and the cells were 
washed in pre-warmed D-PBS. 1 mL 0.05% (w/v) trypsin was added and cells were 
incubated at 37oC for 2-5 minutes till cells had detached from the flask. DMEM 
growth media was added to stop the trypsin reaction and cells were split no more 
than 1 in 6. Volumes were as described in section 3.4.2. Cells added to coverslips 
which were prepared as described in 3.4.2.1.  
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3.5  PREPARATION OF MICROSCOPY SAMPLES 
3.5.1 Transfection of Hela cells 
Hela cells were cultured on glass cover slips, prepared as described in section 3.4.2.1 
till 70% confluence was reached when they were transfected with Lipofectamine 
2000 (LF2K). A ratio of 0.75 µg DNA to 1.5 µL LF2K per well in a 12 well plate was 
used and incubated for 5 hours in Opti-MEM®. 48 hours post transfection cover slips 
where fixed using paraformaldehyde as stated in 3.4.2.2.  
3.5.2 Immunofluorescence staining of HA epitope tag for confocal 
microscopy imaging 
Cells prepared according to type onto coverslip glass (HeLa) or µ-slide IBIDI 8 well 
(3T3-L1 adipocytes). Cells fixed using paraformaldehyde as described in 3.4.2.2 and 
was blocked for 30 minutes at room temperature using immunofluorescence (IF) 
buffer (1X PBS, 0.5% (w/v) fish gelatin, 0.1% (v/v) donkey serum). Cells were not 
permeabilised for this technique to distinguish between extracellular and 
intracellular HA. Primary mouse anti HA antibody was applied to the cells for 1 hour 
at room temperature at a 1 in 3000 concentrations in IF buffer. Cells were carefully 
washed using IF buffer 3 times and was placed on the platform shaker at low setting 
for 5 minutes between washes. Secondary donkey anti-mouse AlexaFluor® 647ηm 
antibody was applied to the cells for 45 minutes at room temperature at a 1 in 5000 
concentrations in IF buffer. Cells were carefully washed 3 times using IF buffer. 
Coverslips were mounted onto slides using ImmunoMount and IBIDI wells were filled 
with 1 x PBS and stored at 4oC. Confocal images were gathered on a  
3.5.3 Preparation of HA-GLUT4-GFP HeLa cells for FACS analysis 
HeLa cells (~150000 cells/well) were seeded into a 6 well plate 48 hours pre-
analysis. When required cells were transfected as per the LF2K transfection 
described in 3.5.1 24 hours prior to analysis. Prior to analysis cells were serum 
starved for two hours, half of the samples were stimulated with 1 µM insulin for 20 
minutes at 37°C. The plates were then placed on ice and all subsequent steps were 
performed on ice and use ice cold solutions.  
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In the well cells were washed three times with PBS, cells were fixed with 1% (w/v) 
electron microscopy grade, methanol free PFA for 20 minutes. Cells were washed 
two times in PBS and blocked with 2 % BSA (w/v) in PBS for 45 minutes on ice. Surface 
GLUT4 was stained for using the HA-epitope tag. Primary anti-HA antibody was 
incubated with cells for 45 minutes and used at 1 in 200 concentrations in PBS 
supplemented with 2 % (w/v) BSA. Cells were washed three times in PBS. Secondary 
antibody conjugated with AlexaFluor® 647 (ThermoFischer) was incubated for 45 
minutes at a 1 in 300 concentrations in 2 % (w/v) BSA in PBS. Cells were washed 3 
times in 2 % (w/v) BSA in PBS.  
The cells were gently dissociated from the tissue culture dish using a cell lifter. 
Dissociated cells were collected and centrifuged at 600 g for 8 minutes at 4°C. The 
resulting pellet of cells was suspended in 350 µL of 2 % (w/v) BSA in PBS. Samples 
were analysed on a BD LSRFortessa X20. Data was collected and analysed using 
Summit Software v4.3. 
3.6 PRODUCTION OF CELL LYSATES 
3.6.1 Production of Protein Lysates 
Cells were serum starved using serum free DMEM for 2 hours at 37oC. Cells were 
washed 3 times in PBS and scraped in RIPA buffer (50 mM Tris pH 8, 150mM BaCl, 
2mM MgCL2,1% Triton (v/v), 0.5% sodium deoxycholate (w/v), 0.1% (w/v) SDS, 1mM 
DTT, 50 units/mL Benzonase) containing EDTA free protease inhibitor (Roche), 200µL 
per 10 cm plate. Samples were homogenised using a 26-gauge needle 8 times. 
Samples were rested on ice for 10 minutes and insoluble material was pelleted from 
the homogenate using 12470 x g centrifugation at 4oC. Lysates were stored at -80oC 
till required.  
3.6.2 mRNA extraction 
Cells were serum starved using serum free DMEM for 2 hours at 37oC. Cells were 
scraped in Qiagen buffer RLT to produce a lysate. mRNA was extracted using Qiagen 
miRNAeasy mini kit as per the instructions. mRNA concentration was measured using 
ThermoFischer Scientific NanoDrop 1000. 
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3.7 CELL LYSATE TECHNIQUES 
3.7.1 Differential Centrifugation 
Twelve 10cm plates of fully differentiated 3T3-L1 adipocytes between day 8 and 10 
were serum starved using serum free DMEM for 2 hours, 6 of the plates were 
stimulated with 1 µM porcine insulin for 30 minutes. Plates were washed using sterile 
HES buffer, scraped and homogenised using a dounce homogeniser. The lysate was 
centrifuged at 10,000 x g at 4oC for 20 minutes, resulting in a pellet of the plasma 
membrane, mitochondria and nuclei. This pellet was re-suspended in HES buffer and 
carefully layered onto high sucrose (1.12M sucrose in HES) cushion and centrifuged 
in a swing out rota at 41,000 x g at 4oC for 60 minutes. The pellet, mitochondria & 
nucleus fraction, was re-suspended in 100 µL 1 x Laemelli sample buffer (LSB) and 
the interphase was collected, as the plasma membrane, re-suspended in 4 mL HES 
buffer and centrifuged at 140, 000 x g at 4oC for 60 minutes. The pellet was re-
suspended in 100 µL 1 x LSB. Simultaneously the supernatant from the original lysate 
spin, which contains the low-density membrane (LDM); high density membrane 
(HDM); and soluble protein fraction, was centrifuged at 12, 500 x g at 4oC for 20 
minutes to pellet the HDM, which was re-suspended in 100 µL 1 x LSB. The 
supernatant from this was centrifuged at 140, 000 x g at 4oC for 60 minutes and the 
pellet, containing the LDM, was re-suspended in 100 µL 1 x LSB. TCA precipitation 
was used to recover the soluble protein fraction from the supernatant, this was re-
suspended in 100 µL 1 x LSB. 
3.7.2 Western Blotting 
SDA-polyacrylamide gel electrophoresis was used to resolve the protein samples. 
Protein samples were boiled prior to loading at 95oC for 5 minutes or 65oC for 10 
minutes when probing for GLUT4. BioRad Precision Plus Protein Standards All Blue 
Markers was used as molecular weight ladder. Following transfer to nitrocellulose, 
the membranes were stained using Ponceau solution prior to immuno-labelling. 
Nitrocellulose was blocked for 30 minutes using 3% BSA in PBS-T solution. Blot was 
incubated O/N at 4oC or 1 hour at room temperature with primary antibody in 3% 
BSA PBS-T solution. Primary antibody was washed for 10 minutes in PBS-T 3 times. 
Blot was incubated with Alexa Flour® conjugated secondary antibody for 1 hour at 
80 
room temperature. Unspecific binding was washed using PBS-T for 10 minutes 3 
times. The western blot was visualised using LICOR.  
3.7.3 Immunoprecipitation of 3T3-L1 adipocytes 
3T3-L1 adipocytes were used on day 10 of the differentiation protocol. 10 cm dishes 
of 3T3-L1 adipocytes were serum starved for 2 hours. For the last 20 min, 1 µM 
insulin was added to the medium of half the dishes. Cells washed in ice-cold PBS 3 
times and then cells were scraped in IP buffer supplemented with 1% or 0.5% Triton-
X. Samples were lysed using a 26G needle and transferred into a clean tube to be 
incubated on ice for 30 minutes. Lysates were centrifuged at 500 x g for 20 minutes 
at 4°C. The supernatant was transferred to a clean tube. To determine the whole 
lysate protein concentrations of the sample a Bradford assay was performed. Total 
protein of 1 mg per sample was used per group. To each sample of protein 
antibody/serum was added; EFR3A (2 µg), PI4KIIIα (5µg) or random rabbit IgG (5µg). 
Samples were rotated for 2 hours at 4°C, and then centrifuged at 500 x g for 1 
minute at 4°C. The pellet was washed 3 times in IP buffer supplemented with 1% or 
0,5% Triton-X and then washed 1x with IP buffer supplemented with 10 times 
reduced Triton-X, 0,1% or 0,05% respectively. Samples were centrifuged at 500 x g 
for 1 minute at 4°C. This pellet was mixed with directly with 2x LSB and boiled at 
95°C for 5 minutes. Samples were stored at -20°C until subjected to 
immunoblotting. 
 
3.8  SEMI-QUANTITATIVE REVERSE TRANSCRIPTASE PCR (RTPCR) 
3.8.1 cDNA preparation 
cDNA was prepared from mRNA using Applied Biosystems reagents for RT-PCR. mRNA 
concentration required was 200 ηg/µL to be prepared in a 96 well PCR plate on ice, 
each reaction was 20 µL. To the reaction 2 µL 10X buffer, 4.4 µL 25 mM MgCl2, 4 µL 
10 mM dNTPs, 1 µL 50 µM random hexamers, 0.4 µL 20 U/µL RNAase inhibitors, 0.5 
µL 50 U/µL multiscribe, 1 µg mRNA sample, and 5.7 µL nuclease free water. PCR 
plate was sealed, and PCR run under cycle conditions; 25oC for 10 minutes, 48oC for 
30 minutes, 95oC for 5 minutes, and 4oC to end the reaction.  
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3.8.2 Quantitative PCR using SYBR® green 
Synthesised cDNA prepared as shown above (3.7.1) was used. A master mix 
containing; 6.25 µL Applied Biosystems Power SYBR® green PCR master mix, 0.05 µL 
100 µM forward primer, 0.05 µL 100 µM reverse primer, and 3.25 µL RNAase free 
water; was prepared per well of PCR reaction. To the master mix 2.5 µL of RT cDNA 
was added to the well. Plates were loaded onto Taqman and thermal cycling 
parameters were set to; 48oC for 30 minutes, 95oC for 10 minutes, 40 cycles of 
denature 95oC for 15 seconds, and anneal/extend 60oC for 1 minute. 
3.9 ANTI-PEPTIDE RABBIT SERUM PURIFICATION 
3.9.1 Column purification 
ThermoFischer® scientific protein purification column was used. The EFR3A peptide 
was added to the column according the protocol of the manufacturer to bind 
covalently with the matrix in the column. This was stored ON at 4°C using the 
degassed buffer from the Kit. The next day, the column was washed with 10 mL 1x 
PBS, and the degassed buffer flows out of the column. Meanwhile 0.2 mL of 10X PBS 
was added to 1.8 mL of the thawed rabbit serum. The serum was added to the 
column and incubated for 15 minutes at room temperature. The serum was collected 
after incubation and added to the column for a second 15-minute incubation. The 
matrix was washed thoroughly with 2 mL of 1x PBS 5 times. To release the bound 
proteins from the column matrix, 4.5 mL glycine (2M; pH 2.0) was added to the 
column and 8 aliquots of 0.5 mL of the flow-out containing the EFR3A anti-peptide 
antibodies were collected. To determine protein concentration the OD-values were 
measured using the spectrometer.  
3.9.2 Sepharose-A bead purification 
100 µL Sepharose-protein A beads were added to 1 mL of serum and 100 µL 10x PBS. 
Serum with beads was rotated for 2 hours at 4°C after which the beads were spun 
down for about 15 seconds in the microfuge. Supernatant was removed, and the 
remaining beads were washed 3x with 1x PBS. 1 mL of 2M glycine was added to the 
beads and incubated for 10 minutes at RT. The samples were spun briefly, and the 
supernatant was collected, this was repeated twice. The OD-values of the 3 fractions 
were measured using the spectrometer. 
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3.9.3 Purified Antibody Concentration 
Using spectrometer absorption spectra of 280λ, the density of antibodies in the 
aliquots was calculated. The aliquots with the highest values were pooled together. 
This pooled sample was purified using a Slide-A-Lyzer™ 3.5K MWCO dialysis cassette 
(ThermoFischer), which was done O/N at 4°C. After dialysis, the purified EFR3A-
antibody was collected, aliquoted in 50 µL aliquots and stored at -80°C.  
3.10 TRANSFECTION OF 3T3-L1 ADIPOCYTES 
3.10.1 Electroporation of 3T3-L1 adipocytes with plasmid DNA 
Cells used at day 4 of differentiation, cells were washed 3 times in 10 mL D-PBS (no 
Ca and no Mg). To detach the pre-adipocytes 3mL of equal 0.05% trypsin: 2mg/ml 
collagenase was added and incubated for 5 minutes at 37oC. Once detached add 
10mL complete media to the plate and transfer to a 50mL conical centrifuge tube. 
Cells were pelleted using 500 x g for 2 minutes and re-suspended in 30mL D-PBS, this 
was repeated twice more. Cells were re-suspended in 0.5mL D-PBS per 10 cm plate 
used. 0.4mL of re-suspended cells was added to a 0.2cm BIO-RAD Gene Pulser® 
electroporation cuvette and 75µg plasmid DNA. Using the BIO-RAD GENE PULSER® II 
set at 0.18kV and 975µF and pulse. Add 1mL complete media to the cuvette and 
stand for 1 minute before removing the fat from lysed cells before adding the cells 
to 6mL pre-warmed complete media and rest for 10 minutes. Only remove the top 
6mL of media and add 300µL per well of collagen coated glass bottom ibidi® µ-Slide 
8 well. Use cells for visualisation 72 hours post electroporation.  
3.10.2 Electroporation of 3T3-L1 adipocytes with siRNA 
Cells used at day 6 of differentiation, cells were washed 3 times in 10 mL D-PBS (no 
Ca and no Mg). To detach the pre-adipocytes 3mL of equal 0.05% trypsin: 2mg/ml 
collagenase was added and incubated for 5 minutes at 37oC. Once detached add 
10mL complete media to the plate and transfer to a 50mL conical centrifuge tube. 
Cells were pelleted using 500 x g for 2 minutes and re-suspended in 30mL D-PBS, this 
was repeated twice more. Cells were re-suspended in 0.5mL D-PBS per 10 cm plate 
used. 0.65mL of re-suspended cells was added to a 0.2cm BIO-RAD Gene Pulser® 
electroporation cuvette and 3ηmol Silencer® select pre-designed siRNA. Using the 
BIO-RAD GENE PULSER® II set at 0.25kV and 950µF and pulse. Add 1mL complete 
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media to the cuvette and stand for 1 minute before removing the fat from lysed 
cells before adding the cells from 3 electroporation’s to 12mL pre-warmed complete 
media and rest for 10 minutes. Only remove the top 12mL of media and add 500µL 
per well of 24 well falcon plate. Use cells for glucose uptake assay 72 hours post 
electroporation.  
3.11  GENERATION OF A STABLE CELL LINE IN 3T3-L1 ADIPOCYTES 
Fibroblast 3T3-L1 adipocytes were transfected when at 70% confluence using LF2K 
as described above in 3.4.7 with plasmids containing the neomycin resistance gene. 
24 hours post transfection split cells 1:10 into growth medium before selection 
medium (containing 0.75mg/ml G418) was applied daily. When single colonies 
appear after applying selection media the cells were split to 1 cell/100µl and added 
to a 96 well plate in selection media. Wells which were positive for single colonies 
were expanded and expression of protein was confirmed by visualisation.   
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4 CHARACTERISATION OF EFR3 IN 3T3-L1 ADIPOCYTES 
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4.1 INTRODUCTION 
Much of our understanding of EFR3 comes from studies of the yeast orthologues and 
from studies of adherent fibroblast cell types (Wu et al., 2014; Bojjireddy et al., 
2015). EFR3 has been shown to be membrane associated, not transmembrane, in 
both yeast and mammalian cells. In both yeast and mammals EFR3 was shown to be 
localised to the plasma membrane (Baird et al., 2008; Wu et al., 2014). The N-
terminus was required for membrane association in yeast and mammals. In yeast the 
presence of a conserved basic patch at the N-terminus (K12A, R46D, K49A, K52A, 
H67E, and R69A) has been determined to be essential for membrane association and 
PM localisation (Wu et al., 2014).  In mammalian cells EFR3 localisation was 
dependent on N-terminus palmitoylation (C6/C7/C8/C9 for EFR3A and C5/C7/C8 for 
EFR3B), and residues 1-37 are sufficient to direct GFP to the PM (Bojjireddy et al., 
2015).  
In mammalian cell lines two homologs of EFR3 have been identified, EFR3A and 
EFR3B which have 64% sequence identity (Bojjireddy et al., 2015). Previous studies 
have shown that EFR3 a and b are ubiquitously expressed in mouse tissue, with 
notably high expression of EFR3A in the testis and EFR3B in the brain (Bojjireddy et 
al., 2015). In skeletal muscle and heart samples expression of EFR3A and EFR3B are 
similar. The expression levels in skeletal muscle show that EFR3A was slightly less 
expressed than EFR3B and vice versa in the heart sample. Skeletal and cardiac 
muscle are examples of insulin responsive tissue containing GLUT4. This information 
confirms a presence of EFR3A and EFR3B in insulin responsive tissues. There was no 
data for the expression levels of EFR3A and EFR3B in adipose tissue.  
The effect insulin signalling has on GLUT4 trafficking can be experimentally 
demonstrated using subcellular fractionation. This technique allows for the 
trafficking of proteins from vesicles to the PM in response to insulin to be observed 
of the endogenous protein in adipocyte cell lines. The trafficking of proteins with 
GLUT4 in response to insulin signalling may indicate a regulatory role within vesicle 
trafficking. Plasma membrane localisation indicates a role within cell surface 
dynamics. The location of endogenous EFR3 and PI4KIIIα will be analysed using this 
technique.  
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HeLa cells are used in this study as a model system, as a cell line expressing HA-
GLUT4-GFP will be used to measure the effect of EFR3 on GLUT4 at the PM. The HA 
epitope tag is extracellularly exposed when GLUT4 is fused at the PM, allowing assay 
of the levels of GLUT4 on the surface in the presence and absence of insulin (Lizunov 
et al., 2012; Sadler et al., 2013; Kioumourtzoglou et al., 2015). The GFP tag was 
cytosolic and therefore acts as a measure of total GLUT4 in the cell. HeLa cells do 
no express endogenous GLUT4 but do exhibit insulin-stimulated GLUT4 delivery to 
the plasma membrane, and thus are a useful cell line for mechanistic studies of this 
process ((Kioumourtzoglou et al., 2015)). Therefore, characterisation of EFR3 in 
HeLa cells was carried out concurrent with studies in 3T3-L1 adipocytes.  
4.2 AIMS 
This chapter aims to characterise EFR3 in 3T3-L1 adipocytes and the model cell line 
HeLa expressing HA-GLUT4-GFP. Semi-quantitative reverse transcriptase PCR will be 
employed to measure EFR3 homolog distribution in cells used in this investigation. 
Subcellular fractionation and fluorescently labelled EFR3 cell imaging will be used 
to determine membrane localisation. This chapter aims to characterise the protein 
levels of EFR3 and PI4KIIIa in samples from mice models of insulin resistance.  
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4.3 EFR3 HOMOLOG DISTRIBUTION  
Semi quantitative reverse transcriptase polymerase chain reaction (rtPCR) was used 
to determine the relative levels of EFR3 mRNA homologs A and B in cell lines in HeLa 
cells, 3T3-L1 fibroblasts and adipocytes, shown in Figure 15. The primer sequences 
used correspond to an intron region of EFR3A, EFR3B and GAPDH. Primers where 
validated using PCR of DNA, all primers resulted in appropriate PCR product. GAPDH 
was used as a housekeeper gene to facilitate the relative quantification of EFR3A 
and EFR3B mRNA expression levels. The cycle threshold (Ct) values and the relative 
quantification to GAPDH values indicate that EFR3B was virtually undetectable in all 
cell types investigated. In 3T3-L1 adipocytes EFR3A was found at 0.7 relative to the 
Ct level of GAPDH. In 3T3-L1 fibroblasts EFR3A was found at 1.7 relative to the level 
of GAPDH.  
These results, shown in graph form in Figure 15, indicate that EFR3A was a relatively 
abundant transcript product. The high transcript levels infer an abundant protein in 
the cell. This information informed our focus on EFR3A in future investigations of 
the role of EFR3A during GLUT4 dispersal at the PM in 3T3-L1 adipocytes.  
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4.4 SUBCELLULAR FRACTIONATION 
Differential centrifugation of 3T3-L1 adipocyte lysates was used to track the 
membrane localisation of EFR3A and PI4KIIIα. The results are shown in relation to 
GLUT4 and in response to insulin stimulation. Cell lysates were separated into 
plasma membrane (PM), high density membrane (HDM), low density membrane 
(LDM), and the soluble protein fraction using differential centrifugation as described 
(Claude, 1946; Hepp et al., 2005). The fractions were immunoblotted for GLUT4, 
PI4KIIIα, EFR3A and various endosomal membrane markers and a typical set of data 
was presented in Figure 16. The results confirm that GLUT4 was enriched in the LDM 
fraction in the absence of insulin stimulation. Twenty-minute insulin stimulation 
results in GLUT4 being enriched at the PM fraction and the levels at the LDM are 
diminished in comparison to non-stimulated samples. This was indicative of the 
translocation of LDM vesicles to the PM in response to stimulation. EFR3A and PI4KIIIα 
WERE predominantly localised to the PM in the absence of insulin stimulation, Figure 
16. With regards to PI4KIIIα and EFR3A the results from subcellular localisation show 
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differentiation) mRNA was extracted and gene expression in each cell type assessed 
using EFR3 homolog A and B probes with GAPDH utilised for normalisation. n=3. 
Primer sequences are shown in the supplemental data.  
 
Figure 15: Semi-quantitative reverse transcriptase PCR relative quantification to 
GAPDH results 
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that insulin stimulation does not result in substantial differences in localisation of 
either proteins; EFR3A or PI4KIIIα. Both proteins remain enriched at the PM in both 
insulin and non-insulin stimulated cells. The subcellular fraction markers used were; 
syntaxin 4 (Sx4) as a PM marker; protein disulphide-isomerase (PDI) as a HDM marker; 
Transferrin receptor as a LDM marker; and GAPDH as a soluble fraction marker. All 
markers showed equal distribution between insulin and non-insulin stimulated 
samples allowing for confidence that PI4KIIIα and EFR3A localisation does not change 
in response to insulin stimulation.  
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Immunoblot of subcellular fractionation of 3T3-L1 adipocyte lysate. Fraction 
controls, which remain unaltered in the presence of insulin stimulation, include; 
Syntaxin (Sx) that was enriched in the PM fraction, transferrin receptor (Trf R) is 
enriched in the LDM, protein disulphide-isomerase (PDI) was enriched in the HDM 
fraction, and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is enriched in 
the soluble fraction. Western blot lanes denoted with – or + for insulin stimulation. 
Fractions; plasma membrane (PM), high density membrane (HDM), low density 
membrane (LDM), soluble (SOL). Insulin stimulation was carried out for 20 minutes 
with 0.1 µM insulin. 
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Figure 16: Representative immunoblot of subcellular localisation of EFR3A and 
PI4KIIIα in 3T3-L1 adipocytes. 
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4.5 CONFOCAL MICROSCOPY VISUALISATION OF EFR3 
4.5.1 HeLa cell visualisation 
Fluorescently labelled EFR3 (A and B) tagged with mCherry at the C terminal was 
expressed in HeLa cells using plasmid DNA transfection. EFR3(A/B)-mCherry was 
under CMV promoter control, resulting in the over expression of the protein in 
transfected cells. The confocal images of EFR3A-mCherry and EFR3B-mCherry are 
shown in Figure 17. The images of EFR3 (A and B), shown in the indicated panel of 
Figure 17, exhibit PM localisation which does not vary between homolog A and B. 
Some cells exhibit an intracellular localisation of EFR3 (A and B), denoted with blue 
arrows, near the nucleus of the cell. Results from adipocyte whole cell lysates shown 
in Figure 17 show no corresponding high-density membrane localisation in the 
immunoblots. This intracellular localisation was therefore believed to be a product 
of over expression of EFR3 using plasmid transfection under CMV promoter control. 
The intracellular localisation was discounted and was attributed as artefact of over 
expression. At the PM EFR3A and EFR3B show similar localisation, denoted with white 
arrows in Figure 17 and 18. This localisation pattern at the PM was expected to be a 
result of PM furrowing in HeLa's and not a patch localisation feature of EFR3 at the 
PM.   
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4.5.2 Visualisation of the effect of insulin stimulation on EFR3A at 
the plasma membrane 
The results of subcellular fractionation above in Figure 16 showed that in 3T3-L1 
whole lysates that there was no insulin-dependent change in subcellular distribution 
of EFR3 or PI4KII. Previous images in Figure 17 showed EFR3A was localised to the 
PM in HeLa cells. Transfection confirms a membrane-associated proteins with 
characteristic morphology. Insulin stimulation of HeLa cells which express 
mammalian GLUT4 results in translocation of GLUT4 to the PM (Sadler et al., 2013). 
We therefore examined whether insulin stimulation altered the distribution of 
EFR3A-mCherry at the plasma membrane, depicted in Figure 18. The data indicated 
that insulin stimulation did not result in any visual morphological changes of EFR3A 
at the PM, shown in Figure 18. This indicated that any affect EFR3A has on GLUT4 
during insulin stimulation was not a result of a translocation event and supports the 
HeLa cells transfected with EFR3A and EFR3B plasmids respectively imaged using 
confocal microscopy. Intracellular concentration (blue arrows). EFR3 localise in 
puncta at the PM (white arrows), α-actin fluorescent immune-staining, and 
antibody concentration in methods Scale bar 20 µm.  Images have been 
brightened for printing purposes. 
 
EFR3A 
EFR3B 
Figure 17: Confocal images of HeLa cells expressing EFR3. 
 α-actin EFR3-mcherry 
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hypothesis that EFR3A acts at the PM. This indicates that any effect insulin 
stimulation has on EFR3A is at the protein level, potentially via the binding or 
activity of PI4KIIIa.  
 
 
 
  
 
 
Basal 
Insulin 
EFR3A-mcherry transfection using plasmid DNA under CMV promoter control in HeLa 
cells. No significant morphological change to the PM organisation of EFR3A was 
noted in response to insulin signalling. Therefore, insulin stimulation does not alter 
global localisation of EFR3A at the PM. Scale bar 25µm. Cells are stimulated with 
0.1 µM insulin after 1 hour 30 minutes serum free media starvation, 3 technical 
repeats with n=10 per condition. Brightness of images has been increased for 
printing purpose. 
Figure 18: Confocal images of EFR3A-mcherry in HeLa cells with insulin 
stimulation. 
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4.5.3 3T3-L1 adipocyte EFR3A-mCherry  
The introduction of fluorescently labelled proteins to adipocyte cells was restricted 
as a consequence of the difficulty in transfecting terminally differentiated cells in 
addition to the high lipid content of the adipocyte cell. To overcome this, 
electroporation was utilised to introduce plasmid DNA and drive the overexpression 
of EFR3A in 3T3-L1 adipocytes (Okada et al., 2003). 48 hours post transfection 3T3-
L1 adipocytes show a distinctive PM distribution of EFR3A-mcherry, indicated by 
white arrows in Figure 19. Localization of EFR3A was also visible in an intracellular 
compartment, indicated by yellow arrows in Figure 19. The size and position of this 
intracellular compartment was suggestive of endoplasmic reticulum localization. 
Previous studies have shown that EFR3A localizes to the PM exclusively in both yeast 
and mammalian cells (Nakatsu, 2012) (Baird, 2008), the intracellular localization 
shown in Figure 17, 18, & 19 was hypothesised to be a result of the over expression 
of CMV promoter controlled EFR3A-mCherry. There was no significant difference of 
EFR3A localization at the PM upon insulin stimulation. The above results using sub 
cellular localisation have shown that EFR3A was predominantly localized to the PM, 
as seen in Figure 16. This information compliments the localization of EFR3A shown 
in the microscopy images below in Figure 19.  
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Representative confocal images of 3T3-L1 cell over-expressing EFR3A-mcherrry 
fusion protein, treated with or without 0.1µM insulin for 20 minutes. Images show 
PM ring around the cell, indicated with white arrows. An intracellular population 
was also denoted using yellow arrows. Three technical repeats and n=10 cells 
examined per condition. Scale bar 5µm. Brightness of images has been increased 
for printing purposes. 
Basal 
Insulin 
Figure 19: Visualisation of EFR3A in 3T3-L1 adipocytes. 
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4.6 GENERATION OF AN ANTI-EFR3A ANTIBODY 
To further investigate and characterise the role of EFR3A in insulin stimulated GLUT4 
dispersal the development of a potent antibody to use when investigating the 
endogenous protein levels was required. Imaging results obtained using CMV 
promoter expression of EFR3A have shown variance in comparison to results obtained 
using subcellular fractionation, Figure 16Figure 19. This variability is believed to be 
a product of the over expression. Visualisation of endogenous EFR3A through 
immunofluorescence labelling of EFR3A was a way to negate the effect of protein 
over production through the CMV promoter.  Immunoprecipitation of endogenous 
EFR3A in 3T3-L1 adipocytes would also be a powerful technique to investigate 
proteins which co-immunoprecipitate with EFR3A. Of special interest would be if 
any changes in immunoprecipitation result as a response to insulin stimulation. The 
current commercially available anti-EFR3A antibodies did not have a high enough 
affinity for either of the desired techniques. Therefore, we sought to generate anti-
EFR3A antibodies raised against EFR3A specific peptide sequences. Two separate 
sequences were tested, both were C-terminus sequences predicted to be exposed 
for antibody binding on the protein. For each sequence two rabbits were inoculated 
with peptide sequences, the T96 batch were raised against the sequence (C)-
SVPVYEMKFPDLCVY, and the CRB batch were raised against the sequence (C)-
VPQVTDEDRLSRRKSIV. Peptide sequence position within EFR3A shown in Figure 20 
below, both sequences are within the disordered C-terminal shown in Figure 11 and 
20. 
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Figure 20: EFR3A amino acid sequence  
 
Amino acid sequence of mouse EFR3A, in bold is the disordered C-terminal region 
aligned from yeast sequence. The two peptide sequences used as antigens are 
highlighted and underlined in blue and red. The red highlighted sequence refers 
to the T96 peptide. The blue highlighted sequence refers to the CRB peptide.  
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4.6.1 Anti-peptide serum testing 
To investigate the initial serum affinity to the target endogenous protein and 
identify candidates for further purification the whole serum was tested using 
immunoblots. Whole HeLa cell lysate were screened and compared with HeLa cells 
transfected with EFR3A-mCherry are used as a positive control. Endogenous EFR3A 
has a molecular weight (MW) of 93 kDa and EFR3A-mcherry has a higher MW of 
120kDa. The results are shown in Figure 21. Pre and post immunisation serum was 
used as primary antibodies to account for any non-specific binding. The red arrows 
denote bands at the correct MW for EFR3A-mcherry. The animals with serum showing 
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Immunoblot with rabbit serum, pre and post EFR3A peptide immunisation, used 
for EFR3A detection of HeLa cell lysates. MW of EFR3A was 93kDa, as a positive 
control HeLa cells transfected with EFR3A-mcherry (MW of 120kDa) are also 
tested. Red arrows denote bands at the predicted MW for EFR3A-mcherry. Black 
arrows denote bands at the predicted MW for EFR3A. Gels loaded with 40µL 
100µg/mL Bradford assay normalised lysate samples, serum diluted 1:200 in 3% 
BSA 
Figure 21: Immunoblots of anti-peptide EFR3A rabbit serums. 
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positive bands at the MW of EFR3A-mcherry are T962, T963, CRB1 (2nd bleed) and 
CRB2 (1st bleed only). Animals with strong positive bands for endogenous EFR3A are 
T962 and CRB2, however both animals have bands at a similar position when the pre-
immunised serum is tested with the same lysates. CRB1 has a weak positive band at 
the molecular weight for endogenous EFR3A. The results from both of the T96 animal 
serums raised against the same peptide (SVPVYEMKFPDLCVY) are not promising from 
these initial immunoblots. The strong signal detected under the 100kDa marker seen 
in the pre-immunised serum of T962 indicates non-specific binding of a protein of 
similar MW to EFR3A, therefore making the serum unsuitable for further purification. 
This is despite T962 serum displaying a specific positive band at 120 kDa correlating 
to EFR3A-mCherry, which is only seen in the EFR3A-mCherry transfected HeLa 
samples of the post-immunisation serum. The non-specific binding of a protein near 
endogenous EFR3A resulted in the discontinuation of use for this serum. T963 has a 
positive band at the MW for EFR3A-mCherry in the post immunisation serum; this 
band is not present pre-immunisation serum blots. There is a weak visible band at 
the MW for endogenous EFR3A in T963 making this candidate suitable for IgG 
purification and concentration. The serum from CRB1 2nd bleed has a strong visible 
band at MW for EFR3A-mcherry and a weaker band at the endogenous EFR3A. These 
bands are not visible in the pre-immunisation serum and the 1st bleed. This indicates 
that immunity is built up against the specific peptide and it is reactive to endogenous 
EFR3A were present, making it a suitable candidate for IgG purification and 
concentration. CRB2 has a weak band at the MW for EFR3A-mcherry and endogenous 
EFR3A at the 1st bleed. However, the band for EFR3A-mcherry disappears in the 2nd 
bleed sample. This makes CRB2 a weaker candidate for further IgG purification as 
the majority of serum is from the second bleed. The sum result from this indicates 
that the whole serum is not very promising and IgG purification to improve the 
specificity of the CRB2 serum is crucial. Serum from rabbits T963, CRB1, and CRB2 
were taken forward for further purification and investigation.   
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4.6.2 Serum purification 
To improve the antibody reactivity the serum was IgG purified using two approaches, 
column and sepharose A bead purification. Column purification involved binding to 
the peptide used during serum production, which should concentrate peptide 
specific binding proteins. IgG purification was used to concentrate whole IgG 
population of the serum using protein A beads. Post purification, protein 
concentrations where measured using a spectrometer, this is to ensure protein is 
present in the eluted sample post purification. The post column purification 
concentration of T693 serum yielded low levels which resulted in the discontinuation 
of this sample. Shown in Figure 22 was a SDS-gel electrophoresis Coomassie staining 
containing the serum samples post purification. IgG antibody heavy chain MW was 
predicted at 50 kDa and light chain MW was predicted at 23 kDa. Only samples that 
have undergone IgG peptide column purification have strong bands at the heavy and 
light chain MW, denoted with * in Figure 22. This indicates that peptide bound 
column purification results in IgG protein purification. As CRB2 preliminary tests 
showed it to be the most promising we tested this against commercially available 
EFR3A antibody, immunoblot results shown in Figure 23. Protein samples used were 
3T3-L1 adipocyte whole cell lysate, a 1:2 diluted 3T3-L1 adipocyte sample, HeLa cell 
lysate and HeLa cells transfected with EFR3A-mcherry. In the immunoblot probed 
with the commercial antibody a band at the expected MW for endogenous EFR3A 
was seen in all lanes, denoted by the black * in Figure 23A. In the commercial blot 
a distinct band at the expected MW for EFR3A-mCherry was only seen in the HeLa 
EFR3A-mCherry sample, shown in Figure 23A with red *. Immunoblots using column 
purified CRB2 as primary antibody, shown in Figure 23B, indicate that no distinct 
band was present for the MW for endogenous EFR3A in any lane. However, a faint 
band for endogenous EFR3A was noted in the lane containing HeLa cells transfected 
with EFR3A-mcherry. A faint band was visible at the correct MW for EFR3A-mCherry, 
denoted by a red * in Figure 23B, only in the EFR3A-mCherry transfected sample. 
Commercial antibody was determined to have the best western blot read out for 
endogenous EFR3A and was used in further experiments.   
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Figure 22: Coomassie staining of purified anti-peptide serums 
 Coomassie stain of the purified samples from the CRB peptide serum. The two 
forms of purification used are peptide bound column purification (denoted with 
Column), and sepharose-A bead (denoted with Seph-A) purification. The Heavy 
chain band was visible at 50kDa and light chain band was visible at 23kDa, marked 
with *, in the peptide column purifications. Equal volume of elution’s prepared 
from each purification, 5µL of elute loaded per lane.  
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Figure 23: Immunoblot using commercial EFR3A antibody and purified EFR3A 
anti-peptide serum 
 Comparative immunoblots of the commercial EFR3A antibody and purified EFR3A 
peptide antibody. A. Immunoblot using commercial EFR3A antibody. B. 
Immunoblot using CRB1 2
nd
 bleed peptide column purified serum. Samples used 
for comparison are in order from left to right; 3T3-L1 adipocyte, 1:2 diluted 3T3-
L1 adipocyte, HeLa lysate and HeLa transfected with EFR3A-mcherry. Black * 
denotes the position for endogenous EFR3A. The red * denotes the position for 
EFR3A-mcherry. Samples normalized using Bradford assay and 40µL 20µg/lysate 
per lane, 1:2 dilution denotes sample dilution to 10µg/mL according to 
normalization. A. Commercial antibody used at 1:250 as stated in materials and 
methods 3.2.1 in 3% BSA B. CRB1 peptide column purified serum used at 1:200 in 
3% BSA. 
* * 
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4.7 IMMUNOPRECIPITATION OF EFR3A  
To investigate the effect insulin has on the molecular complex that EFR3A and 
PI4KIIIα form in 3T3-L1 adipocytes immunoprecipitation was performed. This was 
carried out using commercial antibodies for both EFR3A and PI4KIIIα antibodies. 
Samples from the immunoprecipitation were immunoblotted, as shown in Figure 24. 
Two stringencies of elution conditions were tested, 1% and 0.5% Triton-X100 IP 
buffer. These stringencies are tested as low detergent may result in unspecific 
binding, whereas high detergent may result in sample wash. The results suggest a 
successful immunoprecipitation using the PI4KIIIα antibody, as a clear strong band 
was visible at the expected MW for PI4KIIIα in both 0.5% and 1% Triton-X100 IP buffer. 
In the EFR3A immunoblot of the PI4KIIIα immunoprecipitation a band at the expected 
MW for EFR3A was visible, bands are depicted using red arrows in Figure 24. This 
suggests a positive co-immunoprecipitation, validating that EFR3A and PI4KIIIα 
interact in 3T3-L1 adipocytes.  
The results for the EFR3A immunoprecipitation indicate that the commercial 
antibody cannot immunoprecipitate, since the anti-EFR3A blot does not have defined 
bands at the MW for EFR3A. There are however non-specific bands visible at the 
expected MW for PI4KIIIα in the EFR3A immunoprecipitation sample. This indicates 
an unsuccessful immunoprecipitation, and that the commercially available antibody 
was not appropriate for this technique.  
All samples are incubated with random rabbit IgG and show negligible visible bands. 
This result support the bands present in the PI4KIIIα immunoprecipitation are 
specific. Additionally, it was expected that no GAPDH will co-immunoprecipitate 
with either of the samples. The blots show that GAPDH was not found in the 
immunoprecipitate and was only found in the whole cell lysates and flow through, 
this was shown in the Supplemental Figure 1.    
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Figure 24: Immunoprecipitation of EFR3A and PI4KIIIα 
Immunoblots from samples immunoprecipitated with EFR3A, PI4KIIIα, and random 
IgG. Whole 3T3-L1 lysate was immunoprecipitated and blotted for PI4KIIIα, EFR3A, 
and GAPDH. 1% and 0.5% Triton-X concentrations where used in the IP buffer.  Red 
arrows indicate bands at the expected MW for the corresponding antibody. 3T3-L1 
adipocytes were insulin stimulated for 20 minutes with 0.1 µM insulin. Samples 
normalised using Bradford’s assay before immunoprecipitatation. Commercial anti-
EFR3a antibody used at 1:250 in 3% BSA and commercial anti-PI4KIIIα antibody used 
at 1:250 
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4.8 CHARACTERISATION OF EFR3A AND PI4KIIIΑ PROTEIN LEVELS IN 
STRIATED MUSCLE SAMPLES FROM CHOW V HFD MICE. 
4.8.1 Heart Sample Analysis 
Mice heart samples from normal (CHOW) and high fat diet (HFD) fed animals were 
obtained and the whole organ was lysed as described. Work carried out by Dr Anna 
White pre-cull showed the mice glucose tolerance tests confirmed that mice on HFD 
have impaired glucose tolerance compared to their Chow-fed littermates, shown in 
Figure 25, which is in line with previous findings (Andrikopoulos et al., 2008). 
Impaired glucose tolerance is a common diagnostic indicator of insulin resistance 
and a hallmark on the road to the development of type II diabetes. Previous studies 
have shown that GLUT4 protein levels in these animals remain unchanged (Gurley et 
al., 2016) however there is no data on either EFR3A or PI4KIIIα protein levels. We 
therefore measured protein levels using immunoblotting. The results showed that 
both PI4KIIIα and EFR3A are elevated in HFD mouse cardiac muscle samples, figure 
26. From the mean values of normalised EFR3A immunoblot band intensity values 
show a 2.20-fold increase in HFD mice compared to CHOW fed mice. The mean values 
of normalised PI4KIIIα immunoblot band intensity values show a 2.09-fold increase 
in HFD mice compared to CHOW fed mice. However, the cohort obtained is too small 
to reliably statistically analyse and future work will aim to test this result from a 
larger cohort of mice.  
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Figure 25: Glucose tolerance test 
 Glucose tolerance test preformed on mice at 10-week stage by Dr Anna White. 
Mice injected with 2mg glucose/g body weight and samples measured across time 
points. The CHOW fed mice plasma glucose is lower in comparison to HFD mice 
pre-injection with glucose. HFD mice have increased plasma membrane glucose 
post injection which remains elevated for longer in comparison to CHOW fed 
population. These results are indicative of lowered glucose tolerance. Per 
condition n=6 mice, samples from which are used in the immunoblots below.  
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4.8.2 Quadriceps Sample Analysis 
Samples from CHOW and HFD mice quadriceps where obtained and the protein levels 
of EFR3A and PI4KIIIα where probed using western blotting. As with the heart 
samples the HFD mice samples showed elevated levels of both proteins in 
comparison to the CHOW fed mice, shown in Figure 27. As with the heart samples, 
not enough samples where obtained to preform statistical analysis of the cohort 
probed. The measured mean values of normalised EFR3A immunoblot band intensity 
reveal a 1.47-fold increase in HFD mice compared to CHOW fed mice. The measured 
mean values of normalised PI4KIIIα immunoblot band intensity reveal a 2.72-fold 
increase in HFD mice compared to CHOW fed mice. 
Heart and quadriceps are both examples of striated muscle which are GLUT4 positive 
and insulin sensitive (Kobayashi et al., 1996). Both exhibit a visible increase in EFR3A 
and PI4KIIIα protein levels when immunoblotted when mice are fed a HFD. The 
samples where obtained from different cohorts of mice, in both samples the HFD 
mice had impaired glucose tolerance results. The heart and quadriceps cohorts 
analysed both are of low numbers, which inhibits statistical analysis. However, the 
two separate cohorts exhibit the same trend of increased EFR3A and PI4KIIIα protein 
levels therefore giving bigger leaning to the fact that the elevation was due to the 
HFD of these mice, giving correlation between HFD and the increase in protein 
levels.  
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Figure 26: HFD mouse comparison of EFR3A and PI4KIIIα in cardiac tissue. 
 Mouse samples obtained from CHOW fed or high fat diet (HFD) fed (10 weeks diet) mice 
of same age. B. Immunoblot of whole heart lysates against PI4KIIIα, EFR3A and GAPDH. 
A. Mean intensity of bands was measured using imageJ and normalised to GAPDH bands 
from corresponding samples. Sample number too low to statistically analyse, to fully 
characterise this effect new samples of a greater cohort would need to be obtained. 
From the mean values of normalised EFR3A increase 2.20-fold in HFD mice compared to 
CHOW fed mice. From the mean values of normalised PI4KIIIα increase 2.09-fold in HFD 
mice compared to CHOW fed mice. Total protein level in samples normalised using BCA 
assay. 40µL 36 µg/ml normalised sample run on 12% gel, same gel is probed for all 
proteins. Antibodies used with concentrations described in materials and methods 3.2.1.  
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Figure 27: HFD mouse comparison of EFR3A and PI4KIIIα in quadricep samples. 
 
Mouse samples obtained from CHOW fed or high fat diet (HFD) fed (10 weeks diet) 
mice of same age. B. Immunoblot of whole quadriceps lysates against PI4KIIIα, 
EFR3A, and GAPDH. A. Mean intensity of bands was measured using imageJ and 
normalised to GAPDH bands from corresponding samples.  Sample number too low 
to statistically analyse, to fully characterise this effect new samples of a greater 
cohort would need to be obtained. From the mean values of normalised EFR3A 
increase 1.47-fold in HFD mice compared to CHOW fed mice. From the mean values 
of normalised PI4KIIIα increase 2.72-fold in HFD mice compared to CHOW fed mice. 
Total protein level in samples normalised using BCA assay. 40µL 36µg/mL 
normalised sample run on 12% gel, same gel is probed for all proteins. Antibodies 
used with concentrations described in materials and methods 3.2.1. 
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4.9 DISCUSSION 
4.9.1 Homolog distribution 
Current insight into EFR3A has previously been gathered using the yeast orthologue 
(Baird et al., 2008; Wu et al., 2014). In mammalian cells the two EFR3 homologs 
(EFR3A and EFR3B) share 64% amino acid sequence identity and 78% positive 
sequence alignment, previous work has shown that homolog distribution greatly 
varies across some tissues (Bojjireddy et al., 2015).  To assess the homolog 
distribution of EFR3 a and b in cell lines used; 3T3-L1 adipocytes and HeLa cells, 
qPCR provides an accurate, tried and tested methodology (Bojjireddy et al., 2015). 
In 3T3-L1 and HeLa cell lines EFR3A was the predominantly expressed homolog and 
EFR3B was virtually undetectable. The qPCR results guided the focus for this study 
on EFR3A, and the role for EFR3A plays in an insulin responsive system. 
4.9.2 EFR3A localisation 
To examine the endogenous localisation of EFR3A in 3T3-L1 adipocytes subcellular 
fractionation of the whole lysate membranes was employed. This technique has 
previously been used to characterise the translocation of endogenous GLUT4 in 
adipocytes in response to insulin stimulation (Marette et al., 1992). The results show 
that EFR3A was predominantly found at the PM. Populations of EFR3A was not seen 
in intracellular compartments, and re-distribution in response to insulin signalling 
was not observed. EFR3A serves to localise PI4KIIIα to the membrane and the 
endogenous localisation of PI4KIIIα was shown to be at the PM, in accompaniment 
with the localisation of EFR3A. No intracellular compartment localisation or 
cytosolic localisation was found for PI4KIIIα. These results demonstrate that EFR3A 
and PI4KIIIα remain bound to the PM during insulin signalling and re-localisation from 
an inner compartment was not responsible for any effect EFR3A may have on PM 
GLUT4. This data informs that any effect insulin signalling may have on EFR3A was 
at the PM, and may involve domain localisations at the PM.  
To visualise the localisation of EFR3A in the model HeLa system and 3T3-L1 
adipocytes confocal microscopy was used. To assess the localisation of EFR3 proteins 
C-terminal mCherry tagged proteins were expressed using plasmid transfection. This 
technique allowed for visualisation of EFR3A and EFR3B in the relevant cell lines. 
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Results showed that EFR3A and EFR3B are both localised at the PM in a uniform 
manner in both HeLa and 3T3-L1 adipocytes. Noted from the confocal images are 
intracellular localisations, which are not observed in the results from the subcellular 
fractionation of endogenous protein in 3T3-L1 adipocytes. This visualised 
intracellular localisation was believed to be a facet of the plasmid transfection, in 
which the protein transcription was under CMV promoter control. CMV promoter was 
used in mammalian cells for high level production of recombinant proteins (Wang et 
al., 2017). To circumvent issues with the over expression of proteins the 
development of a CRISPR EFR3A C-terminal fluorescently tagged cell line should be 
undertaken for future investigations. This would allow for the visualisation of 
endogenous EFR3A in adipocytes to negate for the effects of over expression on 
localisation in the cell (Ratz et al., 2015). Transient transfection of EFR3A-mCherry 
was achieved using electroporation and LF2K. These techniques result in a potential 
number of plasmids may be present in per cell, which cannot be controlled for. To 
further investigate EFR3A localisation and co-localisation at the PM future 
investigations would improve results using super-resolution microscopy. The limiting 
resolution of confocal microscopy, 240 ηm, does not allow for the finer details of PM 
localisation to be observed (Huang et al., 2010). TIRF microscopy in conjunction with 
fPALM would provide a greater insight into the effect of insulin on EFR3A at the PM 
specifically (Hess et al., 2006). The visualisation of circular objects of unknown size, 
such as domains at the PM, was greatly improved using fPALM in opposed to dSTORM. 
This was due to the antibody labelling required for dSTORM results in an affected 
size of the visualisation (Tam and Merino, 2015). 
4.9.3 Immunoprecipitation and Generation of EFR3A antibody 
To investigate the interaction between EFR3A and PI4KIIIα at the PM this 
investigation aimed to immunoprecipitation EFR3A and PI4KIIIα to investigate this 
interaction between the proteins in response to insulin stimulation in 3T3-L1 
adipocytes. The commercial antibodies available for EFR3A and PI4KIIIα are used. 
EFR3A antibody does not immunoprecipitation. PI4KIIIα antibody appears to yield a 
successful immunoprecipitation and the generation of a EFR3A specific anti-peptide 
antibody was conducted.  
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This was not achieved in this study and future studies will require an affinity purified 
high specificity antibody to carry out immunoprecipitation investigations, this was 
beyond the scope of this work.   
4.9.4 Characterisation of EFR3A and PI4KIIIα in mouse tissue 
Samples from mouse cohorts which for ten weeks before culling have been divided 
into normal diet (CHOW) or high fat diet (HFD). Mice fed with HFD have impaired 
glucose tolerance in comparison to the CHOW fed mice, shown in Figure 25 (Wang 
and Liao, 2012). Impaired glucose tolerance is a hallmark of insulin resistance and 
type II diabetes (Costa et al., 2002). Samples from the heart and quadriceps were 
obtained from different mice. Striated muscle found in the heart and quadriceps are 
insulin responsive with (Mueckler, 2001). The obtained sample cohort was supplied 
from Dr Anna White to investigate any changes. The numbers are too low to draw 
any significant conclusions from, however the presence of a similar trend in both 
the quadriceps and cardiac sample was promising. The result may hint at a 
compensatory effect by up regulating EFR3A when insulin resistance was developed. 
In genetic models where proteins have been knocked down compensations are a 
widespread occurrence (El-Brolosy and Stainier, 2017). It was conceivable that 
multi-faceted diseases such as type II diabetes have a degree of phenotypic 
compensation as the disease develops. Further investigation of non-insulin 
responsive tissue would be an important control to ensure this elevation was specific 
to GLUT4 containing tissue and not a universal response to HFD. Either result would 
be of interest. Proteins which are upregulated during the development of obesity, 
such as adipokines, are of interest in the study of the growing obesity epidemic 
(Ouchi et al., 2011).  
These results indicate that EFR3A and PI4KIIIα are potentially positive regulators of 
glucose uptake if increased protein expression is a result of compensation during the 
development of insulin resistance and continued increased blood glucose levels. This 
indicated the original hypothesis based on the assumption that fgy1-1 being a loss 
of function mutation may be incorrect and in fact this may be a gain of function 
mutation in yeast allowing for mammalian GLUT4 to be dispersed at the PM in yeast. 
The next chapters aim to generate a better understanding of how EFR3A and PI4P 
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may affect GLUT4 at the PM, and if this effect is a positive or negative one for GLUT4 
dispersal.  
4.10  CONCLUSION 
The findings in this chapter show that EFR3A is the dominant homolog in 3T3-L1 
adipocytes. This allows future avenues of study to focus on the EFR3A homolog. The 
findings confirm EFR3A was primarily PM localised in 3T3-L1 adipocytes and HeLa 
cells. The combination of visualisation and subcellular fractionation allows for the 
effects of over expression for visualisation to be negated for. Future studies looking 
into the behaviour and co-localisation of EFR3A with other proteins in response to 
insulin stimulation will require the generation of an antibody capable of 
immunoprecipitation. Preliminary work with tissue samples show an increase in 
EFR3A and PI4KIIIα in mice fed HFD. This will require a larger cohort to further 
investigate fully however results in this chapter are intriguing.  
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5 CHARACTERISATION OF PLASMA MEMBRANE PI4P IN AN INSULIN 
SENSITIVE SYSTEM 
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5.1 INTRODUCTION 
The study of phospholipids in adipocytes in response to insulin signalling has 
predominantly been focused on PI3,4,5P3 (Kanzaki et al., 2004; Funaki et al., 2006; 
Grainger et al., 2011; Ijuin and Takenawa, 2012). In response to insulin stimulation 
PI3,4,5P3 is generated in adipocytes by the phosphorylation of PI4,5P2 by 
phosphatidylinositol 3-kinase (PI3K). PI3K is activated through SH2 domains of the 
regulatory p85 subunit binding in response to insulin receptor auto phosphorylation 
(Levy-toledano et al., 1995; Shepherd et al., 1998). PI3,4,5P3 acts as an allosteric 
regulator of phosphoinositide-dependent kinase (PDK) which in turn is able to 
phosphorylate to activate Akt and PKC isoforms (PKCz and PKC1) (Alessi et al., 1997; 
Le Good et al., 1998). The activation of PI3K and generation of PI3,4,5P3 through 
catalytic manipulation or external introduction was not capable of mimicking insulin 
signalling (Isakoff, 1995; Wiese et al., 1995). Thus, showing that insulin signalling 
requires a variety of concurrent signals to induce GLUT4 translocation and glucose 
uptake.  
PI4P has long been established as a component of the trans-Golgi network (Wang et 
al., 2007). PI4P has recently been shown to have a distinct role at the PM, separate 
from being the building blocks for PI4,5P2 production (Hammond et al., 2012; 
Dickson et al., 2014). The visualisation of phosphoinositide’s such as PI4P and PI4,5P2 
in the cell has been achieved using fluorescently labelled protein domains which 
specifically bind to the PI of interest. This technique was of particular use when 
characterising PIP and PIP2 as these protein domains only bind to the specific PI with 
the corresponding phosphorylated inositol ring positions. Therefore, PI4P can be 
differentiated from PI5P or PI3P and likewise for PI4,5P2 over other PIP2 groups 
(Idevall-Hagren and De Camilli, 2015).  
Previous studies into phosphoinositide levels in cells have used inhibitors of PI 
kinases such as LY294002 and phenylarsine oxide (PAO). These techniques are 
limited in that there are off target effects and the membrane which was depleted 
cannot be controlled using inhibitors in this manner. A technique which allows the 
direct manipulation of PI4P and/or PI4,5P2 levels at the PM has been developed and 
investigated using mammalian COS-7 cells (Hammond et al., 2012). This technique 
used the rapamycin-inducible dimerization of FRB (fragment of mTOR that binds 
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rapamycin) and FKBP (FK506 binding protein 12) (Heo et al., 2006; Varnai et al., 
2006). The rapamycin-inducible dimerization components FRB and FKBP was bound 
to a membrane specific anchor and phosphatase respectively. To selectively 
manipulate PI4P and PI4,5P2 a chimera protein containing the 5’ phosphatase INPP5E 
(inositol polyphosphate-5-phosphatase E) and the 4’ phosphatase sac1 phosphatase 
named pseudojanin was produced by Hammond et al. (Guo et al., 1999; Varnai et 
al., 2006; Hammond et al., 2012). To direct this system to the PM specifically a 
LYN11 anchor was fused with the FRB component, a schematic is shown in Figure 28. 
This system can be used to selectively remove different populations of PI by using 
double and individual active versions of the chimera phosphatase to disrupt 
specifically PI4P or PI4,5P2 into PI4P or into PI. Upon the addition of rapamycin the 
pseudojanin was localised to the PM within 2 minutes and levels of the PI are 
decreased (Hammond et al., 2012). A double dead pseudojanin can be used as a 
control for the effect of rapamycin on cellular processes.  
Figure 28: Schematic of rapamycin induced phosphatase system 
 The proteins FKBP and FRB (FKBP rapamycin binding) bind in the presence of 
rapamycin. This allows for inducible co-localisation of these two proteins. Linking 
of the FKBP component to the pseudojanin phosphatase enzyme allows for 
dephosphorylation of the 4’ and 5’ position phosphate of phosphoinositide. The 
pseudojanin is composed of two phosphates and is capable of double position 
dephosphorylation or single position dephosphorylation. The FRB component is 
linked to a membrane anchor, in this case LYN11, which specifically targets the 
FRB to the plasma membrane. The introduction of rapamycin results in localisation 
of the pseudojanin phosphatase to the plasma membrane, providing precise 
temporal control for the reduction of specific phosphoinositide populations at the 
plasma membrane inner leaflet. 
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To observe the effect depletion of these specific PI groups at the PM specifically 
have on glucose uptake would provide informative insight as to if PI4P modulates 
GLUT4 dispersal or in fact aids the clustering of GLUT4 at the PM in the absence of 
insulin stimulation. This experiment required high transfection of the above 
mentioned FRB and FKBP components to allow for any measured differences to be 
related to the depletion of the PI identities and not a result of rapamycin addition 
to the cells. High transfection is challenging when working with terminally 
differentiated cells such as 3T3-L1 adipocytes, further more traditional transfection 
using lipid reagents is inhibited when working with high adiposity of adipocyte cell 
lines.  
5.2 AIM 
This chapter aims to characterise localisation of PI4P in 3T3-L1 adipocytes. This aim 
will allow for the characterisation of phosphoinositide behaviour at the PM in 
response to insulin signalling in HeLa and 3T3-L1 adipocyte cell types. This chapter 
aims to directly manipulate PI levels at the PM of adipocytes to monitor the effects 
of P14P depletion and proliferation on PM GLUT4 and glucose uptake.  
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5.3 VISUALISATION OF PI4P AND PI4,5P2 IN HELA  
The protein SidM is secreted by the Legionella pneumophila and binds to PI4P 
specifically through the P4M domain (Brombacher et al., 2009; Hammond et al., 
2014). HeLa cells were transfected with PI4P binding GFP-SidM-P4M probe. Images 
show PI4P localisation to the PM as an even distribution in HeLa cells, which was 
consistent with previous studies, depicted in Figure 29 denoted by white arrows. A 
concentration of intracellular GFP-SidM-P4M was consistent with previous findings 
of Golgi concentrations of PI4P, denoted with red arrows in Figure 29 (Hammond et 
al., 2014).  
 
The probe PH-PLCδ1-GFP was derived from the pleckstrin homology (PH) domains of 
phospholipase C (PLC)δ. PH-PLCδ1-GFP binds specifically to PI4,5P2 via the PH 
domain (Várnai and Balla, 1998). Images shown in Figure 30 show confocal 
microscopy views of HeLa cells fluorescently immuno-labelled expressing PH-PLCδ1-
GFP. PI4,5P2 localisation in HeLa cells was membrane localise to the PM, as shown 
in previous studies (S. Huang et al., 2004). The patches of PI4,5P2 at the PM, denoted 
by the white arrows in Figure 30, have been associated with clusters of PI4,5P2 
required for focal adhesions (Cai et al., 2008). These patches are now mostly 
associated with the formations of furrows of the PM giving the appearance of 
clustering (Ji et al., 2015). The majority of PI4,5P2 localisation was seen at the PM 
Figure 29: Confocal images of SidM-P4M-GFP expressing HeLa cells. 
 Representative confocal images of the PI4P binding probe GFP-SidM-P4M expressed 
in HeLa cells. The left red panel is fluorescent immuno-labelled β-tubulin, the 
middle green panel is GFP-SidM-P4M, and the right panel is the merged image. 
White arrows denote the PM localised PI4P, and the red arrow denotes the 
intracellular Golgi PI4P localisation. Scale bar represents 25 µm. 
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but intracellular perinuclear localisation was also noted in the HeLa cells as previous 
studies have shown, signified by the purple arrow in the merged panel in Figure 30 
(Tan et al., 2015).  
  
Figure 30: Confocal images of PH-PLCδ1-GFP expressing HeLa cells. 
 Representative confocal images of the PI4,5P2 binding probe PH-PLCδ1-GFP 
expressed in HeLa cells. The left red panel is fluorescent immuno-labelled β-
tubulin, the middle green panel is PH-PLCδ1-GFP, and the right panel is the merged 
image. White arrows denote the patches of PM localised PI4,5P2, and the purple 
arrow denotes the intracellular perinuclear localisation. Scale bar represents 25 
µm. 
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5.4 VISUALISATION OF PI4P AND PI4,5P2 IN 3T3-L1 ADIPOCYTES 
Confocal microscopy images of the PI4P probe SidM-P4M-GFP show distinct patch 
localisation in 3T3-L1 adipocytes, shown in Figure 31. Plasmid DNA was introduced 
to day 4 post-differentiation 3T3-L1 cells via electroporation. This results in smaller 
adipocytes due to the transfection process. Arrows denote the patch visualisation of 
GFP-SidM-P4M in adipocytes, which is distinct from when visualising GFP-SidM-P4M 
in HeLa cells. In HeLa cells PI4P localisation was noticeably PM with concentrations 
associated with folds in the PM. The patch visualisation in 3T3-L1 was seen at the 
PM and as fainter intracellular localisations, denoted with white and red arrows 
respectively.  
Figure 31: Confocal images of SidM-P4M-GFP expressing 3T3-L1 adipocytes. 
 Representative confocal images of the PI4P binding probe GFP-SidM-P4M expressed 
in 3T3-L1 adipocyte cells. White arrows denote the brighter PI4P patches believed 
to be PM, and the red arrow denotes the fainter potentially intracellular PI4P 
patch localisation. Cells serum starved for 2 hours and stimulated with 0.1 µM 
insulin for 20 minutes pre PFA fixing. Scale bar represents 5 µm. 
 
 
Basal 
Insulin 
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Confocal microscopy images of the PI4,5P2 probe PH-PLCδ1-GFP show predominant 
PM localisation in 3T3-L1 adipocytes, shown in Figure 32. White arrows denote PM 
localised PI4,5P2, there was no difference in PI4,5P2 localisation in cells stimulated 
with insulin. However, significant intracellular localisation was noted in the majority 
of 3T3-L1 adipocytes in comparison to HeLa cells, denoted with red arrows in Figure 
32.  
 
 
 
Basal 
Insulin 
Figure 32: Confocal images of PLCδ1-GFP expressing 3T3-L1 adipocytes. 
 Representative confocal images of the PI4,5P2 binding probe PH-PLCδ1-GFP 
expressed in 3T3-L1 adipocyte cells. The top panel shows non-insulin 
stimulated cells. The bottom panel shows insulin stimulated cells. White 
arrows denote the PM localised PI4,5P2, and the red arrow denotes the 
intracellular localisation. Cells were serum starved for 2 hours and stimulated 
with 0.1 µM insulin for 20 minutes pre PFA fixing. Scale bar represents 15 µm. 
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5.5 THE EFFECT OF INSULIN STIMULATION ON VISUALIZED POOLS OF PI4P 
Confocal images of 3T3-L1 adipocytes expressing the PI4P binding probe SidM-P4M-
mcherry show distinct patches of PI4P in 3T3-L1 adipocytes, shown in Figure 31. This 
was unlike the PI4,5P2 binding probe PLCδ1-GFP, shown in Figure 32, which showed 
a more uniform PM localisation with no visible changes in distribution in response to 
insulin stimulation. Using ImageJ, the intensity threshold was adjusted to allow for 
the number of foci at the PM to be measured per cell. Threshold intensity was 
automatically set using Fiji clustering threshold to remove biases from the sample 
evaluated (Sezgin and Sankur, 2004). The results shown in Figure 33 are that insulin 
stimulation results in a significant decrease in the number of patches per cell of 
PI4P. The decrease in the number of foci per cell was 3-fold in the population 
measured.  
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Graph showing the number of patches per cell, cells that are insulin stimulated 
have a marked decreased in the number of PI4P patches. Over 30 cells where 
measured per condition. Cells were transfected using electroporation as described 
in 3.10.1, serum starved for 2 hours and insulin stimulated for 20 minutes using 
0.1 µM insulin.  
Figure 33: Measurement of the visualisation of PI4P patches in 3T3-L1 
adipocytes. 
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5.6 GENERATION OF PSEUDOJANIN PHOSPHATASE SYSTEM 
5.6.1  Expression of Pseudojanin in HeLa cells 
The plasmids containing the PI manipulation system, shown in Figure 28, was 
composed of the FRB-LYN11 PM anchor component and the FKBP-pseudojanin 
phosphatase component. The pseudojanin phosphatase was a chimera protein 
containing the 4’ phosphatase Sac1 and the 5’ phosphatase INPPE5. The FKBP and 
FRB proteins bind in the presence of rapamycin allowing the phosphatase to be 
directed to appropriate membrane. There are four phosphatase chimeras versions; 
the double active pseudojanin (PJ), the two single active Sac1 or INPPE5, and the 
double dead PJ-dead developed by Hammond (Hammond et al., 2014). Confocal 
images confirm that the FRB-LYN11 component was plasma membrane localised, 
shown in Figure 34 A. Images confirm that all four of the FKBP-phosphatases are 
cytosolic localised in the absence of the FRB-LYN11 plasmid and rapamycin, shown 
in Figure 34B-E. 
124 
 
C 
B 
A D 
E 
Figure 34 :Confocal images of pseudojanin system components in HeLa cells 
 Confocal images of HeLa cells transfected with plasmid DNA expressing the A. 
LYN11-FRB-CFP; B. FKBP-PJ-mCherry, C. FKBP-PJSac1-mcherry, D. FKBP-PJINPPE5-
mcherry, E. FKBP-PJdead-mCherry. The LYN11-FRB-CFP anchor shows distinctive 
plasma membrane localisation, as per the LYNN11 protein. The Pseudojanin (B-E) 
all show typical cytosolic localisation in the absence of co-transfection with the 
LYN11-FRB-CFP and rapamycin treatment. Scale bar represents 50 µm. 
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5.6.2 Generation of a stable FRB-LYN11 anchor 3T3-L1 cell line 
Due to the high lipid content of 3T3-L1 adipocytes transfection with plasmid DNA 
was inhibited. The disruption of PI at the plasma membrane requires introduction of 
two plasmids. This makes the visualisation of GLUT4 behaviour at the PM in a few 
cells which are transfected not feasible. To assess the effect of PI depletion on 
glucose uptake in adipocytes a high transfection rate must be achieved. Therefore, 
a stable cell line containing FRB-LYN11 was developed. This will allow for a high rate 
of FRB-LYN11 positive cells and improve double expression with the FKBP-PJ 
component to perform the uptake assay. 
 
 
A stable cell line of the FRB-LYN11-mcherry and FRB-LYN11-CFP was generated using 
G418 media, as the plasmid contains neomycin resistance. To obtain colonies from 
single cells the transfected 3T3-L1 fibroblasts are submitted to limiting dilution to 
Figure 35: Confocal images of FRB-LYN11-mcherry stable expression 3T3-L1 
cell line generated through limiting dilution  
 Representative confocal images of limiting dilution generated 3T3-L1 fibroblasts 
stably expressing FRB-LYN11-mcherry as a polyclonal cell line. Random views from 
single colonies show that less than 30% of cells display a successful stable 
transfection of FRB-LYN11-mcherry. None of the colonies had a stable transfection 
rate of above 30%. Scale bar represents 50 µm.  
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generate cell colonies from a single G418 resistant cells. Confocal images from a 
single colony show LYN11-FRB-mcherry positive and negative cells, shown in Figure 
35. 10 colonies in total were tested and none of the colonies have more than 40% 
positive cells. This result shows that this technique for generating a stable cell line 
was inappropriate. 
To improve the percentage of stable transfected 3T3-L1 fibroblasts FACS sorting was 
used to sort for mCherry positive cells from cells which are G418 resistant. Images 
show that FACS sorting did not improve the percentage of LYN11-FRB-mcherry cells, 
shown in Figure 36. This result concluded the use of stable cell line for this 
investigation.  
 
 
Figure 36: Confocal images of 3T3-L1 fibroblast cell which stably express FRB-
LYN11-mcherry and have been FACS sorted. 
 Representative confocal images of FACS sorted 3T3-L1 fibroblasts stable 
polyclonal line expressing FRB-LYN11-mcherry. As is shown in the confocal images 
FRB-LYN11-mcherry positive expressing cells make up less than 10% of cells 
viewed. Scale bar represents 50 µm.  
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5.6.3 Lentivirus production 
The lentiviral expression construct was co transfected with the packing plasmids into 
producing cells, HEK293FT. The packaging plasmids used are the pPACKH1™ 
constructs from system biosciences. Virus production was tested using Lenti-X™ 
GoStix™, the titre test was positive for all components and viral supernatant was 
tested on HeLa cells for efficacy. Images from infected 3T3-L1 fibroblast cells show 
no expression of plasmid inserts, shown in Figure 38. To test that the lentiviral 
expression constructs express the plasmid inserts HEK293FT cells are transfected 
and visualised. Results from lentiviral expression construct transfection are shown 
in Figure 37. The plasmids successfully express mCherry which was cytosolically 
localised, as previous expected for the PJ phosphatases (Hammond et al., 2014). 
The expression of the vectors containing active PJ phosphatases results in a 
significant proportion of cells positive for the PJ phosphatase becoming 
multinucleated, Figure 37A-C. Multinucleation was an indication that cells are not 
able to divide properly when expressing the PJ phosphatases. This indicates issues 
with cytokinesis and viral budding as both of these processes require membrane 
scission. The phosphatases are active when expressed and it was possible that this 
was causing an imbalance in the PI population at the membrane affecting scission 
(Berger et al., 2011; Altan-Bonnet and Balla, 2012).  
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Representative confocal images of HEK293FT cells transfected with plasmid expressing 
mcherry tagged A. pCDH-FKBP-PJ B. pCDH-FKBP-PJ (Sac1) C. pCDH-FKBP-PJ (INPPE5) 
E. pCDH-FKBP-PJdead constructs. Multinucleated cells make up a large proportion of 
transfected cells for A. 51% B. 40% C. 35% E. 12%. Scale bar represents 50 µm. 
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Figure 37: Confocal images of lentiviral plasmid pCDH-FKBP-Pseudojanin-mcherry 
expressed in HEK293FT 
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A. 3T3-L1 adipocyte cells infected with pCDH-Pseudovirus lentivirus on day 
6-post differentiation using recommended TU/million cells. B. 3T3-L1 
adipocyte cells that were not infected with lentivirus. 
Images taken using the same laser intensity settings to account for 3T3-L1 
adipocyte auto fluorescence. Scale bar represents 50 µm. 
 
B 
A 
Figure 38 : Confocal images of 3T3-L1 fibroblast infected with pCDH-
pseudojanin 
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5.7 DISCUSSION 
5.7.1 Visualisation of phosphoinositide’s  
Visualisation of PI4P and PI4,5P2 in HeLa cells demonstrates PM localisation. PI4P 
visualisation shows both intracellular perinuclear compartment localisation, and 
uniform lawn at the PM. PI4P in HeLa cells have minimal patches at the PM 
represented in these images. The images from PI4,5P2 probe show PM localisation 
with numerous concentrated distinct patches noted at the PM. In 3T3-L1 adipocytes 
PI4,5P2 localisation was shown to be at the PM, with patches as seen in HeLa cells. 
Further intracellular localisation was observed in some cells, this was not consistent 
across all images and was therefore potentially a result of plasmid DNA delivery.   
When studying various PI populations at the PM the use of PH domains was ubiquitous 
within in the field (Hammond et al., 2012). A new technique to visualise nanoscale 
landscape PI groups at the PM based on the specific PH probes have been developed 
using super-resolution fPALM microscopy combined with TIRF (Ji et al., 2015). 
However, it was important to consider the possibility that not all PH domains have 
access to all the PIs at the PM due to the presence of endogenous proteins which 
bind to and sequester specific PIs for function (D’Angelo et al., 2008). The binding 
of other effector proteins to the PIs would result in inhibition of fluorescent probe 
binding due to space hindrance. The use of PI probes has previously been employed 
in studies to inhibit binding, of effector proteins to the specific PI (Wang et al., 
2005). It was therefore important to appreciate that the use of these probes in a 
system may inhibit the molecular mechanisms being investigated.  
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5.7.2 Future work investigating PI4P foci at the PM in adipocytes. 
To improve results when investigating PIs in cells other techniques could be 
employed for future investigations. Techniques commonly used to identify and 
quantify PIs in the cell include thin layer chromatography (TLC), and ion-exchange 
HPLC separation in cells labelled with [32P]inorganic phosphate or [3H]inositol (Milne 
et al., 2005; Rusten and Stenmark, 2006; Kim et al., 2010). However, the major 
drawback of these techniques was that the phosphorylation position on the inositol 
ring cannot be distinguished. Therefore, the difference between PI4P and PI5P 
cannot be evaluated. This technique was still viable as overall PIP or PIP2 levels can 
be analysed, with the knowledge that both PI4P and PI4,5P2 are the predominant PI 
populations in higher eukaryotes. Therefore, any significant changes in PIP levels 
are predominantly attributed to be changes in PI4P levels in the cell (Idevall-Hagrena 
and De Camilli, 2015). However, to distinguish between the distinct populations of 
PIP, and PIP2 other techniques are required.  
The development of fluorescent probes fused with PI binding domains which are 
capable of selectively binding to specific PI identities has been integral to the 
microscopic study of PI (Balla et al., 2005). A large number of PI binding protein 
domains have been identified for example; the PX domain from Tubby protein and 
the PH domain from PLCδ1 both selectively bind PI4,5P2 (Várnai and Balla, 1998; 
Santagata et al., 2001). In particular when studying PIs at the PM TIRF microscopy 
has been a powerful method for elucidating events at the PM (Knight and Falke, 
2009).  
Previous studies have shown that the over expression of phosphoinositide binding 
domain probes has an inhibitory effect on the interaction of other PI binding proteins 
in the cell. The over expression of both Akt and Btk PH domains which recognise and 
bind PI3,4,5P3 resulted in the inhibition of PI3,4,5P3 stimulated Akt/PKB activation 
(Varnai et al., 2005). The over expression of PH binding of other proteins, such as 
ARO and GRP1, had no such inhibitory effects (Varnai et al., 2005). The activation 
of the G-protein coupled receptors type 1 muscarinic receptor and bradykinin 2 
receptor, results in the phosphorylation of PI4,5P2 and production of PI3,4,5P3. Cells 
expressing the PI4,5P2 binding probe PLCδ-GFP show that in response to receptor 
stimulation the probe PLCδ-GFP was displaced from the PM to the cytosol (Wang et 
132 
al., 2005). Indicating that the probe was displaced upon receptor stimulation and 
allows for cellular processes to continue uninhibited. These findings show that the 
binding of the PI binding probes can be used as a tool to visualise specific PI 
populations without inhibiting cellular processes. However, it was important to be 
aware that inhibition may occur as a result of over expression of probes containing 
these binding domains if binding partners and effectors of the specific PI exhibit 
competitive binding. Results in this chapter show that the PI4P binding probe SidM-
P4M-GFP localisation was altered in response to insulin stimulation.  
5.7.3 Developing the Pseudojanin system for future studies 
Achieving the direct manipulation of PI populations would have been an impressive 
experiment to observe the effect depletion of specific PI groups (PI4,5P2, PI4P, PI5P) 
on glucose uptake. This would have revealed if the presence of PI4P at the PM was 
important for insulin mediated glucose uptake. Therefore, if the function of EFR3 is 
based on the generation of PI4P at the PM. This experiment required a high 
expression percentage of two vectors to observe effects on glucose uptake, this was 
not achieved using the strategy of generating a stable cell 3T3-L1 cell line with the 
FRB-LYN11 anchor component and a lentiviral vector containing the FKBP-
pseudojanin component for infection of terminally differentiated 3T3-L1 adipocytes. 
Future work may involve changing the CMV promoter of these components as it may 
not be compatible with 3T3-L1 adipocytes for stable cell line generation. An 
inducible promoter would be a more appropriate system for introducing the 
phosphatases due to the formation of multinucleated cells noted in HEK293FT cells 
when generating lentivirus. Viral budding and cytokinesis are two linked process 
which both require similar scission machinery for example ESCRT proteins 
(endosomal sorting complex required for transport) (Wollert et al., 2009).   
5.8 CONCLUSION 
The findings in this chapter reveal that the phospholipid PI4P is present in a distinct 
manner in 3T3-L1 adipocytes. PI4P forms foci in 3T3-L1 adipocytes and the number 
of foci was reduced upon insulin stimulation indicating an insulin dependent effect. 
Crucial experimentation would involve direct manipulation of PI4P at the PM to 
elucidate if the effect on PI4P patches at the PM was a causative or correlative 
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result. Work to achieve this showed the experimental strategy employed was not 
possible using adipocytes for glucose uptake. As this global approach is beyond 
current tools future work may be possible observing single cells using 4 colour 
imaging. This would give a qualitative overview of how PI4P affects the PM GLUT4 
of adipocytes opposed to the more quantitative result the experimental strategy 
followed in this thesis would have yielded. Therefore results herein cannot 
definitively state if it is the levels of PI4P which affect GLUT4 at the PM in response 
to insulin stimulation or an unknown function of EFR3. It is however most likely any 
effect produced by EFR3 is a result of PI4P levels at the PM based on the literature 
available (Baird et al., 2008; Nakatsu, Jeremy M. Baskin, et al., 2012; Bojjireddy et 
al., 2015).  
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6 ROLE OF EFR3A DURING INSULIN STIMULATED GLUT4 
DISPERSAL 
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6.1 INTRODUCTION 
Understanding of GLUT4 response to insulin has long focused on the delivery of 
GLUT4 storage vesicles (GSVs) to the PM (Huang and Czech, 2007). The mechanisms 
underpinning GLUT4 delivery to the PM in response to insulin stimulation rely on 
several distinct processes; endocytosis, sorting, sequestering, release, tethering, 
fusion and dispersal (Shewan et al., 2000; Blot and McGraw, 2006; Stenkula et al., 
2010; Bryant and Gould, 2011; Lizunov, Stenkula, et al., 2013; Brewer et al., 2014). 
Much of the molecular mechanisms behind the majority of these steps have been 
identified and characterised. GLUT4 dispersal at the PM in response to insulin 
signalling has recently been identified and characterised, but the molecular 
mechanism behind this remain uncharacterised (Stenkula et al., 2010; Lizunov et 
al., 2012; Lizunov, Stenkula, et al., 2013). 
To identify a molecular mechanism behind this the results from a previous genetic 
study in yeast was used (Wieczorke et al., 2003). Yeast have no endogenous GLUT4 
transporters, when GLUT4 was expressed it was intracellular sequestered, as in 
mammalian cells. Yeast strain with all hexose transporters deleted (Δhxt) which are 
expressing mammalian GLUT4 are however unable to sustain life when fed glucose. 
This study found that a double mutation fgy1-1 and fgy4X was required for GLUT4 
mediated glucose uptake in yeast. The fgy1-1 mutation was a mutant allele of gene 
FGY1, which encodes the protein EFR3 in yeast. GLUT4 transport has been shown to 
be conserved from yeast to mammals, with yeast capable of sequestering GLUT4 
internally in GSV type bodies (Shewan et al., 2013). EFR3A in 3T3-L1 adipocytes and 
HeLa’s has been characterised to localise to the PM in chapter 4. Results from mice 
samples in chapter 4 indicate that EFR3A and PI4KIIIa protein levels are elevated in 
insulin sensitive tissue of mice which have impaired glucose tolerance. This is 
indicative of a compensatory effect as a disease is developed, and therefore 
indicates our initial hypothesis that fgy1-1 was a loss of function mutation of Efr3 
appears incorrect. This chapter aims to test the hypothesis for how EFR3A may affect 
GLUT4 at the PM in response to insulin stimulation.   
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HeLa cells provide a model system which can be used to demonstrate an effect on 
PM GLUT in the cell expressing HA-GLUT4-GFP. 3T3-L1 adipocytes expressing HA-
GLUT4-GFP also provide a more physiologically relevant model to investigate PM 
GLUT4, the schematic of how  HA-GLUT4-GFP can be used to quantify plasma 
Figure 39: Schematic of HA-GLUT4-GFP plasma membrane staining 
 HA-GLUT4-GFP expressing cells can be used to measure the plasma membrane 
GLUT4 levels relative to total GLUT4 levels of the cell. The HA epitope tag 
expressed on the extracellular loop of GLUT4 is stained using antibody labelling in 
non-permeabilised cells. Therefore, only HA which is extracellularly exposed (ie 
GLUT4 fused to the PM) is stained. The GFP signal is seen for both intracellularly 
localized GLUT4 and PM fused GLUT4 and acts as an internal control for total 
GLUT4. This technique has been employed by others in both HeLa and 3T3-L1 
adipocytes.  
137 
membrane GLUT4 levels is shown above in Figure 39 (Martin et al., 2006; Sadler, 
Bryant, et al., 2015). The HA-epitope tag is exposed at the extracellular surface 
when GLUT4 was fused at the PM. This allows for the HA tag to be fluorescently 
immuno-labelled at the PM in non-permeabilised cells. Therefore in HA-GLUT4-GFP 
expressing cells HA staining intensity correlates to PM GLUT4 levels and GFP 
fluorescence intensity correlates to total GLUT4 content of the cell, and therefore 
can be used to normalise measurements (Kioumourtzoglou et al., 2015). HeLa cells 
are regularly used in this model despite not expressing endogenous IR and GLUT4, 
when expressing HA-GLUt4-GFP translocation from intracellular stores to the PM was 
still triggered by insulin stimulation, the insulin stimulated increase is less than that 
seen in 3T3-L1 adipocytes and therefore it is possible to miss effects on PM GLUT4 
using this model (Haga et al., 2011). The introduction of plasmid DNA to 3T3-L1 
adipocytes by traditional methods was inhibited due to the high lipid content of the 
cell, meaning the introduction of plasmid DNA to adipocytes was not a simple process 
(Okada et al., 2003). HeLa cells however are readily transfected using standard 
protocols, the HA-GLUT4-GFP expressing HeLa cells therefore provide a 
transfectable model system to gather preliminary results in. This can be used to 
investigate if EFR3A has a positive or negative effect on PM GLUT4 and how insulin 
stimulation is involved.  
The end result of translocation of GLUT4 to the PM is to increase glucose uptake of 
the cell. This provides a measurable output for how EFR3A and PI4KIIIa may affect 
GLUT4 via the uptake of glucose within these cells. PI4KIIIa activity can be inhibited 
using phenylarsine oxide, providing a method for inhibiting the production of PI4P 
at the PM inner leaflet.  
6.2 AIMS 
The aim of this chapter was to characterise the role of EFR3A in insulin stimulated 
GLUT4 behaviour at the PM. Chapter 4 has shown that EFR3A was localised to the 
PM in adipocytes, as the molecular mechanism behind insulin stimulated GLUT4 
behaviour  
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6.3 THE EFFECT OF EFR3 OVEREXPRESSION IN GLUT4 EXPRESSING 
HELA MODEL SYSTEM 
6.3.1 Confocal visualisation of the effect of EFR3 on GLUT4 at the 
plasma membrane 
Images of HeLa cell line expressing HA-GLUT4-GFP transfected with high copy EFR3A-
mcherry or EFR3B-mcherry plasmid are shown in Figure 40 &Figure 41 respectively. 
As previously characterised in 4.5.1 EFR3A and EFR3B exhibit PM localization in HeLa 
cells, seen in the white panel of Figure 40 & Figure 41. HA-staining in cells positive 
for EFR3A and EFR3B, depicted with white arrows, was increased in comparison to 
non-transfected cells. HA-staining was increased in insulin stimulated and non-
insulin stimulated samples, indicating that there still was an insulin effect, but it 
was diminished.  
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Figure 40: Confocal microscopy images of EFR3A-mcherry expressing HA-
GLUT4-GFP HeLa cells 
 Representative confocal microscopy images of HA-GLUT4-GFP expressing HeLa 
cells over-expressing with EFR3A-mcherry. EFR3A-mcherry positive expressing 
cells (white panel), HA-GLUT4 staining (blue panel) and GLUT4-GFP (green panel). 
HA staining in non-permeabilised cells represents plasma membrane GLUT4. Cells  
over-expressing EFR3A indicated with white arrows in the blue panel. HeLa cells 
are serum starved for 3 hours and insulin stimulated for 20 minutes with 0.1 uM 
insulin. 
GLUT4-GFP GLUT4-GFP 
GLUT4-GFP GLUT4-GFP 
HA-GLUT4 HA-GLUT4 
HA-GLUT4 HA-GLUT4 
EFR3A-mCherry EFR3A-mCherry 
EFR3A-mCherry EFR3A-mCherry 
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Figure 41: Confocal microscopy images of EFR3B-mcherry expressing HA-
GLUT4-GFP HeLa cells 
 Representative confocal microscopy images of HA-GLUT4-GFP expressing HeLa 
cells over-expressing with EFR3B-mcherry. EFR3B-mcherry positive expressing 
cells (white panel), HA-GLUT4 staining (blue panel) and GLUT4-GFP (green 
panel). HA staining in non-permeabilised cells represents plasma membrane 
GLUT4. Cells over-expressing EFR3B, indicated with white arrows in the blue 
panel. HeLa cells are serum starved for 3 hours and are insulin stimulated for 20 
minutes with  0.1 uM insulin. 
GLUT4-GFP GLUT4-GFP 
GLUT4-GFP GLUT4-GFP 
HA-GLUT4 HA-GLUT4 
HA-GLUT4 HA-GLUT4 
EFR3B-mCherry EFR3B-mCherry 
EFR3B-mCherry EFR3B-mCherry 
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6.3.2 Effect of EFR3 overexpression on plasma membrane GLUT4 in 
HeLa cells 
The HA epitope tag on GLUT4 allows for the relative PM exposed GLUT4 in 
comparison to the total GLUT4 to be measured using fluorescence microscopy images 
and ImageJ to measure mean intensity, results are shown in Figure 42. Results show 
that insulin stimulation of HeLa cells results in a 2.09-fold increase in PM GLUT4. 
HeLa cells over expressing EFR3A have a 1.50-fold increase in PM GLUT4 and cells 
expressing EFR3B have a 2.07-fold increase in PM GLUT4 in response to insulin 
stimulation. HeLa cells stimulated with insulin compared with HeLa cells which are 
not stimulated with insulin but are over expressing EFR3A or EFR3B have similar 
measured PM GLUT4 levels, 1.2 (P>0.1) and 0.98 (NS) fold difference respectively. 
The difference in PM GLUT4 levels in insulin stimulated HeLa cells which over express 
EFR3A and EFR3B was not significant 1.03-fold. The difference between homologs 
was non-significant apart from the increase in PM GLUT4 in response to insulin 
stimulation was greater in cells expressing EFR3B. As previous data indicates that 
EFR3A was the dominantly expressed homolog in HeLa and 3T3-L1 adipocytes future 
investigation will focus on EFR3A. Results show that cells which are overexpressing 
EFR3A or the homolog EFR3B have an increase in PM GLUT4 in comparison to the 
non-transfected HeLa cells.  
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Figure 42 : The effect of over expression of EFR3A and EFR3B on plasma 
membrane GLUT4 in H La c lls 
 HeLa cells stably express HA-GLUT4-GFP were transiently transfected with EFR3A-
mcherry and EFR3B-mcherry. The HA epitope tag was stained at the plasma 
membrane (PM) in non-permeabilised cells. A. Individual cell HA staining 
fluorescence intensity measurements using imageJ were quantified and normalised 
to GFP fluorescent intensity, correlating to total cell GLUT4. HeLa cells have a 
measured 2.09 fold increase in PM GLUT4 in response to 20-minute 0.1 uM insulin 
stimulation. Cells expressing EFR3A and EFR3B have a measured increase in PM 
GLUT4 in non-stimulated cells and an insulin stimulated increase in PM GLUT4 is 
still measured. Error bars represent SEM. Over expression of EFR3 results in 
increased surface GLUT4 in both insulin stimulated (+) and basal (-) conditions 
Number of cells measured; EFR3A (+) n=48, EFR3A (-) n=37, EFR3B (+) n= 70, EFR3B 
(-) n=29, HeLa (+) n=67, HeLa (-) n= 70. *** P value < 0.0001, ** P value < 0.001 
from two way ANOVA analysis. 
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6.3.3 Effect of dominant negative EFR3A mutant EFR3A(C6-9S) on 
plasma membrane GLUT4 in HeLa cells 
6.3.3.1 Visualisation of EFR3A(C6-9S)-tdtomato in HA-GLUT4-GFP 
HeLa cells 
The HeLa cell line stably expressing HA-GLUT4-GFP was transfected with high copy 
EFR3A (C6-9S) – tdtomato containing plasmid (Nakatsu et al., 2012). Mutation of the 
palmitoylation sites C6 – 9 to serine inhibits post translational modification. EFR3A 
was no longer membrane associated and was miss-localised from the PM to the 
cytosol as shown in the white panels in Figure 43. EFR3A(C6-9S) was still able to bind 
to the PI4KIIIα intermediator binding protein TTC7, as the binding domain at the C 
terminal has not been mutated (Nakatsu, et al., 2012; Wu et al., 2014). Therefore 
EFR3A(C6-9S) overexpression will miss-localise PI4KIIIα acting as a dominant negative 
mutant. Images of HA-GLUT4-GFP expressing HeLa cells transfected with EFR3A(C6-
9S) show decrease in HA staining in the insulin stimulated cells in comparison to non-
transfected cells, indicated with white arrows in the HA staining panel of Figure 43.  
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Representative confocal microscopy images of HA-GLUT4-GFP expressing HeLa 
cells transfected with EFR3A (C6-9S)-tdtomato. EFR3A (C6-9S)-tdtomato positive 
expressing cells (white panel), HA-GLUT4 staining (blue panel) and GLUT4-GFP 
(green panel). HA staining in non-permeabilised cells represents plasma 
membrane GLUT4. HA-staining was diminished in insulin-stimulated cells 
transfected with EFR3A (C6-9S)-tdtomato, indicated with white arrows. HeLa 
cells are serum starved for 3 hours and insulin stimulated for 20 minutes with 0.1 
uM insulin. 
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Figure 43: The effect of over expression of EFR3A dominant negative mutant 
on plasma membrane GLUT4 in HeLa cells 
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6.3.3.2 Effect of EFR3(C6-9S) overexpression on plasma membrane 
GLUT4 in HeLa cells 
The HA epitope tag on GLUT4 allows for the relative PM exposed GLUT4 compared 
to total GLUT using the GFP intensity. This can be used to measure PM GLUT4 in a 
cell expressing HA-GLUT4-GFP and was quantified per cell using ImageJ, the data 
from images shown in Figure 43 was shown in Figure 44. Results show that insulin 
stimulation of HeLa cells results in a 1.73-fold increase (P>0.01) in PM GLUT4. HeLa 
cells over expressing EFR3A(C6-9S) have a 0.6901-fold difference (NS) in PM GLUT4 
in response to insulin stimulation. There was a 0.77 (NS) fold difference between PM 
GLUT4 levels in non-insulin stimulated HeLa cells and HeLa cells expressing 
EFR3A(C6-9S). The difference between PM GLUT4 of HeLa and EFR3A(C6-9S) 
expressing HeLa insulin stimulated cells was ~3 fold decrease (P>0.01). The results 
show that EFR3A(C6-9S) expression has minimal effect on PM GLUT4 in HeLa cells 
which are not insulin stimulated. Cells over expressing EFR3A(C6-(S) have eliminated 
the insulin effect, with no increase in PM GLUT4 in response to insulin stimulation. 
Over expression of EFR3A(C6-9S) results in a significant decrease in PM GLUT4 in 
insulin stimulated cells in comparison to non-transfected cells. 
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Figure 44: The effect of over expression of EFR3A dominant negative mutant on 
plasma membrane GLUT4 in HeLa cells 
 Graph showing the levels of PM GLUT4 in HeLa cells expressing different plasmids in 
response to insulin stimulation. Images show a representative confocal image of 
each condition; blue represents HA staining, green represents GFP, and white 
represents transfected tdtomato labelled protein. Error bars represent SEM. Number 
of cells measured; EFR3A (C6-9S) (+) n=23, EFR3A (C6-9S) (-) n=34 HeLa (+) n=30, 
HeLa (-) n= 32. *** P value < 0.001 from two-way ANOVA analysis. Cells are serum 
starved for 3 hours and insulin stimulated for 20 minutes with 0.1 uM insulin. 
 
** 
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6.4 FLUORESCENCE-ACTIVATED CELL SORTING ANALYSIS OF PLASMA 
MEMBRANE GLUT4 IN HELA MODEL SYSTEM 
Previous results using confocal microscopy has shown in the HA-GLUT4-GFP 
expressing HeLa cells that EFR3A over expression affects plasma membrane GLUT4. 
To confirm these results in a manner which has removed bias from the sample 
collection and increased cells analysed FACS was used. This technique allows for 
hundreds and thousands of cells to be analysed in comparison to the tens of cells 
analysed using microscopy. FACS analysis results, displayed below in Figure 45, show 
that over expression of EFR3A in this system leads to an increase in plasma 
membrane GLUT4. FACs analysis of HeLa cells show 1.38 (P<0.001) fold increase in 
PM GLUT4 in response to insulin stimulation. HeLa cells over expressing EFR3A have 
a measured 1.34 (P<0.001) fold increase in PM GLUT4 in response to insulin 
stimulation. In non-insulin stimulated cells over expressing EFR3A the GLUT4 levels 
at the PM was 1.23 (P<0.001) fold increased in comparison to the non-transfected 
insulin stimulated HeLa cells. Cells over expressing EFR3A have a 1.69 (P<0.001) 
increase in PM GLUT4 in comparison to un-transfected cells in the absence of insulin 
stimulation. Over expression of EFR3A results in a larger increase in PM GLUT4 than 
insulin stimulation in FACS analyses HeLa cells. This result shows EFR3A over 
expression results in increased PM GLUT4, and an insulin response was still 
measured. The dominant negative mutant EFR3A (C6-9S) was mutated at the 
palmitoylation site and therefore no longer localises to the plasma membrane. 
Microscopy images, shown in Figure 43, confirm this was now a cytosolic localised 
protein. EFR3A (C6-9sS) was still capable of binding PI4KIIIα machinery, therefore 
localising this to the cytosol. HeLa expressing this dominant negative EFR3A (C6-9S) 
show an impaired insulin response, with a non-significant 1.18-fold increase in 
plasma membrane GLUT4 in response to insulin.  Plasma membrane GLUT4 was also 
significantly lowered in these cells expressing the dominant negative in comparison 
to non-transfected cells. Insulin stimulated cells expressing EFR3A(C6-9S) have a 
1.69 (P<0.001) fold decrease in PM GLUT4 in comparison to non-transfected insulin 
stimulated HeLa cells. The trend observed using confocal microscopy was 
maintained; over expression of EFR3A increases PM GLUT4 maintaining an insulin 
effect and over expression of EFR3A (C6-9S) results in decreased PM GLUT4 and 
inhibition of the insulin effect. 
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HeLa cells stably expressing mammalian GLUT4 with the epitope tag HA and the 
fluorescent tag GFP. Cells where transfected using purefection with EFR3A-mcherry 
or EFR3A(C6-9S)-tdtomato. The HA epitope tag is stained in non-permeabilised cells 
and the fluorescence is measured of both the HA tag, plasma membrane GLUT4, and 
GFP, total GLUT4. Difference between plasmids is P>0.001 from two-way ANOVA 
analysis n numbers as follows; WT basal 13025, WT insulin 12906, EFR3A basal 3071, 
EFR3A insulin 3691, EFR3A (C6-9S) basal 605, EFR3A (C6-9S) insulin 715. Cells are 
serum starved for 3 hours and insulin stimulated for 20 minutes with 0.1 uM insulin. 
 
 
 
 
Figure 45 : FACS analysis of the effect of EFR3A and EFR3A (C6-9S) on plasma 
membrane GLUT4 in HeLa cells 
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6.5 THE EFFECT OF EFR3A OVER EXPRESSION IN 3T3-L1 ADIPOCYTES. 
 3T3-L1 adipocytes are a well characterised model for insulin sensitivity as 
adipocytes are one of the predominant targets of insulin signalling in the body. As 
with the HeLa model system 3T3-L1 adipocytes stably express HA-GLUT4-GFP. The 
HA epitope tag allows for the staining and measuring of PM GLUT4 in non-
permeabilised cells, shown the blue panel in Figure 46. The internal GFP intensity, 
shown in the green panel, visualises total GLUT4 in the cell.  As shown in Figure 46 
below HA staining at the PM was elevated in insulin stimulated adipocytes with a 
ring formation around the majority of cells, denoted with white arrows. In the 
unstimulated adipocytes GLUT4-GFP shows a predominantly intracellular 
localisation, denoted with red arrows. In the insulin stimulated cells GLUT4-GFP 
fluorescence was localised to the PM in a ring co-localised with the HA staining, 
denoted by yellow arrows. The effect of insulin was increased in comparison to the 
model system HeLa cells. Due to the high adiposity of this cell line the delivery of 
plasmid DNA was inhibited and difficult to overcome with most plasmid DNA 
transfection techniques. Electroporation offers a robust technique for the transient 
delivery of plasma DNA to adipocyte cells. 
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Representative confocal images of 3T3-L1 adipocytes expressing HA-GLUT4-GFP. 
The left panel represents non-stimulated basal cells and the right panel 
represents insulin-stimulated cells (20 minutes with 0.1 uM insulin). Blue images 
are HA epitope tag GLUT4 staining and green images are GLUT4-GFP. 
Figure 46: Confocal images of HA-GLUT4-GFP expressing 3T3-L1 adipocytes. 
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6.5.1 Visualisation of EFR3A in HA-GLUT4-GFP 3T3-L1 Adipocytes 
Confocal microscopy of EFR3A-mcherry in HA-GLUT4-GFP expressing adipocytes, 
shown in Figure 47. Cells expressing EFR3A-mcherry (red panel) have elevated HA 
staining in the absence of insulin stimulation, denoted by the red arrow in the blue 
panel of Figure 47A. GLUT4-GFP can be seen at the PM in a ring in the absence of 
insulin stimulation in cells over expressing EFR3A-mcherry, shown in Figure 47A 
depicted with the yellow arrow. The HA-staining co-localises with EFR3A in a ring 
around the cell or across the PM of these cells, depicted in the merged panel with 
white arrows. In the insulin stimulated cells it can be seen the HA-staining of EFR3A-
mcherry positive cells, depicted with red arrows Figure 47B, was in comparison to 
the un-transfected cells.  
Figure 47: Confocal visualisation of EFR3A-mcherry in HA-GLUT4-GFP 
expressing3T3-L1 adipocytes.  
Representative confocal images of 3T3-L1 adipocytes expressing HA-GLUT4-GFP 
transfected with the EFR3A-mcherry plasmid. Top panel of non-stimulated basal 
cells. Bottom panel of insulin stimulated cells (20 minutes with 0.1 uM insulin). Blue 
panel depicts HA epitope staining of GLUT4, green panel depicts GLUT4-GFP, and 
red panel depicts EFR3A-mcherry positive cells. Red arrows denote EFR3A-mcherry 
positive cells in the blue panel. Yellow arrows denote GLUT4GFP ring around EFR3A-
mcherry positive cells in basal cells. White arrows denote EFR3A-mcherry overlay 
with GLUT4 in the merge panel. Scale bar denotes 25 µm 
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Figure 47: Confocal visualisation of EFR3A-mcherry in HA-GLUT4-GFP 
expressing3T3-L1 adipocytes 
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Figure 48: Confocal visualisation of EFR3A (C6-9S)-tdtomato in HA-GLUT4-
GFP expressing 3T3-L1 adipocytes 
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6.5.2 Visualisation of EFR3A(C6-9S) in HA-GLUT4-GFP Adipocytes 
Confocal microscopy of EFR3A dominant negative mutant EFR3A(C6-9S)-tdtomato in 
HA-GLUT4-GFP expressing adipocytes, shown in Figure 48. EFR3A(C6-9S) was 
cytoplasmically localised due to the mutation of the palmitoylation sites, shown in 
red panel in Figure 48. In the absence of insulin cells positive for EFR3A(C6-9S) have 
increased HA in comparison to non-transfected cells, denoted with a red arrow in 
the blue panel of Figure 48A. Insulin stimulated cells positive for EFR3A(C6-9S) the 
HA staining was decreased in comparison to un-transfected cells.  
 
6.5.3 Plasma membrane level of GLUT4 in EFR3A and EFR3A(C6-9S) 
transfected adipocytes 
The HA epitope tag of GLUT4 was stained in non-permeabilised cells to measure the 
level of PM GLUT4 per individual cell in adipocytes through the HA-staining 
fluorescence intensity. Individual cells which over express proteins of interest, 
EFR3A and EFR3A(C6-9S) are analysed and non-transfected cells are used for the 
positive control. As previously reported in HeLa cells over expression of EFR3A in 
3T3-L1 adipocytes results in an increase in measured plasma membrane GLUT4, 
shown in Figure 49. Non-stimulated adipocyte cells over expressing EFR3A have a 
2.60-fold increase in PM GLUT4 in comparison to the WT non-stimulated cells. The 
difference between insulin stimulated WT and non-stimulated EFR3A over-
expressing cells was not significant, at 1.05-fold increase in PM GLUT4. Therefore, 
Figure 48: Confocal visualisation of EFR3A (C6-9S)-tdtomato in HA-GLUT4-GFP 
expressing 3T3-L1 adipocytes.  
Representative confocal images of 3T3-L1 adipocytes expressing HA-GLUT4-GFP 
transfected with the EFR3A (C6-9S)-tdtomato plasmid. Top panel of non-stimulated 
basal cells. Bottom panel of Insulin stimulated cells (20 minutes with 0.1 uM insulin). 
Blue panel depicts HA epitope staining of GLUT4, green panel depicts GLUT4-GFP, 
and red panel depicts EFR3A-mcherry positive cells. Red arrows denote EFR3A (C6-
9S)-tdtomato positive cells in the blue panel. Scale bar denotes 25 µm 
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cells over expressing EFR3A have comparable PM GLUT4 levels to insulin stimulated 
non-transfected adipocytes. This result shows that over expression of EFR3A alone 
can mimic insulin stimulated GLUT4 translocation to the plasma membrane in 
adipocytes. Cells over expressing EFR3A have a measured insulin response of 1.25 
fold increase in PM GLUT4 in comparison to non-transfected cells, which have a 
measured 2.47 fold increase in PM GLUT4. Therefore, over expression of EFR3A does 
not over-ride the insulin response as a measured increase in PM GLUT4 was still seen 
but the effect was not additive. Over expression of the dominant negative EFR3A(C6-
9S) results in a 1.66-fold increase in PM GLUT4 in non-stimulated WT cells. The 
insulin response of EFR3A(C6-9S) expressing cells was a non-significant 0.76 fold 
increase in PM GLUT4. The difference between insulin stimulated cells expressing 
EFR3A(C6-9S) and WT cells was a 0.51 fold increase. Therefore, insulin stimulated 
PM GLUT4 increase has been inhibited by the expression of EFR3A(C6-9S) in 
adipocytes. This trend has previously been shown in HeLa cells using both confocal 
microscopy and FACS analysis.  
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Figure 49 Confocal analysis of plasma membrane GLUT4 in 3T3-L1 adipocytes.   
 
3T3-L1 adipocytes stably expressing mammalian GLUT4 with the epitope tag HA and the 
fluorescent tag GFP. Cells where transfected using electroporation with EFR3A-mcherry or 
EFR3A (C6-9S)-tdtomato plasmids. Confocal images where used from figures 47 and 48, cells 
which where mCherry or tdtomato positive used to measure HA and GFP fluorescence 
intensity. Difference between plasmids is P>0.001 from two-way ANOVA analysis n numbers 
as follows; WT basal 33, WT insulin 38, EFR3A basal 31, EFR3A insulin 38, EFR3A (C6-9S) 
basal 21, EFR3A (C6-9S) insulin 23. Cells are serum starved for 3 hours and insulin 
stimulated for 20 minutes with 0.1 uM insulin. 
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6.6  THE EFFECT ON GLUCOSE UPTAKE USING PHENYLARSINE OXIDE 
INHIBITION OF PI4KIIIA ACTIVITY 
Inhibition of PI4K family has been tested using a variety of inhibitors. PI4K type was 
initially divided based on inhibitors. Phenylarsine oxide (PAO) was determined to be 
specific to PI4KIIIα at below 2.5 µM concentrations. Using 3H labelled 2-deoxy glucose 
to measure glucose uptake in 3T3-L1 adipocytes treated with known doses of PAO 4 
hours pre-uptake assay, the results from the assay are shown in Figure 50. Un-
treated 3T3-L1 adipocytes have measured mean glucose uptake of 10.04 
ρmol/min/million cells in the basal sample and 108.61 ρmol/min/million cells in the 
insulin stimulated sample. This represents a 10.81-fold increase in glucose uptake, 
typical for 3T3-L1 adipocytes. Cells treated with 0.5 µM PAO have a measured mean 
glucose uptake of 21.93 µM ρmol/min/million cells in the basal sample and 73.98 µM 
ρmol/min/million cells in the insulin stimulated sample. This represents a 
diminished total glucose uptake in response to insulin stimulation. 0.5 µM PAO 
treatment results in a marked decrease in the fold increase in glucose uptake in 
response to insulin stimulation, down to 3.4-fold increase in glucose uptake in 
comparison to 10.8-fold increase in non-treated cells. Cells treated with 1 µM PAO 
have a measured mean glucose uptake of 55.20 ρmol/min/million cells in the basal 
sample and 60.89 ρmol/min/million cells in the insulin stimulated sample. This 
represents a further diminished glucose uptake in response to insulin stimulation. 
The treatment with 1 µM PAO results in an inhibition of the insulin response with a 
measured 1.10-fold increase in response to insulin. Basal glucose uptake was 
markedly increased 5.50-fold in cells treated with 1 µM PAO in comparison to non-
treated cells. In cells treated with 1 µM PAO the combined decrease in glucose 
uptake in response to insulin stimulation compared to non-treated cells and increase 
in basal glucose uptake compared to non-treated cells results in an inhibition of an 
insulin effect in these samples. Cells treated with 2.5 µM PAO have a measured mean 
glucose uptake of 30.48 ρmol/min/million cells in the basal sample and 20.25 
ρmol/min/million cells in the insulin stimulated sample. This represents full 
inhibition of insulin stimulated glucose uptake.  
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Figure 50: Effect of phenylarsine oxide dosage on glucose uptake in 3T3-L1 
adipocytes.  
Glucose uptake was measured using 3H labelled 2-deoxy glucose. Cells are incubated 
with phenylarsine oxide 4 hours prior to uptake assay. Cells are insulin stimulated for 
30 minutes with 0.1µM insulin and a 10-minute uptake of the 25 ηmol 2-Deoxyglucose. 
Data was from 3 technical and 3 biological repeats, graph represents mean 
ρmol/min/million cells and error bars SEM. Un-treated 3T3-L1 adipocytes have 
measured mean glucose uptake of 10.04 ρmol/min/million cells in the basal sample 
and 108.61 ρmol/min/million cells. Cells treated with 0.5 µM PAO have a measured 
mean glucose uptake of 21.93 µM ρmol/min/million cells in the basal sample and 
73.98 µM ρmol/min/million cells in the insulin stimulated sample. Cells treated with 
1 µM PAO have a measured mean glucose uptake of 55.20 ρmol/min/million cells in 
the basal sample and 60.89 ρmol/min/million cells in the insulin stimulated sample 
2.5 µM PAO have a measured mean glucose uptake of 30.48 ρmol/min/million cells 
in the basal sample and 20.25 ρmol/min/million cells in the insulin stimulated 
sample.  
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6.7 CHARACTERISATION OF GLUCOSE UPTAKE IN 3T3-L1 ADIPOCYTES 
TREATED WITH EFR3A AND PI4KIIIA SIRNA  
We have developed a robust delivery system for siRNA in adipocytes using 
electroporation. Electroporation of 3T3-L1 adipocytes with EFR3A siRNA results in a 
50% KD of EFR3A detected using western blotting, shown in Figure 51. PI4KIIIα siRNA 
results in 42% KD of PI4KIIIα detected using western blotting, shown in Figure 51. 
Electroporation has a minimal effect on the insulin stimulated glucose uptake in 
adipocytes, results shown in Figure 51. The measured glucose uptake of scramble 
(SC) siRNA treated cells was 9.28 ρmol/min/well in basal cells and 78.04 
ρmol/min/well in insulin stimulated cells. The mean measured fold increase in 
electroporated cells treated with SC siRNA was 8.4-fold in comparison to non-
electroporated cells which exhibit a 10-fold increase in glucose uptake. Cells treated 
with EFR3A siRNA have a mean measured glucose uptake of 4.97 ρmol/min/well in 
basal cells and 18.38 ρmol/min/well in insulin stimulated cells. Insulin stimulated 
glucose uptake was inhibited in the adipocytes treated with EFR3A siRNA, results 
show a 3.4-fold increase in glucose uptake in response to insulin stimulation. Cells 
treated with PI4KIIIα siRNA have a mean measured glucose uptake of 8.46 
ρmol/min/well in basal cells and 26.86 ρmol/min/well in insulin stimulated cells. 
Insulin stimulated glucose uptake was similarly inhibited in the adipocytes treated 
with PI4KIIIα siRNA, as with the EFR3A siRNA treated samples, with a measured 3.2-
fold increase in glucose uptake in response to insulin stimulation. 
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Glucose uptake was measured using 3H labelled 2-deoxy glucose. Cells are 
stimulated for 30 minutes with 0.1µM insulin and a 10-minute uptake of the 25 
ηmol 2-Deoxyglucose.  Due to this assay requiring electroporation numbers of 
cells between experiments was variable meaning the fold difference within each 
biological repeat was represented. The mean measured uptake of the scramble 
(SC) siRNA samples was 9.28 ρmol/min/well in the basal samples and 78.21 
ρmol/min/well in the insulin stimulated cells. The mean measured uptake of the 
EFR3A siRNA samples was 4.97 ρmol/min/well in the basal samples and 18.38 
ρmol/min/well in the insulin stimulated cells. The mean measured uptake of the 
PI4KIIIα samples was 8.46 ρmol/min/well in the basal samples and 26.86 
ρmol/min/well in the insulin stimulated cells. The siRNA knockdown was 
measured using western blotting and imageJ to measure the band mean intensity 
a 50% KD was measured for EFR3A and 42% KD was measured for PI4KIIIα. Error 
bars represent SEM. SC siRNA data from 5 biological replicates, with 5 technical 
replicates. EFR3A siRNA data from 4 biological repeats, with 5 technical 
replicates. PI4KIIIα siRNA data from 3 biological repeats, with 5 technical 
replicates.  
Figure 51 Glucose in 3T3-L1 adipocytes treated with EFR3A siRNA.  
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6.8 DISCUSSION 
6.8.1 The effect on GLUT4 at the PM  
6.8.1.1 HeLa Cells 
The findings from this chapter have shown a role for EFR3 for GLUT4 at the PM. In 
confocal microscopy experiments images are taken using the same laser intensity 
for each experiment. HeLa cells have no endogenous insulin receptor, however 
stimulation with insulin was possible through tyrosine kinase epidermal growth 
factor receptor present in HeLa cells. HeLa cells do not express endogenous GLUT4, 
the HeLa cells use stably express HA-GLUT4-GFP. The output measured was an 
increase in PM GLUT4 in response to insulin stimulation, this protocol has been 
established as a model system for GLUT4 (Kioumourtzoglou et al., 2015). This due 
to the difficulty gaining high numbers for statistical analysis which was introduced 
when working with 3T3-L1 adipocytes which are not easily manipulated using 
standard molecular protocols.  
The overexpression of EFR3A and the homolog EFR3B in HA-GLUT4-GFP expressing 
HeLa cells result in an increase in PM GLUT4 in unstimulated cells similar to levels 
seen in control insulin stimulated cells. The over expression of EFR3A and EFR3B was 
achieved using transient plasmid transfection, a technique which does not allow for 
normalisation of expression in transfected cells. To investigate if the level of over 
expression of EFR3A-mcherry or EFR3B-mcherry had an effect on PM GLUT4 levels 
the mean intensity of mCherry fluorescence per cell was gathered and plotted 
against the HA/GFP mean intensity. Increased mCherry fluorescence was correlated 
with increased EFR3A or EFR3B expression. No correlation between intensity of 
mCherry fluorescence and HA/GFP was discernible from the sample data, shown in 
Supplemental Figure 2. Therefore, this data suggests that EFR3A and EFR3B 
overexpression must reach a threshold for effect with a low number of plasmid 
transfections. The results show that overexpression of EFR3A and EFR3B results in 
the maintenance of an insulin response, with increased PM GLUT4 in cells stimulated 
with insulin. The fold increase in PM GLUT4 was maintained in HeLa cells over 
expressing EFR3B, with cells over expressing EFR3A exhibiting a lowered fold 
increase in PM GLUT4, 1.5-fold increase in comparison to 2-fold increase. However, 
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this fold increase was still significant and indicates that EFR3A and EFR3B 
overexpression does not inhibit the insulin response and a pool of GSVs are still 
present and able to respond to insulin in cells over expressing EFR3. Images of HeLa 
cells over expressing EFR3A which are not insulin stimulated have visible internal 
pools of GSVs, these are diminished upon insulin stimulation. Together these results 
indicate that EFR3A and EFR3B overexpression works to capture GLUT4 at the PM.  
The effect of the dominant negative EFR3A mutant on PM GLUT4 was analysed in 
HeLa cells using confocal microscopy. The EFR3A mutant has the N terminal 
palmitoylation sites mutated (C6-9S), resulting in cytosolic localisation of EFR3A. 
This mutation does not inhibit EFR3A binding of TTC7 and PI4KIIIα, thus resulting in 
localisation of the majority of PI4KIIIα to the cytosol and not the PM due to 
overexpression (Nakatsu,  et al., 2012). Images confirm cytosolic localisation of 
EFR3A(C6-9S) as reported. Results obtained using confocal microscopy in HA-GLUT4-
GFP HeLa cells showed that expression of EFR3A(C6-9S) inhibits insulin stimulated 
increase in PM GLUT4. Levels of PM GLUT4 in cells expressing EFR3A(C6-9S) are 
significantly reduced in comparison to non-transfected non-stimulated HeLa cells.  
To remove implicit bias from the analysis of PM GLUT4 in the HeLa model system 
FACS analysis was performed. HA-GLUT4-GFP expressing HeLa cells transfected with 
EFR3A, and the dominant negative mutant EFR3A(C6-9S) were analysed using this 
technique. Results using FACS followed the same trend observed from the confocal 
data. The over expression of EFR3A resulted in increased PM GLUT4 in unstimulated 
cells similar to PM GLUT4 levels seen in insulin stimulated HeLa cells. Cells over 
expressing EFR3A still exhibit an insulin stimulated increase in PM GLUT4. HeLa cells 
overexpressing the dominant negative EFR3A(C6-9S) mutant exhibit inhibited insulin 
response, with a non-significant response to insulin stimulation. EFR3A(C6-9S) 
expression in HeLa cells results in decreased level of PM GLUT4 in comparison to 
non-transfected HeLa cells. The fold increase in PM GLUT4 in non-transfected HeLa 
cells measured using FACS was lower than that from confocal data. However, the 
result has increased statistical significance due to the number of cells assessed 
increasing 100 fold when FACS was used in comparison to confocal microscopy. Thus, 
confirming that FACS analysis was a valuable tool when investigating PM GLUT4 in 
this model system.  
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Future investigation into the effect of EFR3A on PM GLUT4 could examine the dwell 
time of individual GLUT4 molecules at the PM in cells with altered EFR3A expression. 
The dawn of CRISPR has improved the capability of super-resolution techniques. 
Introduction of mutations to endogenous EFR3A, such as the C6-9S mutation, may 
have effects on GLUT4 dwell time at the PM. To elucidate the role for EFR3A in the 
sequence of GLUT4 arrival and behaviour at the PM the effect EFR3A has on GSV 
fusion events at the PM. The recent development of a functional GLUT4 tagged with 
pHluorin would allow for the direction visualisation and co-localisation of GSV fusion 
events to EFR3A in cells expressing EFR3A-mcherry (Ashrafi et al., 2017).  
6.8.1.2 3T3-L1 Adipocytes 
The effects of EFR3A and EFR3A(C6-9S) over expression observed in model HA-
GLUT4-GFP expressing HeLa cells was maintained when tested in HA-GLUT4-HA 
expressing 3T3-L1 adipocytes. The analysis of PM GLUT4 in 3T3-L1 adipocytes was 
only performed by confocal analysis. DNA plasmids are introduced into 3T3-L1 
adipocytes using electroporation, as standard methods of DNA transfection are 
inefficient in 3T3-L1 adipocytes (Okada et al., 2003). Electroporation results in 
reduced cell size, however results in vastly improved transfection rates if still low 
in comparison to other cell types (Okada et al., 2003). FACS analysis of 3T3-L1 
adipocytes was not possible due to the size and adiposity of this cell type. The lipid 
content of 3T3-L1 means once ruptured adipocytes cause a cascade of autolysis of 
cells in the sample. This effect makes FACS an inappropriate technique as the cells 
are scraped before analysis.   
The parallel results of PM GLUT4 in HeLa and 3T3-L1 adipocytes show that HA-
GLUT4-GFP expressing HeLa’s are an appropriate model for testing the role of EFR3A 
during insulin stimulated GLUT4 dispersal. This provides a solid representation of 
results to base future studies of EFR3A and GLUT4 on. These results indicate that 
EFR3A alone may have a role for GLUT4 PM behaviour as overexpression of EFR3A 
alone affects PM GLUT4. To confirm that over expression of EFR3A alone has an 
affect future studies could investigate PI4KIIIα expression in cells over expressing 
EFR3A. However, as this was a transient expression of 48 hours pre sample analysis 
it was expected that minimal effects are a result of transcriptional changes of 
PI4KIIIα. 
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6.8.2 PAO inhibition of PI4KIIIα 
PAO is a trivalent arsenical which is capable of forming stable ring complexes with 
vicinal dithiols. PAO has been demonstrated to have a variety of effects when 
applied to 3T3-L1 adipocytes (Frost and Lane, 1985; Gould et al., 1988; Liao et al., 
1991). PAO is a known phosphotyrosine phosphatase inhibitor, which has been 
demonstrated to have a variety of effects in many cell types (Fletchert et al., 1993). 
Previous studies analysing the effect of PAO on glucose uptake showed a 3 fold 
increase in glucose uptake in adipocytes when used at 10 µM concentration in 3T3-
L1 adipocytes (Gould et al., 1988). Studies using higher concentrations of PAO (10 – 
40 µM) show PAO blocks insulin stimulated glucose uptakes with minimal effect on 
the basal glucose uptake and auto-phosphorylation of IR (Fletchert et al., 1993).  
Inhibition of PI4KIIIα using PAO uses lower concentration than previous studies of the 
effects of PAO on glucose uptake, as PAO was an inhibitor of type III PI4Ks with a 
greater specificity for PI4KIIIα (IC50 1 – 5 µM) (Dumaresq-Doiron et al., 2010). We 
assume inhibition of PI4KIIIα activity by PAO is the mechanism of action measured 
here, but due to the nature of PAO we cannot be certain of this but have minimised 
other targets with these concentrations. The results show a simultaneous decrease 
in insulin stimulated glucose uptake and an increase in glucose uptake of 
unstimulated 3T3-L1 adipocytes. This results in an inhibition of insulin stimulate 
increase of glucose uptake in 3T3-L1 adipocytes. This effect was comparable to the 
effect of the overexpression of the dominant negative EFR3A(C6-9S) mutant, which 
results in the inhibition of increased PM GLUT4 in response to insulin stimulation.  
6.8.3 siRNA knockdown of PI4KIIIα and EFR3A 
To achieve a knock down of PI4KIIIα and EFR3A electroporation was employed to 
deliver siRNA. As previously described electroporation affects size of remaining 
adipocytes and increases distribution of fibroblasts in the sample, as these are a 
hardier cell type which are less likely to succumb to the effects of electroporation. 
Using immunoblots from cell lysates the knockdown was measured at 42% and 50% 
for PI4KIIIα and EFR3A respectively. To obtain a more accurate knockdown level in 
samples future experiments may evaluate mRNA levels of PI4KIIIα and EFR3A 
concurrent with immunoblot evaluation. Previous titration results of siRNA treated 
adipocytes show an importance of timing of sample use. Due to the time constraints 
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of the glucose uptake assay and mRNA sample preparation could not be concurrently 
run.  
Results from the glucose uptake of both PI4KIIIα and EFR3A siRNA treated adipocytes 
showed a 3-fold decrease in insulin stimulated glucose uptake individually in 
comparison to scrambled siRNA-treated cells. Due to the known interaction between 
PI4KIIIα and EFR3A, the similarity in effect and knockdown levels the results are 
likely a result of the same pathway during insulin stimulated glucose uptake. Further 
investigation into the effect of double knockdown could elucidate this for certain. 
However, as using electroporation does not guarantee siRNA delivery to the same 
cell, meaning this technique was not optimal to investigate an additive effect. These 
glucose uptake results coupled with the results from PM GLUT4 experiments indicate 
that a role for EFR3A and PI4KIIIα exists during insulin mediated PM GLUT4 
behaviour.  
6.8.3.1 Issues surrounding electroporation 
As mentioned electroporation results in reduced cell size of remaining 3T3-L1 
adipocytes. The population of 3T3-L1 fibroblasts was increased in electroporated 
samples as these cell types are more robust than adipocytes to electroporation. 
Previous studies have determined that electroporation does not affect GLUT4 
trafficking (Martin et al., 2006). To determine suitability of 3T3-L1 adipocytes post 
electroporation initial experiments characterised the effect of electroporation on 
insulin stimulated glucose uptake, results shown in supplemental data. The results 
show a 9-fold increase in glucose uptake in response to insulin stimulation. This 
represents no significant difference in the fold increase in glucose uptake between 
electroporated cells and electroporated cells treated with SC siRNA. A minimum of 
a 7-fold increase in glucose uptake was arbitrarily set for future experiments of 
electroporated cells treated with SC siRNA. To confirm results obtained using 
electroporated siRNA treated 3T3-L1 adipocytes an EFR3A knockout cell line 
generated using CRISPR could be used. Knockout of EFR3A would require testing of 
3T3-L1 adipocyte differentiation, as EFR3A may be a requirement for differentiation 
and function of adipocytes. EFR3 was an embryonic lethal knock out gene, however, 
tissue specific or inducible knockout mice are potentially suitable to study the effect 
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on glucose uptake in vivo (Vijayakrishnan et al., 2010; Mirantes et al., 2013; Ablain 
and Zon, 2016).  
6.8.3.2 Future investigations of GLUT4 at the PM 
Kinase deficient PI4KIIIα mutant, K1792L, has been generated based on the ATP 
binding site and validated in other studies (Harak et al., 2014). CRISPR single 
nucleotide editing can be utilized in future investigations to confirm results observed 
using PAO inhibition of PI4KIIIα (Ran et al., 2013). Using single nucleotide editing of 
endogenous PI4KIIIα protein to the kinase deficient mutant (K1792L) would create a 
cell line where GLUT4 behaviour at the PM can be investigated. Due to the 
promiscuous nature of PAO as an inhibitory molecule an experiment carried out using 
PAO requires validating using a separate methodology to block PI4KIIIα activity. The 
use of PAO cannot be discounted from future investigation as it provides a transient 
method of inhibition, which may be a requirement.  Super resolution microscopy 
such as dSTORM has the ability to provide insight into the dispersal of GLUT4 clusters 
at the PM. Of particular interest would be the effect of siRNA depletion of EFR3A 
and PI4KIIIα on GLUT4 dispersal.  
6.9 CONCLUSIONS 
The results indicate that EFR3A alone has a potential role in GLUT4 behaviour at the 
PM. This was due to the noted effect of EFR3A overexpression alone on PM GLUT4 in 
HeLa and 3T3-L1 adipocyte cells. It would be of interest to investigate this result 
further as there may be other roles for EFR3A. The siRNA knockdown of EFR3A 
represents a significant inhibitory effect on glucose uptake. This effect was 
concurrent with results defined in HA-GLUT4-GFP expressing cells of EFR3A(C6-9S) 
mutant, both demonstrate an inhibitory effect on insulin stimulated GLUT4 effects. 
Inhibition of PI4KIIIα has similar effects to EFR3 this indicates that Inhibition of 
PI4KIIIα activity through protein depletion using siRNA or using PAO inhibition have 
similar inhibitory outcomes on insulin stimulated glucose uptake. This result 
supports the use of PAO at <2.5 µM concentrations within this system to inhibit 
PI4KIIIα activity. Taken together a role for EFR3A and PI4KIIIα was envisaged in 
increasing PM GLUT4 and further testing whether mobility of GLUT4 is directly 
influenced by these factors.  
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7 SUMMARY OF RESULTS 
This project aimed to observe the mechanism behind the dispersal of GLUT4 at the 
plasma membrane, and as part of this we investigated the role of EFR3, a protein 
identified to play a role in GLUT4 dispersal in budding yeast. The evidence that 
GLUT4 behaviour at the PM is regulated by insulin stimulation has been mounting in 
advance of this work being undertaken. This thesis aimed to determine a molecular 
mechanism behind insulin stimulated GLUT4 PM behaviour, in particular how EFR3 
affects GLUT4 at the PM, and if this is part of the insulin signal to increase GLUT4 
dispersal and mobility at the PM in insulin stimulated cells.  
Results identify EFR3A as the predominantly expressed homolog in 3T3-L1 
adipocytes. Localisation of EFR3A was determined to be PM, and not to undergo 
translocation in response to insulin stimulation. This indicated that EFR3 and PI4P 
are involved with GLUT4 control at the PM and not the formation or delivery of GSVs 
in response to insulin stimulation.  
EFR3 was investigated due to the discovery for the requirement of the mutant allele 
of Efr3, fgy1-1, in yeast for mammalian GLUT4 translocation to the PM. The initial 
hypothesis for the mechanism of control was the generation of PI4P by the PI4KIIIa 
localised to the membrane by EFR3 served to corral GLUT4 delivered to the PM. In 
response to insulin stimulation PI4P production is perturbed, a schematic of this is 
shown in Figure 20. This mechanism of action assumed that the fgy1-1 mutation was 
a loss of function mutation as this information is not available.  
The results show that increased EFR3A at the PM results in increased GLUT4 at the 
PM, even in the absence of insulin stimulation. This indicates that EFR3A is positively 
involved in glucose uptake. These results show that the original hypothesis of PI4P 
production at the PM inhibits GLUT4 dispersal at the PM was incorrect. The increase 
in PM GLUT4 in the absence of insulin stimulation may be a result of GLUT4 dispersal 
resulting in increased retention at the PM, stalling endocytosis of GLUT4. The 
increase measured may also be a result of increased GSV fusion with retention in the 
unstimulated cell. The activity of EFR3A on this system is a result of its PM 
localisation, this was tested using the cytosolic mutant EFR3A(C6-9S). Expression of 
which resulted in no increase in GLUT4 at the PM in response to insulin stimulation. 
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The results from samples of striated muscle from HFD mice, a model of insulin-
resistance, show increased protein expression of both EFR3A and PI4KIIIα. This is an 
indication of physiological compensation in response to the HFD and impaired 
glucose tolerance to improve glucose uptake within the animal. The results showing 
that EFR3A at the PM is required for increased PM GLUT4 indicate that its role is 
within localisation of the PI4KIIIα which allows for the production of PI4P. EFR3A(C6-
9S) is still capable of binding with this kinase machinery and therefore over-
expression will serve to divert PI4KIIIα from its membrane localisation (Nakatsu, et 
al., 2012).  This ties in with the result that inhibition of PI4KIIIα activity with PAO 
inhibits glucose uptake indicating reduced GLUT4 at the PM. As PAO is not a specific 
inhibitor inhibition of PI4KIIIα activity these results taken together with the siRNA 
depletion resulting in similar insulin-stimulated glucose uptake inhibition.  
These results indicate that EFR3A and PI4KIIIα are significant at the PM for the 
insulin-stimulated dispersal of GLUT4, depicted in Figure 52 and that dispersal of 
GLUT4 is integral to a sustained increase in glucose uptake. Based on the results 
within this thesis a conceivable mode of action is the production of PI4P at the PM 
increases lipid mobility by increasing the negative charge of the PM, this allows for 
the increased mobility of GLUT4 at the PM in insulin stimulated cell and therefore 
dispersal from the original cluster at fusion.  
There is a solid basis to indicate a role which warrants further investigation using 
techniques described in the chapters. In particular dissecting if EFR3A is involved by 
its localisation of PI4KIIIα and the production of PI4P. The results indicate a positive 
role, however to definitively state that increased PI4P production at the PM is 
responsible for increased GLUT4 mobility and dispersal in response to insulin 
requires further investigation.   
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Based on the findings within this thesis the dispersal of GLUT4 at the PM is 
stimulated by EFR3A machinery. Increased EFR3A in cells result in increased PM 
GLUT4 in cells. Inhibition of PI4KIIIα using PAO results in decreased glucose 
uptake, indicating production of PI4P has a role during insulin stimulated glucose 
uptake. siRNA depletion of both EFR3A and PI4KIIIα results in decreased insulin 
stimulated glucose uptake. This model postulates that EFR3A and PI4P 
production is important for the dispersal of GLUT4 across the plasma membrane.   
Figure 52: Schematic of EFR3A and PI4P involvement during GLUT4 dispersal 
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8 SUPPLEMENTAL  
8.1 PRIMER 
Primer-BLAST from NCBI was used to design primers for qPCR (Ye et al., 2012) 
8.1.1 EFR3A  
8.1.1.1 Mouse 
Left - ggtgacagatgaagatcgcc 
Right - ccacatcatcagaaggcaca 
8.1.1.2 Human 
Left - caaagcttcgagggatcaga 
Right - cagctgttgcccattctttt 
8.1.2 EFR3B  
8.1.2.1 Mouse 
Left - aagcccgttcttatccacct 
Right - gctgcggctgaattgagta 
8.1.2.2 Human 
Left - tcaagcctgttctcatccatc 
Right - tgcggctgaattgagtacat 
8.1.3 GAPDH 
8.1.3.1 Mouse 
Left - gttgtctcctgcgacttca  
Right - ggtggtccagggtttctta  
8.1.3.2 Human 
Left - gtctcctctgacttcaacagcg 
Right - accaccctgttgctgtagccaa 
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8.2 IMMUNOPRECIPITATION FLOW THROUGH BLOT 
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Immunoblot from immunoprecipitation experiments. The antibodies used during 
immunoprecipitation are shown in the top lane, commercial EFR3A, PI4KIIIα, and 
random IgG as a control. Total cell lysate (L) as a control, the flow through (F), and 
immunoprecipitant eluted sample (Co-IP) is loaded for each precipitation. Elution 
stringency of 0.5% and 1% Triton-X 100 is shown in the top and bottom panel 
respectively. 
Supplemental Figure 1: Immunoprecipitation immunoblot 
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8.3 EFR3A-MCHERRY INTENSITY AGAINST PLASMA MEMBRANE GLUT4 
INTENSITY. 
 
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
0 500 1000 1500 2000 2500 3000
HA
/G
FP
 m
ea
n 
in
te
ns
ity
mCherry mean intensity
+Insulin (With EFR3a) +Insulin (no EFR3a) Basal (with EFR3a) Basal (no EFR3a)
Effect of EFR3A-mCherry intensity on HA/GFP mean intensity. EFR3A-mCherry 
intensity correlates to expression levels of plasmid product. HA/GFP mean 
intensity correlates to level of PM GLUT4 in the cell. Increased HA/GFP mean 
intensity is shown in response to insulin stimulation.  EFR3A-mCherry mean 
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n>30. 
Supplemental Figure 2: HA/GFP mean intensity vs mCherry mean intensity 
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